OLITIS A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2003 by ICON Group International, Inc. Copyright ©2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Colitis: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83833-X 1. Colitis-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on colitis. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON COLITIS ...................................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Colitis.......................................................................................... 27 E-Journals: PubMed Central ....................................................................................................... 87 The National Library of Medicine: PubMed ................................................................................ 92 CHAPTER 2. NUTRITION AND COLITIS .......................................................................................... 137 Overview.................................................................................................................................... 137 Finding Nutrition Studies on Colitis......................................................................................... 137 Federal Resources on Nutrition ................................................................................................. 152 Additional Web Resources ......................................................................................................... 152 CHAPTER 3. ALTERNATIVE MEDICINE AND COLITIS.................................................................... 155 Overview.................................................................................................................................... 155 National Center for Complementary and Alternative Medicine................................................ 155 Additional Web Resources ......................................................................................................... 183 General References ..................................................................................................................... 192 CHAPTER 4. DISSERTATIONS ON COLITIS...................................................................................... 193 Overview.................................................................................................................................... 193 Dissertations on Colitis.............................................................................................................. 193 Keeping Current ........................................................................................................................ 194 CHAPTER 5. CLINICAL TRIALS AND COLITIS ................................................................................ 195 Overview.................................................................................................................................... 195 Recent Trials on Colitis.............................................................................................................. 195 Keeping Current on Clinical Trials ........................................................................................... 205 CHAPTER 6. PATENTS ON COLITIS ................................................................................................ 207 Overview.................................................................................................................................... 207 Patents on Colitis....................................................................................................................... 207 Patent Applications on Colitis ................................................................................................... 228 Keeping Current ........................................................................................................................ 260 CHAPTER 7. BOOKS ON COLITIS .................................................................................................... 261 Overview.................................................................................................................................... 261 Book Summaries: Federal Agencies............................................................................................ 261 Book Summaries: Online Booksellers......................................................................................... 263 The National Library of Medicine Book Index ........................................................................... 267 Chapters on Colitis..................................................................................................................... 269 Directories.................................................................................................................................. 286 CHAPTER 8. MULTIMEDIA ON COLITIS ......................................................................................... 289 Overview.................................................................................................................................... 289 Video Recordings ....................................................................................................................... 289 Bibliography: Multimedia on Colitis ......................................................................................... 290 CHAPTER 9. PERIODICALS AND NEWS ON COLITIS ...................................................................... 293 Overview.................................................................................................................................... 293 News Services and Press Releases.............................................................................................. 293 Newsletters on Colitis ................................................................................................................ 296 Newsletter Articles .................................................................................................................... 298 Academic Periodicals covering Colitis ....................................................................................... 299 CHAPTER 10. RESEARCHING MEDICATIONS ................................................................................. 301 Overview.................................................................................................................................... 301 U.S. Pharmacopeia..................................................................................................................... 301 Commercial Databases ............................................................................................................... 303
viii Contents
Researching Orphan Drugs ....................................................................................................... 303 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 307 Overview.................................................................................................................................... 307 NIH Guidelines.......................................................................................................................... 307 NIH Databases........................................................................................................................... 309 Other Commercial Databases..................................................................................................... 312 The Genome Project and Colitis................................................................................................. 312 APPENDIX B. PATIENT RESOURCES ............................................................................................... 317 Overview.................................................................................................................................... 317 Patient Guideline Sources.......................................................................................................... 317 Associations and Colitis............................................................................................................. 329 Finding Associations.................................................................................................................. 332 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 335 Overview.................................................................................................................................... 335 Preparation................................................................................................................................. 335 Finding a Local Medical Library................................................................................................ 335 Medical Libraries in the U.S. and Canada ................................................................................. 335 ONLINE GLOSSARIES................................................................................................................ 341 Online Dictionary Directories ................................................................................................... 342 COLITIS DICTIONARY............................................................................................................... 343 INDEX .............................................................................................................................................. 455
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with colitis is indexed in search engines, such as www.google.com or others, a nonsystematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about colitis, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to colitis, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on colitis. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to colitis, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on colitis. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON COLITIS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on colitis.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and colitis, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “colitis” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Medical Treatment of Severe Ulcerative Colitis Source: Alimentary Pharmacology and Therapeutics. 16(Supplement 4): 7-12. July 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: Approximately 15 percent of patients with ulcerative colitis (UC, a type of inflammatory bowel disease, or IBD) have a severe attack requiring hospitalization at some time during their illness. This article reviews the medical treatment of severe UC. The authors note that hospitalization leads to a remission in 60 to 80 percent of patients. However, nonresponders may require a total colectomy. Mortality (death) in severe episodes of UC decreased from 31 to 61 percent in the 1950s to 5 to 9 percent in the
4
Colitis
1960s, thanks to the introduction of steroids and to a policy of early colectomy. Recently, some new drugs have been shown to be effective in the treatment of severe steroidrefractory (resistant) UC. This review article concludes on the clinical evaluation, prognostic factors, and new developments in medical therapy in severe UC. The authors also report on a retrospective evaluation of a consecutive series of patients with severe UC who were admitted to a Gastroenterology Department in Torino, Italy. 1 figure. 3 tables. 37 references. •
Prevalence of Celiac Disease in Collagenous and Lymphocytic Colitis Source: Canadian Journal of Gastroenterology. 14(11): 919-921. December 2000. Contact: Available from Pulsus Group, Inc. 2902 South Sheridan Way, Oakville, Ontario, Canada L6J 7L6. Fax (905) 829-4799. E-mail:
[email protected]. Summary: Both collagenous and lymphocytic colitis (inflammation of the colon) have been described in patients with celiac disease, suggesting an association between the conditions. Over the past few years, the availability, sensitivity, and specificity of serological (blood) markers for celiac disease have improved; the most recent advancement is the description of tissue transglutaminase as the major antigen for endomysium antibody. This article describes how a quantitative ELISA test was used to measure titres of immunoglobulin A (IgA) antibody to tissue transglutaminase (tTG) along with an immunofluorescent technique for IgA endomysium antibody (EmA) in 15 patients with lymphocytic colitis and 8 with collagenous colitis to determine whether celiac disease latency could be detected. One patient with lymphocytic colitis demonstrated both elevated titres of tTG antibody and positive EmA, and small bowel biopsy confirmed celiac disease. One patients with collagenous colitis had a slightly elevated titre of tTG antibody with a negative EmA, and results of a small bowel biopsy were normal. Three other patients with lymphocytic colitis were already treated for previously diagnosed celiac disease. The prevalence of celiac disease occurring in lymphocytic colitis was found to be 27 percent, but no cases of celiac disease in association with collagenous colitis were found. 1 figure. 1 table. 23 references.
•
Pseudomembranous Colitis: An Update Source: Canadian Journal of Gastroenterology. 14(1): 51-56. January 2000. Contact: Available from Pulsus Group, Inc. 2902 South Sheridan Way, Oakville, Ontario, Canada L6J 7L6. Fax (905) 829-4799. E-mail:
[email protected]. Summary: Clostridium difficile is the most common nosocomial infection of the gastrointestinal tract. Most cases are associated with antibiotic therapy that alters the fecal flora, allowing overgrowth of C. difficile with production of its toxins. This article focuses on the diagnosis and therapy for C. difficile associated disease, as well as on illness complicated by ileus, toxic megacolon, or recurrences. Diagnosis is made by detection of the organism or toxin in the stools. A variety of different tests can be used, but none is ideal. A stool culture can be positive in someone without diarrhea (i.e., a carrier). While the cytotoxin is the gold standard, it is expensive, and there is a delay before results are available. Thus, many laboratories use the enzyme linked immunoassay tests to detect toxin of C. difficile because they are a more rapid screen. First line therapy for C. difficile disease should be metronidazole 250 mg four times a day for 10 days. Vancomycin should be reserved for severe cases where metronidazole has failed or where metronidazole cannot be tolerated or is contraindicated. Recurrent C. difficile disease is a particularly vexing clinical problem. A variety of biotherapeutic approaches have been used. The authors caution that retreatment with antibiotics is
Studies
5
almost always necessary. In addition, the nonpathogenic yeast Saccharomyces boulardii has been shown to be of benefit as an adjunct in preventing further recurrences. 2 tables. 48 references. •
Budesonide Treatment for Collagenous Colitis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Source: Gastroenterology. 123(4): 978-984. October 2002. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452. Website: www.gastrojournal.org. Summary: Collagenous colitis is an idiopathic (of unknown cause) microscopic colitis characterized by chronic watery diarrhea, a typical subepithelial collagen layer, and lymphoplasmacellular infiltration. This article reports on a randomized, double-blind, placebo-controlled multicenter study that investigated the effect of budesonide on symptoms and histology in patients with collagenous colitis. Patients with chronic diarrhea and histologically proven collagenous colitis were randomized to receive either oral budesonide 9 milligrams per day for 6 weeks, or placebo; 45 patients were available for per protocol analysis. The rate of clinical remission was significantly higher in the budesonide group than in the placebo group. Histologic improvement was observed in 14 patients of the budesonide group (60. 9 percent) and in 1 patient of the placebo group (4.5 percent). Two patients in the budesonide group (7.7 percent) and 1 patient in the placebo group (4.0 percent) discontinued treatment prematurely because of side effects. The authors conclude that oral budesonide (Entocort capsules) is an effective and safe treatment modality for patients with collagenous colitis. Long-term follow up of these patients is necessary to investigate whether clinical and histologic remission is sustained. 2 figures. 5 tables. 34 references.
•
Microscopic Colitis Source: Gastroenterology Nursing. 22(4): 167-169. July-August 1999. Contact: Available from Williams and Wilkins. 351 West Camden Street, Baltimore, MD 21201-2436. (410) 528-8555. Summary: Endoscopy nurses and associates occasionally find themselves assisting with colonoscopies in which biopsy specimens are obtained from normal appearing mucosa to rule out microscopic colitis. This article reports on a review of the literature that was undertaken to learn more about this uncommon but troublesome cause of chronic diarrhea in patients. The author notes that the few studies completed have been small and have yielded some conflicting and controversial data regarding many aspects of the two forms of microscopic colitis. Some findings, however, have been consistent and may help to provide a better understanding of this challenging syndrome for gastroenterology nurses. Several authors have described similar clinical features in microscopic colitis, typically chronic watery, nonbloody diarrhea with 5 to 10 (but as many as 30) stools per day. The lack of alternating constipation helps to distinguish the disease from irritable bowel syndrome (IBS). Colorectal biopsies are needed to make a diagnosis, regardless of the appearance of the colonic mucosa on colonoscopy. The inflammatory changes seen in collagenous colitis, ulcerative colitis (UC), and Crohn's disease differ from one another. A few patients improve initially with symptomatic treatment such as avoidance of lactose containing food, NSAIDs (nonsteroidal antiinflammatory drugs), and caffeine; use of antimotility and bulking agents; and ingestion of a low fat diet if steatorrhea (fatty stools) is present. Usually, however, it is necessary to treat these patients with antiinflammatory agents such as sulfasalazine or
6
Colitis
5ASA. Corticosteroids may be added if there is no response to these medications. The author concludes that gastroenterology and endoscopy nurses and associates who familiarize themselves with these diseases improve the quality of care delivered to their patients, especially in the form of patient education. 7 references. •
Nutritional Therapies for Ulcerative Colitis: Literature Review, Chart Review Study, and Future Research Source: Alternative Therapies in Health and Medicine. 6(1): 55-63. January 2000. Contact: Available from Innovision Communications. 101 Columbia, Aliso Viejo, CA 92656. (800) 899-1712. Fax (949) 362-2022. E-mail:
[email protected]. Website: www.healthonline.com/altther.htm. Summary: Few clinical studies suggest a significant influence of diet or nutritional supplementation on ulcerative colitis (UC). One reason is that UC, like many chronic diseases, is multifactorial. This article describes and reviews the relevant literature on UC, including studies of diet and intravenous therapy; nutritional status and nutritional supplementation; and bowel flora and immune function and their influences. Also, results of a retrospective chart review study that was done at a complementary medicine office are presented. Finally, suggestions for future research are discussed based on a nutritional model of UC. The authors hope that, taken together, these areas will clarify the current status of UC research and promote the types of investigations that are necessary to establish the validity of nutritional influences on UC, as well as the mechanisms that are involved. The authors conclude that their retrospective chart review study suggests that a dietary and nutritional supplementation regimen may significantly benefit UC patients. The study finding is based on significant improvements in symptoms and medication dosage needed to control symptoms. One figure offers a multifactorial model of the use of nutritional therapy in UC. 3 figures. 4 tables. 65 references.
•
Crohn's Disease and Ulcerative Colitis Are Associated with the DNA Repair Gene MLH1 Source: Annals of Surgery. 225(6): 718-725. June 1997. Contact: Available from Lippincott-Raven Publishers. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030. Summary: Identification of genes involved in the etiology of inflammatory bowel disease (IBD) may lead to the development of markers that objectively can define disease and permit therapy. The treatment of Crohn's disease of the colon and ulcerative colitis also is complicated by difficulties in differentiating the two conditions. This article reports on a study undertaken to determine whether there is an association between Crohn's disease and ulcerative colitis (two types of IBD) with MLH1, a DNA repair gene. The DNA and clinical data were obtained on 126 unrelated individuals (45 with Crohn's disease, 36 with ulcerative colitis, and 45 control subjects without intestinal disease). Polymerase chain reaction (PCR) products were analyzed. The association between single haplotypes and disease was expressed as relative odds. The authors found that novel associations exist between IBD and two genetic markers within, and one nearby, the DNA mismatch repair gene MLH1. Two categories of haplotypes were associated with the family history of Crohn's disease or ulcerative colitis. The significant association of MLH1 exon 15/D3S1611 haplotype with colonic Crohn's disease, as opposed to ulcerative colitis, may prove to be useful in distinguishing these two diseases. This information may also be helpful in the identification of individuals who
Studies
7
are at high risk of developing IBD. Appended to the article is a discussion by three specialists in the field. 2 figures. 3 tables. 24 references. •
Is Ileal Pouch-Anal Anastomosis Really the Procedure of Choice for Patients with Ulcerative Colitis? Source: Diseases of the Colon and Rectum. 41(1): 41-45. January 1998. Contact: Available from Williams and Wilkins. 351 West Camden Street, Baltimore, MD 21201-2436. (800) 638-6423 or (410) 528-8555. Summary: Ileal pouch-anal anastomosis is widely claimed to have replaced total proctocolecotomy with ileostomy as the 'procedure of choice' for ulcerative colitis (UC), largely on the basis of a perceived improved quality of life (QOL). There exists relatively little support for this assertion in the literature. This article reports on a study undertaken to determine if informed patients choosing total proctocolectomy with ileostomy have a similar QOL to those who choose ileal pouch-anal anastomosis. All patients with UC referred to a single surgeon and deemed an appropriate surgical candidate were educated about the available surgical options, and then offered a choice between the two options. Age, gender, and complications (including pouchitis) were recorded prospectively, and all patients were questioned regarding functional outcome and level of satisfaction. They were then asked to complete a slightly modified Inflammatory Bowel Disease Questionnaire, which was analyzed by categoric and overall scores. Sixty-seven patients underwent elective surgery for UC during the study period: 55 patients chose ileal pouch-anal anastomosis and 12 had total proctocolectomy with ileostomy. The groups were similar except for younger age and longer followup in the ileal pouch-anal anastomosis group. Patients undergoing the ileal pouch procedure had significantly more short term or long term complications (49 versus 8 percent), with pouchitis being the most frequent complication. There was no difference in level of satisfaction between the two groups, and no patients in either group wished they had undergone the other procedure. Patients who undergo ileal pouch-anal anastomosis can expect a high level of satisfaction, with a good QOL. However, educated patients choosing an ileostomy can achieve the same quality of life, without the higher complication rate associated with a pelvic pouch. 2 figures. 4 tables. 10 references. (AAM).
•
Management Strategies for C. Difficile Colitis Source: IM. Internal Medicine. 20(8): 26-29. August 1999. Contact: Available from Medical Economics. 5 Paragon Drive, Montvale, NJ 07645. (800) 432-4570. Summary: Infections caused by Clostridium difficile are very common, especially in hospitalized patients. In this article, the author reviews the pathophysiology of C. difficile, the clinical features of infections, appropriate diagnostic testing, and treatment regimens for this pathogen. There are two patient populations that appear to be particularly vulnerable to C. difficile infection: patients receiving antibiotics who are exposed to an environmental source of C. difficile (in the hospital, for example); and carriers of C. difficile who are subsequently treated with an antibiotic that allows the bacteria to proliferate. Specific antibiotics that put patients at risk for infection with C. difficile include ampicillin, amoxicillin, clindamycin, and cephalosporins. A wide range of conditions are associated with C. difficile infection: asymptomatic carrier state, antibiotic associated diarrhea without colitis, antibiotic associated colitis without pseudomembrane formation, pseudomembranous colitis, fulminant colitis with toxic
8
Colitis
megacolon, C. difficile complicating inflammatory bowel disease (IBD), and nonantibiotic associated C. difficile colitis. The gold standard laboratory test for C. difficile colitis is the tissue culture bioassay for toxin B performed on the patient's stool. The goal of therapy in C. difficile infection is to eliminate the organism from the feces. Oral metronidazole (250 mg four times per day) is the drug of choice for treating C. difficile infection because of the drug's comparable efficacy and lower cost compared to vancomycin. The author concludes by reviewing the treatment of recurrent infection and summarizing the key points of patient care management. 1 figure. 2 tables. 18 references. •
When to Suspect Ischemic Colitis: Why Is This Condition So Often Missed or Misdiagnosed? Source: Postgraduate Medicine. 105(4): 177-180, 183-184, 187. April 1999. Contact: Available from McGraw-Hill, Inc. 1221 Avenue of the Americas, New York, NY 10020. (612) 832-7869. Summary: Ischemic colitis is the most common ischemic injury (injury due to deficiency of blood, usually from constriction or obstruction of blood vessels) of the gastrointestinal tract and one of the most common disorders of the large bowel in the elderly. In this article, the authors review predisposing and identifying factors, the usual course of the disease, and diagnostic and management measures. A sudden drop in the colonic blood supply is key to its development, but in most patients, no specific cause can be identified. Presentation can range from acute abdominal cramping, distention, and bloody diarrhea to mild pain, but typically patients are otherwise well. Diagnosis is challenging because of the wide disparity between symptoms and objective findings. Common predisposing factors are atherosclerosis, shock, and congestive heart failure, but often, elderly patients have no obvious predisposing or precipitating factors. Common early radiographic signs are bowel wall thickening with thumbprinting, and later, ulceration and strictures may be found. Endoscopy is valuable in revealing the sharp demarcation between viable and necrotic colonic mucosa that is a strong indicator of ischemia. Within 48 hours, most patients show favorable response to conservative measures consisting of intravenous hydration, bowel rest, antibiotic therapy, and correction of precipitating processes. Vasoconstricting drugs and corticosteroids are contraindicated. When surgical intervention is indicated, it usually consists of resection of the ischemic segment and exteriorization of the remaining ends of the bowel. 3 figures. 1 table. 10 references. (AA-M).
•
Prevalence of Appendectomy Among Ulcerative Colitis Patients and Their Relatives Source: European Journal of Gastroenterology and Hepatology. 13(10): 1231-1233. October 2001. Contact: Available from Lippincott Williams and Wilkins. 241 Borough High Street, London SE1 1GB, UK 44(0)20-7940-7502. Fax: 44(0)20-7940-7574. Website: http://www.eurojgh.com/. Summary: It has been suggested that appendectomy (removal of the appendix) may protect against ulcerative colitis (UC). However, the incidences of appendectomy and UC in developed countries have diverged over the last 50 years, possibly as a consequence of environmental factors. This study was undertaken to determine whether the incidence of appendectomy is lower in patients with UC than in the general population. Patients with UC (n = 153), their relatives (n = 116), and members of the general population (n = 306) that had been matched for age, sex, and educational status
Studies
9
were studied. Six percent of UC patients had undergone appendectomy. The corresponding figure for non family controls was 20 percent. The rate of appendectomy within families (cases plus siblings) was 17 of 269 patients (6.3 percent) and was similar to that for UC patients alone. A negative association between appendectomy and UC exists in our patients with UC. In addition, the appendectomy rate in families of UC patients was lower than that in the general population, possibly implying that common environmental and genetic factors could play an important role in the divergent incidences of appendicitis and UC over the last 50 years. 2 tables. 18 references. •
Critical Approach to New Forms of Treatment of Crohn's Disease and Ulcerative Colitis Source: Alimentary Pharmacology and Therapeutics. 16 (Supplement 4): 53-58. July 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: Most patient with inflammatory bowel disease (IBD) can be managed with conventional immunosuppressive therapy. However, the recent increase in knowledge of inflammatory mechanisms and the high incidence of toxicity with prolonged steroid use, together with the fact that controlled trials have clearly shown that glucocorticosteroids do not maintain remission, warrants a rational approach to the choice of newer and less well tested therapeutic approaches in those patients who are not responding effectively to the standard treatment. In this review article, the authors offer a critical approach to the newer forms of treatment in the management of severe cases of IBD. 45 references.
•
Surgical Therapy for Ulcerative Colitis and Crohn's Disease Source: Gastroenterology Clinics of North America. 28(2): 371-390. June 1999. Contact: Available from W.B. Saunders. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452 or (407) 345-4000. Summary: Over the past two decades, there has been considerable progress in the surgical management of inflammatory bowel disease (IBD). This article reviews the surgical therapy for ulcerative colitis (UC) and Crohn's disease (CD). Crohn's disease is a chronic, nonspecific inflammatory disease of the gastrointestinal tract of unknown cause. It involves mainly the ileum, colon, and rectum, most often producing symptoms of obstruction or localized perforation with fistula. Although surgical treatment is palliative, operative excision in combination with strictureplasty, where appropriate, provides effective symptomatic relief and reasonable long term benefit. Chronic ulcerative colitis is a diffuse inflammatory disease of the mucosal lining of the colon and rectum. Total removal of the colon and rectum provides a complete cure. Newer surgical alternatives have eliminated the need for a permanent ileostomy following definitive resection of the involved colon and rectum. 7 figures. 2 tables. 42 references. (AA-M).
•
Screening and Surveillance of Ulcerative Colitis Source: Gastrointestinal Endoscopy Clinics of North America. 7(1): 129-145. January 1997.
10
Colitis
Contact: Available from W.B. Saunders Company. Periodicals Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 654-2452. Summary: Patients with longstanding ulcerative colitis (UC) are at a higher risk of developing cancer than the normal population. In this article, the author reviews guidelines for the screening and surveillance of cancer risk in people with UC. The relative risk is difficult to assess because published figures vary markedly. A number of centers have instituted annual colonoscopy screening for patients in the at-risk group. No randomized controlled clinical trials have been undertaken using mortality as end point and power calculations suggest that to obtain a useful answer it is necessary to randomize over 4,000. This number is 10 times larger than the largest surveillance study reported to date and it is unlikely that it will ever be undertaken. A critical analysis of the descriptive studies published to date suggests that there may be some benefit from surveillance, but if so it amounts to a saving of perhaps one life for every 200 to 400 colonoscopies. The author concludes that it is better to adopt a flexible and pragmatic approach to the surveillance of patients with UC, providing patients themselves with the information that is available and drawing attention to the advantages and disadvantages of longterm regular colonoscopy. 1 figure. 66 references. (AA-M). •
Ulcerative Colitis of the Appendix ('Ulcerative Appendicitis') Mimicking Acute Appendicitis Source: Canadian Journal of Gastroenterology. 15(3): 201-204. March 2001. Contact: Available from Pulsus Group, Inc. 2902 South Sheridan Way, Oakville, Ontario, Canada L6J 7L6. Fax (905) 829-4799. E-mail:
[email protected]. Summary: The appendix may be involved in ulcerative colitis (UC, a type of inflammatory bowel disease), in the setting of either diffuse or distal disease, and is usually diagnosed incidentally at the time of proctocolectomy (surgery to treat the UC). This article describes a patient in whom a rare case of 'ulcerative appendicitis' occurring on a background of clinically quiescent (no active symptoms) UC presented with the signs and symptoms of acute appendicitis. Prior to this presentation, the patient's UC was in remission for over 2 years. The patient was treated with laparotomy and the appendix was removed. Pathology showed acute inflammation confined to the mucosa, with neutrophilic crypt epithelial infiltration (cryptitis) and crypt abscesses consistent with appendix involvement by UC. Following appendectomy, the patient made a rapid and uneventful recovery; he was asymptomatic one day after the operation and was discharged home on day 2. Six months later, the colitis remained in complete clinical remission, and there has been no recurrence of right lower quadrant symptoms. The authors suggest that this patient's acute appendiceal pain syndrome derived from a complex interplay of mucosal immune, vascular, and neurogenic factors, driven by a localized, active focus of UC. Appendectomy provided both the diagnosis and the cure of this acute illness. The authors conclude that although rare (and perhaps underrecognized), acute right lower quadrant pain in the setting of clinically quiescent UC may herald active ulcerative appendicitis, rather than typical suppurative appendicitis. 1 figure. 24 references.
•
Sensorineural Hearing Loss and Ulcerative Colitis Source: Journal of Laryngology and Otology. 111(3): 277-278. March 1997. Contact: Available from Headley Brothers Ltd. The Invicta Press, Ashford, Kent, England TN24 8HH. Fax 01483-451874.
Studies
11
Summary: The association of sensorineural hearing loss and ulcerative colitis is well documented and it is speculated that this is autoimmune in origin. This article reports the case of a 12 year old boy who developed acute onset asymmetrical hearing loss, at the same time as a diagnosis of ulcerative colitis (UC) was made. He was treated with olsalazine and prednisolone for three months; his bowel symptoms were controlled and his hearing improved almost immediately. Four years after the onset of disease, he experienced bilateral, profound sensorineural hearing loss in spite of good control of his bowel disease. Tests of immune function showed a raised IgA suggestive of chronic immune response, positive anti-nuclear antibodies, and an ESR of 35 mm per hour. The patient's hearing thresholds did not improve following maximal steroid therapy. Treatment with immunosuppressive drugs was offered to the patient but he refused this line of treatment after the potential side effects were explained to him. Immunological tests may provide a clue as to the etiology of suspected cases of autoimmune inner ear disease. The authors stress that immediate treatment with steroids, with or without immunosuppressive therapy, is essential since delay may lead to irreversible hearing loss. 3 figures. 11 references. (AA-M). •
Is Maintenance Therapy Always Necessary for Patients with Ulcerative Colitis in Remission? Source: Alimentary Pharmacology and Therapeutics. 13(3): 373-379. March 1999. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: The efficacy of sulfasalazine and mesalazine in preventing relapse in patients with ulcerative colitis (UC) is well known. It is less clear how long such maintenance should be continued, and if the duration of disease remission is a factor that affects the risk of recurrence. This article reports on a study undertaken to determine whether the duration of remission affects the relapse rate by comparing the efficacy of a delayed release mesalazine against placebo in patients with UC and whose remission is of short or long duration. The study included 112 patients (66 men, 46 women, mean age 35 years) whose intermittent chronic UC in clinical, endoscopic and histologic remission with sulfasalazine or mesalazine for at least 1 year. Patients were stratified according to the length of their remission, prior to randomization into group A (in remission from 1 to 2 years) or group B (in remission for over 2 years, median 4 years). Patients were treated daily with 1.2 grams of oral mesalazine, for a followup period of 1 year. In group A, while no difference was found between the two treatments after 6 months, mesalazine was significantly more effective than placebo in preventing relapse at 12 months. By contrast, in group B, no statistically significant difference was observed between the two treatments, either at 6 or 12 months. Patients in group B were older, and the disease and remission had lasted longer in their case. The authors conclude that mesalazine prophylaxis is necessary for the prevention of relapse by patients with UC in remission for less than 2 years. This study casts doubt on whether continuous maintenance treatment is necessary in patients with prolonged clinical, endoscopic, and histologic remission, and who are at very low risk of relapse. 2 figures. 1 table. 20 references. (AA-M).
•
Induction and Maintenance of Clinical Remission by Interferon-B in Patients with Steroid-Refractory Active Ulcerative Colitis: An Open Long-term Pilot Trial Source: Alimentary Pharmacology and Therapeutics. 16(7): 1233-1239. July 2002.
12
Colitis
Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: The imbalance of pro and anti-inflammatory cytokines plays an important role in the pathogenesis (development) of inflammatory bowel disease (IBD). Shifting this disturbed ratio by means of TNF antibodies or interferon has been shown to be helpful in treating Crohn's disease (a type of IBD) and multiple sclerosis, respectively. This article reports on a pilot study that investigated whether interferon beta can induce clinical remission in patients with corticoid-refractory ulcerative colitis (UC, another type of IBD, n = 25). Twenty-two of the 25 patients (88 percent) went into remission during induction treatment. Mean time to response was 3.0 weeks (plus or minus 1.3 weeks); mean length of remission was 13.0 months (plus or minus 19.7 months). Only eight of 22 patients in remission relapsed during maintenance treatment. Five of these went into remission again after increasing the dose. Adverse events consisted of slight to moderate flu-like symptoms and slight to moderate hair loss in five of 15 female patients. The authors conclude that, although this open pilot study included only a small number of patients, the high response rate suggests that interferon beta may be a safe and effective treatment for steroid refractory active UC. 31 figure. 4 tables. 33 references. •
Clinical Evaluation and Management of Acute Severe Colitis Source: Inflammatory Bowel Diseases. 6(3): 214-227. August 2000. Contact: Available from Lippincott Williams and Wilkins, Inc. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030. Fax (301) 824-7390. Summary: The patient with acute severe colitis usually presents with frequent diarrheas that are more or less bloody. Fever and abdominal pain occur, but not always. This review article concentrates on the clinical evaluation, imaging, therapy, and prognostic factors in acute severe colitis of idiopathic (unknown) as well as infectious origin. The authors note that an immediate rigid rectosigmoidoscopy is essential for diagnosis and quick fecal sampling for cultivation of fecal pathogens, including Clostridium difficile toxin if there is suspicion of such an infection. The medical history and rectosigmoidoscopic appearance is usually sufficient to make a preliminary diagnosis of ulcerative colitis (UC). The next step is to evaluate the severity of the attack, extent of inflammation in the colon, and prognostic factors. Plain abdominal x-ray is often sufficient for a preliminary opinion about the extent of disease if the lumen is outlined by gas. The authors describe the superiority of colonoscopy performed at an early state, compared to other imaging modalities. Colonoscopy is the most adequate technique to evaluate both the extent and degree of inflammation, and the degree of ulceration. The introduction of early stage surgery resulted in a dramatic decrease in mortality due to severe attacks of UC. However, intensive medical treatment (rather than surgery) of a severe or moderately severe attack of UC may be followed by longstanding remission. This intensive treatment is based on corticosteroids, total parenteral nutrition (TPN), bowel rest, and antibiotics. Other treatments discussed include cyclosporine A, tacrolimus, anti tumor necrosis factor (TNF) alpha; the authors also discuss factors predicting outcome. A short section on Crohn's disease is followed by a section on acute infectious colitis, including the role of various pathogens, including Campylobacter jejuni, Yersinia enterocolitica, Escherichia coli, Salmonella, Shigella, Aeromonas, Clostridium difficile, Entamoeba histolytica, and cytomegalovirus. 188 references.
Studies
•
13
Update in Medical Therapy of Ulcerative Colitis: A Practical Approach Source: Journal of Clinical Gastroenterology. 34(4): 397-407. April 2002. Contact: Available from Lippincott Williams and Wilkins, Inc. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2300. Summary: The vast array of medications use in the therapy of inflammatory bowel disease (IBD) often confounds the clinician in the choice of specific agents regarding the balance between safety and efficacy. This review article surveys and evaluates the currently available IBD therapies as well as those used in clinical trials of ulcerative colitis (UC). The author provides the busy clinician with a practical guide to the use of established and newly emerging medical therapies of IBD. The approach to therapy is divided into categories for the treatment of mild to moderate, moderate to severe, and severe disease; maintenance strategies; and pouchitis. The author stresses that the key is to design an individualized program geared to each patient's specific needs. The practitioner must evaluate the patient's response to treatment with each visit, weighing the risks of drug toxicity, cancer surveillance, long-term debility, and surgical candidacy. 9 tables. 129 references.
•
Long-Term Aminosalicylate Therapy is Under-used in Patients With Ulcerative Colitis: A Cross-Sectional Survey Source: Alimentary Pharmacology and Therapeutics. 16(11): 1889-1893. November 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: There is evidence from case-control studies that aminosalicylates drugs can reduce colorectal cancer risk by 75 to 81 percent in patients with ulcerative colitis. Patients may fail to comply with long-term therapies, however, or may have been advised to discontinue treatment once in remission. This article reports on a study undertaken to describe the usage of long-term aminosalicylates therapy in patients with ulcerative colitis (UC). The cross-sectional study was performed using data extracted from general practitioner clinical records on demographic features, extent and duration of disease, use of aminosalicylates therapy, and specialist care. The study included 363 people who had UC and no history of colorectal surgery. Ninety-five of 175 patients (54 percent) with proctitis, 78 of 123 patients (63 percent) with left-sided colitis, and 28 of 45 patients (62 percent) with extensive colitis were currently taking an aminosalicylate drug. Those doing so were more likely to be under specialist care than to be definitely or possibly discharged. The likelihood of current aminosalicylates therapy was not related to gender or the extent of disease, but was negatively related to the duration of disease. The authors conclude that a substantial minority of patients with ulcerative colitis does not take long-term aminosalicylates therapy. Those who do are more likely to be under specialist care, to be older, or to have disease of shorter duration. 2 tables. 23 references.
•
Review Article: Insurance Risks for Patients With Ulcerative Colitis or Crohn's Disease Source: Alimentary Pharmacology and Therapeutics. 11(1): 51-59. February 1997. Contact: Available from Mercury Airfreight International, Ltd. 2323 EF, Randolph Avenue, Avenel, NJ 07001. E-mail:
[email protected].
14
Colitis
Summary: This article addresses the issue of insurance risks for patients with ulcerative colitis (UC) or Crohn's disease. Prospective population-based studies have allowed a reevaluation of the risks of insuring patients with UC or Crohn's disease. Life expectancy, the risk of cancer, and working capacity are very much better than previously recognized and are normal for many patients. Three population-based studies in UC have shown a mortality similar to or slightly less than the general population except in the first year after diagnosis, while two have shown a slightly higher mortality, except for those with proctitis. In Crohn's disease, two populationbased studies have also shown an increased mortality that is similar to that of unskilled manual laborers from all causes of death. Three other studies have shown no increase in overall mortality, except in the first 5 years after diagnosis, in those with proximal small intestinal disease, and in some patients needing multiple operations. Insurance risks should be evaluated on an individual basis, after details of the extent and pattern of disease have been obtained. Although the 'standard life' in insurance terms differs from that of the general population, because people who seek life insurance are self-selected from a more affluent section of society, many patients can be identified who have a particularly good prognosis. These include patients with ulcerative proctitis, those with leftsided colitis in extended remission (more than 12 months), and patients more than 30 years old with localized ileal or ileocecal Crohn's disease that has responded to treatment. The author concludes that, from the published data, it is difficult to justify increasing the insurance premium in such patients. 6 tables. 23 references. (AA-M). •
Rare Case of Ulcerative Colitis Complicating Wilson's Disease: Possible Association Between the Two Diseases Source: Journal of Clinical Gastroenterology. 35(1): 43-45. July 2002. Contact: Available from Lippincott Williams and Wilkins, Inc. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2300. Summary: This article describes a rare case of ulcerative colitis (UC, a type of inflammatory bowel disease, or IBD) complicated by Wilson's disease. Wilson's disease is a genetic disorder in which failure of copper excretion causes accumulation of copper in the liver and other organs. In this case, a 24 year old Japanese man, UC occurred 12 years after the diagnosis of Wilson's disease, and the colitis was intractable to prednisolone and salazosulfapyridine. Because copper is one of the trace elements necessary for antioxidant defenses during the inflammatory process, altered copper metabolism may have contributed to the intractability of the UC in this case. 2 figures. 31 references.
•
Collagenous Colitis and Lymphocytic Colitis Source: Journal of Clinical Gastroenterology. 30(3): 245-249. April 2000. Contact: Available from Lippincott Williams and Wilkins, Inc. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2300. Summary: This article discusses the most recently recognized and least understood forms of inflammatory bowel disease (IBD), two types of idiopathic microscopic colitis: collagenous colitis and lymphocytic colitis. Collagenous and lymphocytic colitis are the two recognized presentations of microscopic colitis, a syndrome of chronic watery diarrhea with a chronic inflammatory infiltrate in the colonic mucosa and without specific endoscopic abnormalities. These disorders share many clinical and histologic features, but they have a few notable differences. Whether these are two distinct entities or different presentations of the same disease remains controversial. Bismuth salicylate
Studies
15
is effective in some patients and treatment is symptomatic and empirical in others. Unlike ulcerative colitis (UC) and Crohn's disease (CD), these forms of inflammatory bowel disease rarely require surgery. Ileostomy with or without colectomy is curative for the rare patient with severe symptoms that are refractory to medical measures. Collagenous and lymphocytic colitis are not associated with an increased risk of malignancy. 4 figure. 48 references. •
Surgical Options in Ulcerative Colitis Source: Surgical Clinics of North America. 77(1): 85-94. February 1997. Contact: Available from W.B. Saunders Company. Periodicals Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 654-2452. Summary: This article outlines controversies in surgical options for ulcerative colitis (UC). The authors review the current literature concerning pouch design, the need for a defunctioning ileostomy after the ileal pouch-anal anastomosis, whether a mucosectomy should be performed, and whether a pouch is safe in the setting of cancer. The J configuration appears to be satisfactory if sufficient length of terminal ileum is used. Functional outcome does not appear to be affected if a mucosectomy is performed. The need for defunction should be based on technical and patient-related considerations. Early cancer does not contraindicate ileal pouch-anal anastomosis. 4 tables. 40 references. (AA).
•
Modern Medical Management of Acute, Severe Ulcerative Colitis Source: European Journal of Gastroenterology and Hepatology. 9(9): 831-835. July 1997. Contact: Available from Rapid Science Publishers. 400 Market Street, Suite 750, Philadelphia, PA 19106. (800) 552-5866 or (215) 574-2210. Summary: This article outlines the medical management indicated for patients with acute, severe ulcerative colitis (UC), a condition that the authors stress requires careful in-hospital assessment of the patient and the coordinated treatment of a team of experienced gastroenterologists and surgeons. Complete understanding of the potential complications and their management, especially toxic megacolon, is essential. The authors review the current medical arsenal and advocate a standardized approach to management that includes continuous, high dose intravenous hydrocortisone, more aggressive use of topical steroids as well as feeding the patients and continuing (but not initiating) oral 5-aminosalicylic acid (5-ASA) agents. For those patients whose disease proves refractory to intravenous steroids, intravenous cyclosporin (with an acute response rate of 82 percent) is an essential component of medical management. Antibiotics should be used only when specifically indicated. Total parenteral nutrition has not been shown to be helpful in the acute setting. Air contrast barium enema and colonoscopy have been used to predict response but may be dangerous diagnostic modalities in these acutely ill patients and are no better than good clinical judgment. The authors review and advocate long term management of acute response using 6mercaptopurine or azathioprine. The surgical experience and the postoperative complications of the ileal pouch anal anastomosis, which include acute pouchitis in 50 to 60 percent, chronic pouchitis in 5 to 10 percent, and recent reports of dysplasia among patients with chronic pouchitis, must be considered before colectomy is advised. The authors conclude that more than 80 percent of patients with acute severe colitis can be spared colectomy using the current arsenal of drug therapies. 27 references (20 annotated). (AA-M).
16
Colitis
•
Transient Ischemic Colitis in Young Adults Source: American Family Physician. 56(4): 1103-1108. September 15, 1997. Summary: This article presents and describes three cases in young adults of transient ischemic colitis, a benign, self-limited form of colitis. The authors note that this disorder should be included in the differential diagnosis in patients presenting with abdominal pain and hematochezia or bloody diarrhea. Estrogen or oral contraceptive therapy is associated with transient ischemic colitis, so its use should further raise suspicion. The effectiveness of discontinuation of estrogen therapy is controversial, but this measure should be considered. Conservative management includes repeated careful assessment, pain management, and fluid replacement. Complications are rare and the prognosis is excellent. A potential long term complication of transient ischemic colitis is colonic stricture formation from mucosal scarring. Occasionally, patients have recurrences. 3 figures. 2 tables. 22 references. (AA-M).
•
Guidelines for the Diagnosis and Management of Clostridium Difficile-Associated Diarrhea and Colitis Source: American Journal of Gastroenterology. 92(5): 739-750. May 1997. Summary: This article presents guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis in adults. Guidelines for clinical practice are intended to suggest preferable approaches to particular medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. C. difficile causes a spectrum of diarrheal syndromes that vary widely in severity and merge with one another. The author considers the pathophysiology and epidemiology of C. difficile diarrhea, the clinical manifestations, diagnostic guidelines, primary treatment, management of relapses or recurrences of C. difficile diarrhea or colitis, and guidelines for prevention. The typical symptoms of C. difficile diarrhea are cramping abdominal pain, profuse diarrhea consisting of mucoid, greenish, smelling, water stools, low grade fever, and leukocytosis. These can start a few days after antibiotic therapy is begun or up to 8 weeks after its discontinuation. The differential diagnosis of C. difficile diarrhea includes benign or simple antibiotic-associated diarrhea, acute and chronic diarrhea caused by other enteric pathogens, adverse reactions to various medications other than antibiotics, ischemic colitis, idiopathic inflammatory bowel diseases, and intraabdominal sepsis. One table presents guidelines for preventing C. difficile diarrhea; these include limiting the use of antimicrobial drugs, washing hands between contact with all patients, using stool isolation precautions for patients with C. difficile diarrhea, and educating the medical, nursing, and other appropriate staff members about the disease and its epidemiology. 4 tables. 63 references. (AA-M).
•
Ulcerative Colitis Practice Guidelines in Adults Source: American Journal of Gastroenterology. 92(2): 204-211. February 1997. Summary: This article presents the ulcerative colitis (UC) practice guidelines in adults from the American College of Gastroenterology. Guidelines for clinical practice are intended to indicate preferred approaches to medical problems as established by scientifically valid research. Guidelines are intended to be flexible and must be distinguished from standards of care, which are inflexible and rarely violated. Ulcerative colitis recommendations are presented for diagnosis and assessment, for management of mild-moderate distal colitis, for maintenance of remission in distal disease, for management of mild-moderate extensive colitis, for management of severe
Studies
17
colitis, for surgery, and for cancer surveillance. In a patient presenting with persistent bloody diarrhea, rectal urgency, or tenesmus, stool examinations and sigmoidoscopy and biopsy should be performed to confirm the presence of a colitis and to rule out infectious causes. Characteristic endoscopic and histologic findings with negative evaluation for infectious causes will suggest the diagnosis of UC. Patients with mild to moderate distal colitis may be treated with either oral aminosalicylates, topical mesalamine, or topical steroids. When the acute attack is controlled, a maintenance regimen is usually required, especially in patients with severe, extensive, or relapsing disease. The patient with severe colitis refractory to maximal oral treatment with prednisone, oral aminosalicylate drugs, and topical medications, or the patient who presents with toxicity, should be treated for 7 to 10 days with intravenous steroids. Failure to demonstrate significant improvement within 7 to 10 days is an indication for either colectomy or treatment with intravenous cyclosporine in specialized centers. After 8 to 10 years of colitis, annual surveillance colonoscopy with multiple biopsies at regular intervals should be performed. 119 references. (AA-M). •
Lower Gastrointestinal Bleeding and Ischemic Colitis Source: Canadian Journal of Gastroenterology. 16(9): 597-600. September 2002. Contact: Available from Pulsus Group, Inc. 2902 South Sheridan Way, Oakville, Ontario, Canada L6J 7L6. Fax (905) 829-4799. E-mail:
[email protected]. Summary: This article reports on a study that compared the incidence and clinical characteristics of lower gastrointestinal (LGI) bleeding due to ischemic colitis with those with LGI bleeding of other causes. A chart review was performed of patients admitted with LGI bleeding to Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, between July 1, 1997 and January 31, 2000. Of 124 patients with LGI bleeding, 24 cases were due to ischemic colitis, 62 to diverticulosis, 11 to inflammatory bowel disease (IBD), and 27 to all other causes ('others'). The average ages of patients in each group were 66.5, 76.5, 40.5, and 77.5 years, respectively. Patients with ischemic colitis were statistically younger than those with diverticular bleeding and 'others.' Patients with IBD were younger than those in the other three groups. The only statistical difference for vascular disease risks was hypertension, because of its absence from the IBD group. Three patients with ischemic colitis underwent blood transfusions, while 23 with diverticulosis, 15 'others' and none with IBD received blood. Three patients with ischemic colitis and one patient from the 'others' group died. More women (75) than men (49) had LGI bleeding, in total and within each subgroup. Of women with LGI bleeding, many more with ischemic colitis (44.4 percent) than with diverticulosis (3.0 percent), IBD (0 percent) or 'others' (5.6 percent) were taking estrogen. 16 references.
•
Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial Source: Annals of Internal Medicine. 126(5): 364-371. March 1, 1997. Summary: This article reports on a study undertaken to determine the efficacy of transdermal nicotine for controlling clinical disease activity in active ulcerative colitis (UC), a type of inflammatory bowel disease (IBD). The doubleblind, placebo controlled design studied 64 nonsmoking patients with mildly to moderately active UC despite the use of medication. Patients were stratified on the basis of smoking history, extent of disease, and concomitant medical therapy. After stratification, patients were randomly assigned to daily treatment with transdermal nicotine (n = 31) at the highest tolerated dose (11 mg for 1 week and then less than 22 mg for 3 weeks) or placebo (n = 33).
18
Colitis
Clinical features were assessed at baseline and at 4 weeks by endoscopy, physician assessment, and a patient diary of daily symptoms. At 4 weeks, 12 of 31 patients (39 percent) who received nicotine showed clinical improvement compared with 3 of 33 patients (9 percent) who received placebo. Four patients receiving nicotine discontinued therapy because of side effects (contact dermatitis, nausea, acute pancreatitis). The authors conclude that transdermal nicotine administered at the highest tolerated dosage for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active UC. The authors briefly consider the phenomenon of 'opposite effects' wherein smoking adversely affects Crohn's disease (another type of IBD). 2 figures. 4 tables. 21 references. (AA-M). •
Surgery for Ulcerative Colitis: Historical Perspective, A Century of Surgical Innovations and Refinements Source: Diseases of the Colon and Rectum. 42(3): 299-306. March 1999. Contact: Available from Williams and Wilkins. 352 West Camden Street, Baltimore, MD 21201-2436. Summary: This article reviews a century of surgical innovations and refinements in the treatment for ulcerative colitis (UC). The authors begin with a discussion of the early role of surgery (1890s) and the Brooke ileostomy, then discuss ileorectal anastomosis, Kock's continent ileostomy, the ileoanal anastomosis, and the evolution and refinements of these techniques. In the early 20th century, UC as a disease entity was largely unknown and almost never resected. Initially, surgeons used cecostomies or appendicostomies to irrigate and put the bowel at rest. Diversion of the fecal stream by ileostomy or colostomy had some proponents, but the inadequacies of stomas and stoma appliances and the risk of surgery limited its use. It was not until Brooke devised and successfully used the everted ileostomy that complete removal of the disease began to be practiced more widely and that surgery became an integral part of therapy. It was the advent of Kock's continent ileostomy that revolutionized the entire surgical approach to UC by eliminating the need for an external appliance and still curing the disease. The ileal pouch anal anastomosis provided patients with a curative resection and a functional outcome that gave them an even better quality of life, without the need for a permanent external appliance or a stoma. 4 figures. 64 references.
•
Microscopic Colitis: Collagenous Colitis and Lymphocytic Colitis Source: Practical Gastroenterology. 26(9): 41-42, 44, 46, 48. September 2002. Contact: Available from Shugar Publishing. 12 Moniebogue Lane, Westhampton Beach, NY 11978. (516) 288-4404. Fax (516) 288-4435. Summary: This article reviews collagenous colitis and lymphocytic colitis are chronic relapsing diarrheal illnesses, which are often referred to together as microscopic colitis. Microscopic colitis most commonly occurs in women in their fifth to sixth decade. The symptoms usually include profuse watery diarrhea and crampy abdominal pain. Laboratory and endoscopic studies are generally normal but microscopic inflammation is seen when colonic biopsies are performed. In collagenous colitis there is a subepithelial collagen band in addition to chronic inflammation in the lamina propria (the layer of connective tissue just below the epithelium). The etiology (cause) is not known, but multiple theories exist including autoimmune, infectious, and medicationinduced. Although the course is generally benign, patients may have multiple relapses over many years. Treatment regimens vary and have included anti-diarrheals,
Studies
19
antibiotics, 5-aminosalicylates, steroids, and immunosuppressive agents. 2 figures. 3 tables. 32 references. •
Maintenance of Remission in Ulcerative Colitis Source: Alimentary Pharmacology and Therapeutics. 16(Supplement 4): 21-24. July 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: This article reviews strategies undertaken to maintain remission in patients with ulcerative colitis (UC, a type of inflammatory bowel disease, or IBD). The author notes that 70 percent of patients with UC can expect to experience a relapse over a 12 month period. Sulfasalazine was the first drug demonstrated to reduce this relapse rate to 21 percent. Subsequent studies have demonstrated that 5 aminosalicylic acid (5ASA) is the main active component and preparations containing only 5ASA have similar efficacy to sulfasalazine. 5ASA is readily absorbed from the small intestine; special release formulations are indicated. A variety of 5ASA preparations is available, differing in their release mechanisms, efficacy, and side effect profile. Most patients can be maintained in remission using oral 5ASA medication. For patients with distal or left sided disease, the use of rectal 5ASA is also of proven benefit in maintaining remission. Some patients with frequent or severe relapses require stronger immunosuppression, and in those patients, azathioprine or 6 mercaptopurine (6MP) are of proven benefit. Azathioprine is also of great use for maintaining remission in patients who have been treated with cyclosporine for a fulminant acute episode of colitis. The author concludes by commenting that the area of natural therapies (probiotics) deserves further exploration. 14 references.
•
Colitis: Key Components of the Evaluation Source: Consultant. 38(2): 375-378, 381-383. February 1998. Contact: Available from Cliggott Publishing Company. 55 Holly Hill Lane, Box 4010, Greenwich, CT 06831-0010. Summary: This article reviews the key components of the evaluation of colitis. Colitis is a nonspecific condition that has a variety of causes, including inflammatory bowel disease, infections, ischemia, radiation, and antibiotic therapy. The mainstays of evaluating patients who have colitis include the history and physical examination, sigmoidoscopy with mucosal biopsy, stool examination, and barium radiography. These tools are used to determine if colitis is present, how severe it is, the cause of the colitis, and the anatomic extent of the disease. In addition to the typical symptoms of colitis (diarrhea, abdominal pain, and tenesmus), the authors recommend that physicians look for signs of more severe disease, such as orthostasis, pallor, fever, fatigue, and tachycardia. Also, physicians should be alert for extraintestinal manifestations of chronic inflammatory bowel disease (IBD), such as mouth ulcers, erythema nodosum, and arthritis. Laboratory findings that may suggest severe colitis include a low hemoglobin level, leukocytosis, an elevated erythrocyte sedimentation rate, and hypoalbuminemia. After confirming the presence of colitis with proctosigmoidoscopy or flexible sigmoidoscopy, stool cultures and parasite testing should be ordered to identify the specific cause. Complications of colitis include toxic megacolon, perforation, hemorrhage, and obstruction in ischemic disease. 4 figures. 3 tables. 16 references. (AAM).
20
Colitis
•
Review Article: The Management of Severe Ulcerative Colitis Source: Alimentary Pharmacology and Therapeutics. 11(3): 419-424. June 1997. Contact: Available from Mercury Airfreight International, Ltd. 2323 EF, Randolph Avenue, Avenel, NJ 07001. E-mail:
[email protected]. Summary: This article reviews the management of severe ulcerative colitis (UC), a potentially life threatening condition. The authors note that the mortality has fallen dramatically over the past 4 decades to less than 2 percent, including surgical mortality. Early recognition of the severity of the colitis, intensive medical therapy, close liaison between physician and surgeon, and prompt surgery when necessary have all contributed to this improved outcome. Despite the use of high-dose intravenous corticosteroids, 20 to 30 percent of patients will make a poor response and will require urgent surgery. The use of intravenous cyclosporin has proved effective at reducing the immediate surgical rate in this group of unresponsive patients and appears safe. Whether cyclosporin reduces the need for surgery in the longer term is much less uncertain. The authors describe how clinical, radiological, endoscopic, and laboratory parameters can now be used to predict the course of a severe attack. These help in the timing of urgent surgery and are potentially helpful in determining when to begin other therapies such as cyclosporin. 1 table. 36 references. (AA-M).
•
Ulcerative Colitis: Surgical Indications and Treatment Source: Alimentary Pharmacology and Therapeutics. 16(Supplement 4): 25-28. July 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: This article reviews the treatment options for ulcerative colitis (UC, a type of inflammatory bowel disease, or IBD), including the surgical indications. The author notes that the indication for surgery is a balance between the severity of the disease despite full medical treatment and the potential disadvantages of surgery. The decision requires cooperation between the gastroenterologist and surgeon. Colectomy with ileostomy and preservation of the rectum in the emergency setting is the accepted procedure and can rapidly restore the patient to normal health, allowing withdrawal of anti-inflammatory medication. After recovery, all surgical possibilities are then open for the future. The elective indications for surgery include failure of medical treatment, retardation of growth in a child or adolescent, and neoplastic (precancerous) transformation. The choice of operation includes conventional proctocolectomy, restorative proctocolectomy (RPC), and colectomy with ileo-rectal anastomosis. Causes of failure include sepsis (50 percent), dysfunction (30 percent), and pouchitis (10 percent). In selected cases, salvage surgery to avoid failure can be successful with rates of around 70 percent for outlet obstruction and fistulation and 50 percent for pelvic sepsis. 26 references.
•
Monitoring Activity in Ulcerative Colitis Source: Alimentary Pharmacology and Therapeutics. 16(Supplement 4): 3-6. July 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com.
Studies
21
Summary: This article reviews therapeutic strategies and the monitoring of patients with ulcerative colitis (UC, a type of inflammatory bowel disease, or IBD). The authors note that monitoring is easier in these patients than in patients with Crohn's disease (another type of IBD) for several reasons. The severity of symptoms and activity of inflammation tend to run parallel in UC when involvement of the large bowel is more extensive. The easy accessibility of the colonic mucosa by endoscopic and histologic examination provides further information concerning the degree of inflammation. In severe attacks, the patients must be admitted to the hospital and monitored carefully. Clinical and laboratory parameters (such as daily stools, CRP, fever, hemoglobin, albumin, etc) and plain abdominal x-ray are useful in monitoring the activity of the disease and to predict the outcome. In mild to moderate attacks, endoscopic and histologic evaluation are the best methods for choosing the appropriate treatment and for assessing response. 2 tables. 18 references. •
Is the Appendix a Vestigial Organ? Its Role in Ulcerative Colitis Source: Gastroenterology 121(3): 730-737. September 2001. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. (800) 654-2452. Website: www.gastrojournal.org. Summary: This article summarizes a research study that considers the role of the appendix in ulcerative colitis (UC, a type of inflammatory bowel disease), including the possible role of appendectomy (removal of the appendix) in protecting against UC. The author briefly reviews the research in this area, then focuses on one particular study that was reported in the New England Journal of Medicine in 2001 (Andersson, R.E., et al, Volume 344). The investigators in that study conclude that the inflammatory response leading to an appendectomy rather than the removal of the appendix was the significant clinical factor negatively associated with developing UC at a later date. The absence of this protective effect in older patients with appendicitis also suggests that the immune mechanisms resulting in appendicitis in these patients may differ from those resulting in appendicitis before the third decade. The author then appends a lengthy commentary exploring the ramifications of these results. The author concludes that in the absence of evidence supporting a more causal role for the appendix, adoption of therapeutic appendectomy as a strategy to affect the incidence or clinical course of UC is premature, despite recent case reports suggesting clinical improvement and reduction in mucosal inflammatory mediators after appendectomy. Numerous studies are referred to in the text of this article.
•
Ulcerative Colitis in Adults: Summary of the Latest Practice Guidelines Source: Consultant. 37(4): 1085-1086. April 1997. Contact: Available from Cliggott Publishing Company. 55 Holly Hill Lane, Box 4010, Greenwich, CT 06831-0010. Summary: This article summarizes the latest practice guidelines (developed by the American College of Gastroenterology) for the assessment and treatment of ulcerative colitis (UC) in adults. Stool examinations, sigmoidoscopy, and biopsy are indicated to confirm the presence of colitis and to rule out infectious causes in patients who have persistent bloody diarrhea, rectal urgency, or tenesmus. The mucosal changes characteristic of UC, as detected by proctosigmoidoscopy or colonoscopy, include loss of the typical vascular pattern, granularity, friability, and ulceration. Once the diagnosis is confirmed, it is necessary to establish whether the inflammation is distal or extensive. Oral aminosalicylates, topical mesalamine, or topical corticosteroids are appropriate for
22
Colitis
patients with mild to moderate distal colitis. Oral corticosteroids should be reserved for patients whose disease is refractory to oral aminosalicylates. Mercaptopurine or azathioprine is effective in patients who do not respond to oral prednisone, provided they are not so acutely ill that they require intravenous therapy. A maintenance regimen is usually required for patients with mild to moderate extensive colitis, particularly those who have severe or relapsing disease. In adults with UC, the absolute indications for surgery are exsanguinating hemorrhage, perforation, and documented or strongly suggested carcinoma. Surgery is also indicated in patients with severe colitis (with or without toxic megacolon) that is unresponsive to conventional maximal medical therapy and in patients with less severe but medically intractable symptoms or intolerable corticosteroid side effects. Annual cancer surveillance colonoscopy with multiple biopsies at regular intervals is warranted after 8 to 10 years of colitis. 1 table. 4 references. •
Surgical Outcomes in Ulcerative Colitis and Crohn's Disease Source: Canadian Journal of Gastroenterology. 13(10): 804-805. December 1999. Contact: Available from Pulsus Group, Inc. 2902 South Sheridan Way, Oakville, Ontario, Canada L6J 7L6. Fax (905) 829-4799. E-mail:
[email protected]. Summary: This article summarizes two descriptive studies that provide information on the postoperative aspects of patients who have undergone colonic resective surgery for ulcerative colitis (UC) or Crohn's disease (the two types of inflammatory bowel disease, or IBD). For UC, colonic resection usually results in amelioration of the morbid effects of the disease and substantially eliminates the risk of later malignancy. For Crohn's disease, especially with extensive colonic involvement, resection of the colon and rectum may also be required. For most patients, the early short term results of these surgical therapies have been generally quite satisfactory, with the goal being that the patient may return to a normal life as soon as possible following treatment. For patients with UC, operative treatment is performed during the most sexually active and reproductive years. Thus, most patients faced with restorative proctocolectomy (removal of the colon) may have significant concerns related to sexual function and fertility following surgical treatment. Sexual dysfunction may develop in males, but with variable frequency. In the second study, of Crohn's disease patients undergoing total colectomy and ileostomy, preoperative steroid therapy and associated perforating disease were associated with a high incidence of postoperative complications. The author stresses that convincing data on the effectiveness of antibiotic regimens, immunosuppressive agents or biological therapies (e.g., antitumor necrosis factor) are simply not available, particularly data that may demonstrate a more transient benefit. Until truly effective medical therapies for anorectal disease becomes available, proctocolectomy may well be the surgical treatment of choice.
•
Ulcerative Duodenitis with Ulcerative Colitis: Is It Crohn's Disease Or Really Ulcerative Colitis? (editorial) Source: Journal of Clinical Gastroenterology. 32(2): 97. February 2001. Contact: Available from Lippincott Williams and Wilkins, Inc. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2300. Summary: This editorial comments on an accompanying article in which two patients present the dilemma in differentiating between Crohn's disease and ulcerative colitis (the two subtypes of inflammatory bowel disease, IBD). The first case was that of a man, 31, with a history of left sided colitis who subsequently developed erosive duodenitis
Studies
23
responsive to methylprednisolone. The second case was that of a woman, 30, with pancolitis who was admitted for closure of an ileostomy after a staged subtotal proctocolectomy with ileoproctostomy and diverting ileostomy. Her hospital course was complicated by the development of ulcerative duodenitis, again responsive to methylprednisolone. Crohn's disease may involve the stomach, the duodenum, or both, usually in conjunction with a more distal disease, although this is not always the case. Ulcerative colitis, on the other hand, is a disease of the colon almost always involving the rectum. The authors conclude that upper gastrointestinal tract inflammation (such as duodenitis) warrants further observation and maximum documentation to sustain the issue of whether ulcerative colitis can involve the upper gastrointestinal tract. They note that there might be a third type of IBD, whether occurring from a separate origin or arising from conversion of one type of IBD to the other. 8 references. •
Explaining Ulcerative Colitis to Friends and Family Source: Insights and Answers. 7-8. Summer 1999. Contact: Available from Insights and Answers. P.O. Box 3217, Cincinnati, OH 452738266. (800) 663-6698. Website: www.living-better.com. Summary: This newsletter article, written by a man with ulcerative colitis (UC, one of the types of inflammatory bowel disease) considers the issues involved in explaining UC to friends and family members. The author underscores the need of letting family and friends be supportive, help the patient through everyday trials and tribulations, comply with the recommended treatment schedule, and stay focused on recovery. The author lists the benefits of telling loved ones about UC, and then offers strategies for exactly how to go about telling them about the disease. These strategies include gather general information, practice what is going to be said, pick out an appropriate time and place to talk, and explain why it is important for them to learn about the disease. The author concludes by reminding readers that even the smallest efforts of support and words of encouragement can go a long way toward helping others who are coping with inflammatory bowel disease.
•
Under the Microscope: Research News Bulletin from the Crohn's and Colitis Foundation of America Source: Under the Microscope. Summer 2001. p. 1-6. Contact: Available from Crohn's and Colitis Foundation of America (CCFA). 386 Park Avenue South, 17th Floor, New York, NY 10016-8804. (800) 932-2423. E-mail:
[email protected]. Website: www.ccfa.org. PRICE: Single copy free. Summary: This newsletter offers a summary of research news that may be of interest to people with Crohn's disease or colitis. The articles review current research activities, focusing on those projects supported by the Crohn's and Colitis Foundation of America (CCFA). For example, this issue includes a report on a recent breakthrough in the genetic understanding of Crohn's disease, a report on the Digestive Disease Week conference (the major medical conference of the year for everyone who plays a role in studying and treating inflammatory bowel disease, IBD), and sidebars about current research projects in which readers may wish to participate. The news report from Digestive Disease Week covers clinical trials of IBS medications, including entanercept, infliximab, Budesonide, and natalizumab; adolescents in transition; cancer surveillance in IBD; animal models of IBD; and a burden of disease (economic) study. 2 figures.
24
Colitis
•
Surveillance Issues in Inflammatory Bowel Disease: Ulcerative Colitis Source: Journal of Clinical Gastroenterology. 32(2): 99-105. February 2001. Contact: Available from Lippincott Williams and Wilkins, Inc. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2300. Summary: This review article on the surveillance of patients with ulcerative colitis (UC) provides an overview of the criteria for evaluating screening and surveillance programs and applies the criteria to the available evidence to determine the effectiveness of the surveillance of patients with UC. The authors examine the clinical outcomes associated with surveillance, the additional clinical time required to confirm the diagnosis of dysplasia and cancer, compliance with surveillance and followup, and the effectiveness of the individual components of a surveillance program, including colonoscopy and pathologist's interpretation. The disability associated with colectomy is considered, as are the cost and acceptability of surveillance programs. Patients with longstanding UC are at risk for developing colorectal cancer, therefore recommended surveillance colonoscopy should be supported. The diagnosis of cancer at an early stage in this group is associated with a good prognosis. The authors conclude that new endoscopic and histopathologic techniques used to improve the identification of high risk patients may enhance the effectiveness and cost effectiveness of surveillance practices. 2 figures. 5 tables. 44 references.
•
Therapy for Ulcerative Colitis Source: Current Opinion in Gastroenterology. 14(4): 312-316. July 1998. Contact: Available from Lippincott-Raven Publishers. 227 East Washington Square, Philadelphia, PA 19106. (800) 638-3030. Summary: This review article presents the 1997 literature on the medical therapy of ulcerative colitis (UC). Several recent studies have addressed aspects of this topic, including optimization of current therapies, pilot studies, definitive placebo-controlled trials of newer novel therapies, and reports of associated complications. Combination therapy with rectal and oral 5-aminosalicylate may be more effective than either formulation alone, and the renal safety of high-dose oral 5-aminosalicylate has been confirmed. Rectal 5-aminosalicylate is more effective than conventional rectal corticosteroids, and delayed release oral budesonide may also be beneficial for patients with active UC. Treatment with intravenous cyclosporine is only required in 22 percent of patients with severe UC, and cyclosporine may be associated with severe toxicity, including death. Transdermal nicotine is effective in treating active UC but results in side effects, which may be overcome by administering nicotine directly to the colon. Preliminary studies suggest that both anti-tumor necrosis factor-alpha antibody and heparin may benefit patients with UC. Also, 5-Lipoxygenase inhibitors, short chain fatty-acid enemas, olestra, and ciprofloxacin are not effective therapies for UC. Oral therapy with a probiotic bacterial preparation may maintain remission in patients with UC. Finally, folate or folinic acid may decrease rectal cell proliferation and subsequent development of neoplasia (cancer) in patients with longstanding UC. 60 references (13 annotated). (AA).
•
Surgical Therapy for Ulcerative Colitis Source: Ostomy Quarterly. 34(1): 36-40. January 1997. Contact: Available from Ostomy Quarterly. 36 Executive Park, Suite 120, Irvine, CA 92614-6744. (800) 826-0826 or (714) 660-8624. Fax (714) 660-9262.
Studies
25
Summary: Ulcerative colitis (UC) is a disease that involves the inner lining (mucosa) of the colon and rectum. While the cause of UC remains elusive, surgical removal of the entire colon and rectum is curative. The authors of this article describe surgical therapy for UC. They note that the indications for surgery can be divided into three categories: immediately life threatening, chronically disabling, and an increased cancer risk. They discuss each of these indications and then describe the advantages and disadvantages of each of five surgical alternatives for managing UC. Those alternatives are subtotal colectomy with ileostomy, colectomy with ileorectal anastomosis, proctocolectomy with Brooke ileostomy, proctocolectomy with continent ileostomy, and proctocolectomy with ileal pouch anal anastomosis. The authors stress that, as in all operations, the risks of surgical therapy must be balanced against the benefits to the patient. The risks of surgery include the morbidity and mortality associated with the procedure itself and the alteration in lifestyle resulting from the removal and reconstruction of the colon and rectum. The benefits include a cure of UC if the entire colon and rectal mucosa is removed, removing the risk of developing cancer, and improving an individual's lifestyle. Limitations in social activities such as work, as well as the lack of well-being and a reduced energy level, are often significantly improved after surgery. 5 figures. 2 tables. 9 references. •
Avoiding Common Errors in Maintenance Therapy for Ulcerative Colitis Source: Practical Gastroenterology. 22(4): 49-50, 52, 54-56, 58. April 1998. Contact: Available from Shugar Publishing, Inc. 99B Main Street, Westhampton Beach, NY 11978. (631) 288-4404. Fax (631) 288-4435. E-Mail:
[email protected]. Summary: Ulcerative colitis (UC) is a medically incurable chronic disease in which the mucosal lining of the colon becomes inflamed. The goal of medical therapy is to quickly induce remission and maintain it for as long as possible, without creating side effects or adversely affecting quality of life. This article outlines strategies to avoid common errors in maintenance therapy for UC. The authors note that, since therapy is often lifelong, the chance for treatment errors is greatly increased. Aminosalicylates are usually the best choice for long term maintenance of mild to moderate disease. Corticosteroids can quell acute flares in moderate to severe disease, but are contraindicated as maintenance therapy. Immunomodulators are safe and effective as maintenance therapy in more severe cases of steroid resistance and steroid dependence. All of these drugs are safe during pregnancy. Antibiotics are rarely helpful, but resumption of cigarette smoking may sometimes be recommended in lieu of surgery (the potentially life threatening adverse effects associated with smoking must be weighed heavily against the benefits). The only cure for UC is colectomy, which can significantly increase the quality of life for patients who have chronically active symptoms despite optimal medical management. 3 tables. 31 references. (AA-M).
•
Ulcerative Colitis in Young Adults: Complexities of Diagnosis and Management Source: Postgraduate Medicine. 103(1): 45-49, 53-54, 56, 59. January 1998. Contact: Available from McGraw-Hill, Inc. 1221 Avenue of the Americas, New York, NY 10020. (612) 832-7869. Summary: Ulcerative colitis (UC) is difficult to differentiate from other inflammatory bowel diseases or to treat with precision. This article discusses the characteristics of UC, the medications used to treat it, and the challenge of recognizing and managing UC. The intestinal inflammation associated with UC may involve the entire colon (36 percent of the patients), or be limited to distal areas such as the left colon (17 percent) or rectum (46
26
Colitis
percent). Patients with active disease commonly present with bloody diarrhea, abdominal pain, and rectal urgency. However, symptoms may differ depending on the extent of the colonic inflammation. The diagnosis of UC depends on a combination of findings from the history, physical examination, laboratory evaluation, and endoscopic and histopathologic studies, as well as exclusion of other causes of colitis. Response to therapy and continued observation of the patient over time help to confirm the diagnosis. The author reviews the medical treatment of ulcerative colitis and summarizes factors related to ulcerative colitis, including smoking status, nutritional therapy, and cancer. The mainstays of treatment are sulfasalazine for mild to moderate disease and corticosteroids for moderate to severe disease. Side effects of sulfasalazine limit its use in some patients. Refractory UC is best treated surgically. 1 figure. 2 tables. 23 references. (AA-M). •
Ulcerative Colitis: A Rational Approach to Management Source: Consultant. 41(4): 541-548. April 1, 2001. Contact: Available from Cliggott Publishing Company. 330 Boston Post Road, Darien, CT 06820-4027. (203) 661-0600. Summary: Ulcerative colitis (UC), a type of inflammatory bowel disease can manifest as proctitis or proctosigmoiditis, left sided colitoss, or pancolitis. This article offers a rational approach to the management of patients with UC. Frequent low volume bowel movements, urgency, rectal bleeding, and tenesmus (ineffective spasms of the rectum) alone suggest proctitis. Prostration, fever, tachycardia (racing heartbeat), dehydration, and complications of blood loss (which may or may not be accompanied by symptoms of proctitis) suggest more severe disease or more extensive bowel involvement. For patients with mild to moderate disease, mesalamine is recommended to induce and maintain remission. Systemic corticosteroids can induce remission in patients with moderate to severe disease but are not useful for maintenance therapy. Azathioprine or 6 mercaptopurine can be used to wean patients with moderate to severe colitis from corticosteroids and to maintain remission. If severe colitis does not respond to corticosteroids, immunosuppressive therapy or colectomy may be needed. Other indications for surgery include development of acute complications related to disease activity and chronic complications, such as dysplasia, carcinoma, recurrent hemorrhage, or growth retardation in children. Annual surveillance colonoscopy with biopsy is recommended for patients with pancolitis and left sided colitis.
•
Increase in Colorectal Epithelial Apoptotic Cells in Patients with Ulcerative Colitis Ultimately Requiring Surgery Source: Journal of Gastroenterology and Hepatology. 17(7): 758-764. July 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Up to one-third of patients with ulcerative colitis (UC) need to undergo surgery, but the factors that exacerbate inflammation (and thus lead to surgery) remain unclear. The authors of this study hypothesize that excessive apoptosis (sloughing of skin crust) reported in active UC may disrupt epithelial defenses and exacerbate the disease. The present study was undertaken to clarify whether apoptotic epithelial cells and histiocytes engulfing them increased in patients with active UC who ultimately require surgery (UC-S) rather than those receiving medication alone (UC-M). The study included 29 patients with UC-S, 35 patients with UC-M, 18 with infectious colitis, and 16
Studies
27
healthy controls. The apoptotic indices in UC-M patients were significantly higher than those in controls but almost equal to those in infectious colitis patients. In the upper and lower halves of the mucosa, both apoptotic indices and histiocyte densities were significantly higher for UC-S than in UC-M. The results suggest that epithelial apoptosis is a non-specific phenomenon and that an increased number of apoptotic cells exceeding histiocyte phagocytic capacity may play a part in the disruption of epithelial defenses and further accelerate mucosal inflammation. 2 figures. 2 tables. 38 references.
Federally Funded Research on Colitis The U.S. Government supports a variety of research studies relating to colitis. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to colitis. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore colitis. The following is typical of the type of information found when searching the CRISP database for colitis: •
Project Title: AGING AND INTESTINAL NEURO-IMMUNE REGULATION IN COLITIS Principal Investigator & Institution: Javed, Najma H.; Physiology and Health Science; Ball State University Muncie, in 47306 Timing: Fiscal Year 2000; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: The long term goal of the proposed project is to elucidate the role of intestinal immune system in modulating the activity of the enteric nervous system in inflammatory bowel disease (IBD) in our aging population. There is much evidence which indicates functional decline in systemic immune responses with aging. However there is no clear evidence suggesting specific effects of aging on gastrointestinal associated immune system and enteric nervous system. The fact that gastrointestinal tract is the largest immune organ in the body, has been ignored and much less attention has been given to the role of lamina propria T cells and intraepithelial lymphocytes (IEL), and antibody producing B cells. The changes may be related to quantitative and qualitative release of cytokines and inflammatory mediators and their interaction with secretory neurons within the wall of the gut. With the use of Lewis rat colitis model (chemical induction), we will pursue the following specific aims: 1) To ascertain if colonic tissues from rats have altered neurosecretory responsiveness associated with age during experimental colitis; 2) To ascertain the immunohistological distribution pattern, quantitation and phenotypic localization of T and B cells in intestinal compartment of
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
28
Colitis
Lewis rats of various age groups; 3) To isolate and ascertain the activity of isolated intestinal T cells to proliferate by in vitro proliferative assay; 4) To analyze cytokine profiles of the immune T cells such as IL-1, IL-2, IL- 4, IL-6, IL-8, IFN-gamma among others which accompany the induction of inflammatory response in-he gut; 5) To study the histological and ultra structural changes within the intestine during inflammatory phase in different age groups. The results of this study will contribute significantly to our knowledge of neuroimmune interactions and their role in IBD in aging rats. It will also provide insight into etiology, pathogenesis and strategies for management and basis for future development and selection of therapeutic measures for different age groups for intestinal inflammatory conditions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTI-INFLAMMATORY INFLAMMATION
LIPIDS
IN
ACUTE
MUCOSAL
Principal Investigator & Institution: Gronert, Karsten; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-DEC-2004 Summary: (provided by applicant) Inflammatory bowel diseases (IBD) that are associate with a dramatic increase in colorectal cancer occur throughout the world with an annual incidence of approximately 12/100,000 people. Aberrant activation of neutrophils and a profound increase in lipid and peptide mediators are cardinal signs of these inflammatory diseases as well as for ischemia reperfusion injury, a known complication of surgical procedures. How acute inflammatory responses switch from vital host defense to aberrant inflammation and neutrophil mediated tissue injury remains to be completely elucidated. Therefore, endogenous mechanisms that disrupt proinflammatory circuits are of interest. Aspirin and omega-3 polyunsaturated fatty acids (PUFA) are therapeutic agents that demonstrate benefits in inflammatory diseases as well as prevention of colon cancer. However, their mechanisms of action still needs to be clearly defined but targets the formation of lipid mediators namely eicosanoids. Both therapeutic agents trigger the formation of novel classes of anti-inflammatory lipids, namely 15R-lipoxins and omega-3 PUFA derived 15R-and 18R-series eicosanoids. This study shall test the hypothesis that acute inflammation induces a regulated and temporal generation of anti-inflammatory lipid signals and that omega-3 fatty acid and aspirin augment these protective lipid mediator circuits. The specific aims of this application will employ a combined approach of structural elucidation, molecular biology and transgenics to delineate three main aspect of the role of lipid signals in neutrophil mediated intestinal injury: i) Establish the temporal relationship of pro- and anti-inflammatory eicosanoids. ii) Determine the impact of aspirin and omega-3 PUFA on eicosanoid profiles and elucidate novel protective lipid mediators. iii) Determine if novel aspirin and omega-3 PUFA triggered lipid mediators are protective against aberrant PMN activation and if changes in expression of receptors for lipid mediators are markers for aberrant intestinal inflammation. The broad and long-term objectives of this application are to elucidate endogenous pathways that block PMN mediated injury to promote resolution of inflammation. Results from this project may provide novel anti-inflammatory tools for controlling inflammatory diseases such as Ulcerative Colitis and Chron's Disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
29
Project Title: AUTOIMMUNE MECHANISM IN ULCERATIVE COLITIS Principal Investigator & Institution: Das, Kiron M.; Professor; Medicine; Univ of Med/Dent Nj-R W Johnson Med Sch Robert Wood Johnson Medical Sch Piscataway, Nj 08854 Timing: Fiscal Year 2001; Project Start 30-SEP-1993; Project End 31-AUG-2003 Summary: The overall hypothesis for this proposal is that in patients with ulcerative colitis (UC) the colonic epithelium expresses autoantigen(s) which ma drive the immune destruction of the epithelial cells. We earlier identified a putative colonic autoantigen, p40, that belongs to cytoskeletal tropomyosin (TM) family, and majority of UC sera react with p40/TM. Utilizing recombinant hTM isoforms (hTM-5) and isoform specific monoclinal antibodies (mAb) developed by us, we have observed that the normal colon epithelial cells (CEC) contain mostly hTM5 and hTM4 and not hTM1-3. We demonstrated autoantibody response in UC against hTM5 and hTM1. We will examine if there is any qualitative and/or quantitative differences in hTM isoform expression I CEC from UC compared. Using the hTM5 isoform, we identified two HLA DR2-binding peptides. We will focus on T cell responses against hTM5 and the peptides. We will also examine I cells responses against hTM4 and other hTM isoforms. For T cell responses, we will use both peripheral blood mononuclear cells (PBMC) and lamina propria lymphocytes (LPL). We have shown both in UC mucosa as well as in selected colon cancer cells that UC associated autoantibodies bind at the same site as the 7E12H12 mAb (developed by us earlier using highly enriched p40) does. This mAb has unique organ distribution such as colon, biliary tract, skin, eyes and joints. Recently we identified that 7E12H12 mAb reacts with unioval colonic epithelial protein (CEP) of Mr>200K. Preliminary experiments suggest that CEP may act as a "shuttle" to externus hTM5. We will critically examine the relationship between hTMs and CEP. Using purified CEP, we will also be cloned. Human colon cDNA expression libraries from normal and UC colon mucosa and cDNA libraries from two colon cancer cell lines are developed and will be utilized. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PATHWAYS
BACTERIAL
MODULATION
OF
EPITHELIAL
SIGNALING
Principal Investigator & Institution: Neish, Andrew S.; Pathology; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-AUG-2004 Summary: (adapted from the application) Salmonella typhimurium is a common cause of food-borne enterocolitis in this country and the developing world. The clinical manifestations of Salmonella typhimurium infection result from inflammatory cells that are recruited to, and accumulate in, the intestinal mucosa. The intestinal inflammatory response is mediated in large part by synthetic upregulation of secreted cytokines and other inflammatory effector molecules. These inflammatory mediators are activated at the transcriptional level by the action of DNA binding transcription factors such as NFkappaB. Experiments with cultured intestinal epithelial cells have shown that S. typhimurim associated with inflammatory intestinal disease activate NF-kappaB via a calcium dependant activation pathway, while other, non-pathogenic Salmonella strains repress activation of this key regulator. Our overall hypothesis is that Salmonella (and potentially other enteric bacteria) have evolved novel mechanisms to modulate epithelial signaling pathways that may serve to establish either a pathologic or a commensal state. Elucidation of these influences will increase our understanding of the
30
Colitis
epithelial and bacterial factors involved in human enterocolitis, as well as the microbiology of this class of enteric infections. This application describes a variety of experimental methods to study the host inflammatory response including pathogen induced calcium dependant activation of the NF-kappaB pathway. These methods will be applied to signals elicited by S. typhimurium, a series of Salmonella mutants and variety of other enteric pathogens. Secondly, similar assays will be used to study the mechanism by which some bacteria repress host immune and inflammatory reactions by modulation of the NF-kappaB signaling cascade. These studies will be supported using well characterized murine models of intestinal inflammation to correlate the antiinflammatory properties of these bacteria in vivo. Finally, a novel electroporation based method to introduce purified proteins into intact model epithelia will be used to dissect the cellular responses to internalization of a variety of bacterial effector proteins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BACTERIOPHAGE THERAPY IN C DIFFICILE INTESTINAL DISEASE Principal Investigator & Institution: Rolfe, Rial D.; Microbiology and Immunology; Texas Tech University Health Scis Center Health Sciences Center Lubbock, Tx 79430 Timing: Fiscal Year 2001; Project Start 15-FEB-1999; Project End 31-JAN-2004 Summary: Toxigenic Clostridium difficile is the cause of essentially all cases of antibiotic-induced pseudomembranous colitis, a life-threatening disease, and the cause of approximately 40 percent of cases of antibiotic-induced diarrhea without intestinal inflammation. The present therapy for patients with C. difficile-associated intestinal disease is the administration of an antibiotic directed against C. difficile. However, there are problems with this current therapy including disease relapse, normal flora disruption, and antibiotic resistance. An alternative to antibiotic therapy of C. difficileinduced intestinal disease is the therapeutic use of bacteriophage. Recent studies indicate that bacteriophage can persist and multiply in tissue, blood and the intestinal tracts of animals and can be effective therapeutic and prophylactic agents. Preliminary experiments demonstrate that administration of bacteriophage to hamsters, treated with clindamycin and a toxigenic strain of C. difficile, prevents development of a fatal ileocecitis. It is the purpose of this research application to more rigorously examine these bacteriophage. Specific Aim number 1 will isolate and characterize a collection of C. difficile bacteriophage with respect to their virulence and host-range so that the most effective phages for use in in vivo studies will be identified. Specific Aim number 2 will examine in vivo properties of C. difficile bacteriophage and their efficacy in the treatment and prevention of C. difficile-associated intestinal disease employing a hamster animal model. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BLOOD BASED IBD DIAGNOSIS USING MICROARRAY GENE PROFILES Principal Investigator & Institution: Dervieux, Thierry; Prometheus Laboratories, Inc. 5739 Pacific Center Blvd San Diego, Ca 921214203 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): The pathogenesis of ulcerative colitis (UC) and Crohn's disease (CD) has been the focus of an intense research effort to improve diagnostic accuracy, shorten the time to confirmed diagnosis, identify new therapeutic agents, and predict responses to therapeutic agents. Inflammatory bowel disease (IBD)
Studies
31
continues to present monumental challenges to the basic understanding of the onset and control of inflammatory processes. However, the new science of microarray gene expression profiling provides an incomparably powerful technique to 1. identify the molecular participants of the inflammatory process and 2. differentiate the mechanisms of these IBD diseases at the molecular level. Microarray technology allows the simultaneous study of thousands of expressed genes and the comparison of diseased versus control gene expression profiles. The goal of this project is to apply microarray gene expression technology to patient matched peripheral blood and biopsy samples and directly compare over-expressed and under-expressed genes in CD and UC versus non-IBD controls. From the thousands of genes studied, this project seeks to identify a very small number of genes (a Focused Gene Expression Profile) that will allow development of an accurate, non-invasive blood test for IBD diagnosis and definitive stratification of Crohn's disease and ulcerative colitis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BOVINE SPECIFIC VIRULENCE FACTORS OF S.TYPHIMURIUM Principal Investigator & Institution: Baumler, Andreas J.; Associate Professor; Medical Microbiol & Immunology; Texas A&M University Health Science Ctr College Station, Tx 778433578 Timing: Fiscal Year 2003; Project Start 01-DEC-1998; Project End 31-MAY-2007 Summary: (provided by applicant): Salmonella serotypes are the leading cause of foodborne infections with lethal outcome in the United States. The pathogenesis of this diarrheal disease has not been intensively studied in Salmonella since diarrhea does not develop in rodent models. In contrast, calves infected with S. Typhimurium develop similar signs of disease and pathology as observed in humans. Our long-range goal is to elucidate the molecular mechanisms involved in the pathogenesis of S. Typhimuriuminduced enterocolitis. The objectives of this application are to study how the invasion associated type III secretion system (TTSS-1) of S. Typhimurium directs migration of neutrophils into the intestinal mucosa and to determine the role of neutrophils in causing fluid accumulation and intestinal pathology in the calf. Our central hypothesis is that upregulation of CXC chemokines in the bovine intestinal mucosa induced by TTSS-1 secreted effector proteins elicits a neutrophil influx, which is the main mechanism leading to tissue injury and diarrhea during S. Typhimurium-induced enterocolitis. The rationale for the proposed research is that a better understanding of the complex series of events leading to inflammation and fluid accumulation during the interaction of S. Typhimurium with host tissue in vivo will be required for the development of new and innovative approaches for treatment and prevention. We will test different aspects of our hypothesis by pursuing the following four specific aims: (1) Determine the role of TTSS-1 in inducing the production of CXC chemokines in the intestinal mucosa; (2) Investigate CXC chemokine expression in bovine tissue on the cellular level; (3) Determine the contribution of CXC chemokines to neutrophil recruitment during S. Typhimurium induced enterocolitis; (4) Determine the role of neutrophils in S. Typhimurium induced fluid accumulation. We are particularly well prepared to perform the proposed studies because we have established the calf model of human enterocolitis and have identified S. Typhimurium virulence factors, which are essential for causing this disease syndrome. It is our expectation that our approach will establish the complex series of events leading to fluid accumulation during enterocolitis. This outcome will be significant because identification of the key events during S Typhimurium interaction with host tissue in vivo will have a considerable impact on the design of in vitro models used by other investigators in the field.
32
Colitis
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CENTER FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE Principal Investigator & Institution: Podolsky, Daniel K.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2001; Project Start 05-FEB-1991; Project End 31-DEC-2005 Summary: (Adapted from the application) The Center for the Study of Inflammatory Bowel Disease (CSIBD) is a multidisciplinary program to define fundamental mechanisms underlying Crohn?s disease and ulcerative colitis. This Center encompasses sixty-seven investigators at the Massachusetts General Hospital (MGH) and allied institutions pursuing research in a broad spectrum of basic science relevant to IBD. Since its formation eight years ago, the CSIBD has served as a vehicle to achieve advances in our understanding of these diseases through the study of relevant basic biological processes and the directed study of the diseases themselves. The research program of this Center is organized around the central hypothesis that IBD results from activation by luminal antigens (dietary or microbial in origin) of an upregulated chronic immune response due to genetically determined alterations of epithelial cell or immune function including, a lack of appropriate downregulatory functions. Major advances made possible by the CSIBD in the nine years since its inception include the development and characterization of new genetic mouse models of IBD, delineation of mechanisms of lymphocyte activation and leukocyte recruitment to sites of inflammation, identification of key peptides involved in sustaining mucosal integrity, characterization of the mechanisms of mucosal healing following injury, and improved understanding of the regulation of mucosal immune responses and the complex network of regulatory peptides (cytokines) that modulate mucosal immune and epithelial cell function. Over the next five years, the CSIBD will promote further progress in the study of basic aspects of mucosal biology with translation to the study and treatment of IBD using the tools of molecular and cellular biology. A major focus of CSIBD research in the next five years will be the coordinated multi-disciplinary study of mechanisms leading to chronic intestinal inflammation in the available murine genetic models of "IBD". Experiments will delineate interactions between environmental factors and different genetic loci. The overall goal of advancing our knowledge of IBD will continue to be carried out through five Biomedical Cores. These include Molecular Biology, Morphology and Immunology Cores to provide access to advanced technologies. The Genetic Animal Models and Clinical/Tissue Cores will provide access to relevant animal models and patient tissues for study. In addition to advancing the understanding of IBD per se, the goals of this Center will continue to include the recruitment of established investigators to the study of IBD, enhancing collaboration among Center investigators and encouraging the development of young investigators committed to pursuing IBD research. These goals are fostered by Pilot/Feasibility Study awards which support new research initiatives as well as an enrichment program of seminars, workshops and symposia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHEMOKINE SIGNALING AND COLITIS IN GIA2 DEFICIENT MICE Principal Investigator & Institution: Edwards, Robert A.; Pathology; University of California Irvine Campus Dr Irvine, Ca 92697 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007
Studies
33
Summary: (provided by applicant): Following MSTP-funded MD/ PhD training, residency and board certification in combined Anatomic and Clinical Pathology at Baylor College of Medicine, Dr. Edwards is currently conducting a year-long research fellowship at the University of Michigan. This revised application has been developed in the course of research performed at these two institutions. It address the role of Gprotein coupled chemokine signaling in T-cell activation, trafficking, and polarized cytokine production in the Gia2-deficient mouse model of inflammatory bowel disease. Deletion of the G-protein alpha subunit Gia2 in mice produces diffuse colitis which can progress to invasive adenocarcinoma, mimicking human ulcerative colitis. Much evidence suggests a central role for G-protein coupled chemokine signaling in mucosal immunity. Before clincial disease is present, T-cells from Gia2 (-/-) mice spontaneously develop a Th1 phenotype, producing elevated levels of Th1-type cytokines (TNFa, IFNg, and IL12). Two new lines of transgenic mice expressing Gia2 only in CD4+ T-cells or colon epthelium are currently being produced and will be used to investigate the mechanisms whereby Gi alpha subunit- dependent signaling contribute to maintaining balanced T-cell responses to environmental antigen. T-lymphocyte subsets from wildtype, Gia2 (-/-), and transgenic mice as described above will be studied to identify whether they respond normally to Th1- or Th2- skewing conditions. These cells will also be used to determine whether particular Gi alpha subunits selectively couple with chemokine receptors known to be involved in T-cell activation and differentiation. Finally, these cells will be screened for changes in chemokine and chemokine receptor expression patterns using gene array, TagMan, and RPA analysis. The responses seen in vitro will be correlated with the development of disease in the strains of mice. These experiments will provide insight into the specificity with which chemokine receptors couple with individual G-protein alpha subunits, and how the loss of Gia2 may lead to alterations in chemokine signaling that predispose to colitis. This application has the support of outstanding mentors at two institutions, and funding of this application will foster Dr Edwards' continued development as a physician-scientist. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHEMOKINES IN HOST DEFENSE TO CAMPYLOBACTER JEJUNI Principal Investigator & Institution: Dwinell, Michael B.; Microbiol & Molecular Genetics; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532264801 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): This R21 research proposal, submitted in response to "Biodefense and Emerging Infectious Diseases Research Opportunities", NOT-AI-02023, has two specific aims designed to increase our understanding of the pathogenesis of Campylobacter jejuni enterocolitis. The intestinal epithelium comprises a dynamic physical barrier that maintains an active repertoire of innate host defense responses to limit entry of clinically significant food- and water-borne pathogens. These mechanisms include the regulated production of chemokines to coordinate the appropriate innate and adaptive immune effector response. C. jejuni is a leading cause of bacterial diarrheal disease in the world. However, while relatively little is known of the pathophysiologic mechanisms employed to infect the human intestinal tract and elicit disease, interaction at the intestinal epithelium is the most common pathogenic feature of infection. The overall objective of this research proposal is to obtain novel information on the mechanisms of pathogenesis to C. jejuni enterocolitis and will, as an important first step, focus on the coordinated production of chemokines by the cells of the intestinal epithelium as a significant host defense mechanism. Studies in Aim 1 will test the hypothesis that C. jejuni infection of human intestinal epithelial cells stimulates
34
Colitis
production of chemokines for neutrophils, dendritic cells and T lymphocytes, effectors cells that we postulate act in concert to limit C. jejuni entry in vivo. A culture model intestinal epithelium will be infected with C. jejuni and the signaling mechanisms regulating epithelial chemokine production assessed. To define bacterial pathogenicity, studies in Aim 2 will utilize C. jejuni mutants to test the hypothesis that specific Campylobacter virulence factors induce host epithelial cell chemokine expression. Induction of epithelial chemokine expression will be tested in C. jejuni flagella mutants, as well as mutants selected from candidates revealed from a promoter trap-based approach to define novel virulence factors. Together, these studies will provide new insights into the cellular signaling mechanisms and bacterial gene products regulating intestinal epithelial chemokine production as a central host defense function to C. jejuni. Understanding the cellular and biochemical mechanisms of intestinal epithelial host defense to human C. jejuni infection are central to the development of preventative therapeutic strategies to modulate host-pathogen interactions to favor the host. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL COMPONENT Principal Investigator & Institution: Plevy, Scott E.; Associate Professor of Medicine; Children's Hosp Pittsburgh/Upmc Hlth Sys of Upmc Health Systems Pittsburgh, Pa 15213 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008 Summary: The clinical component of the University of Pittsburgh Autoimmune Center of Excellence proposes three clinical trials targeting autoimmune disorders involving three different organ systems. In the first trial, a non-Fc receptor-binding anti-CD3 humanized monoclonal antibody will be studied in patients with moderate to severe corticosteroid-refractory ulcerative colitis (UC). The specific immunomodulatory agent is Visilizumab, developed and manufactured by Protein Design Laboratories, Inc. This is a humanized IgG2 monoclonal antibody with amino acid substitutions in the CH2 domain of the Fc region, designed to reduce binding to the FcR and minimize toxicities associated with conventional anti-CD3 monoclonal antibodies. This study is based on preliminary data derived from a Phase I dose escalation trial of anti-CD3 in patients with UC led by investigators at the University of Pittsburgh. In the Phase I trial, five of five patients treated at the lowest proposed dose (15 mcg/kg on two consecutive days) were in clinical remission by day 30. In the new study, the investigators propose to enroll a total of 100 subjects who will be randomly assigned to two treatment groups at a 1:1 ratio. Group 1 will receive a placebo infusion and Group 2 will receive anti-CD3 mAb as a single IV injection. The primary end-point will be the proportion of patients with a clinical remission at week 4. No mechanistic studies are proposed in the context of this clinical trial. The second clinical trial is a Phase I dose escalation study of Visilizumab in patients with rheumatoid arthritis (RA). The study design is derived from the ongoing Phase I dose escalation study in UC at the University of Pittsburgh that served as the basis for the first clinical trial in this component. Twenty patients with active RA will be enrolled in the study. Eligible patients will receive Visilizumab at one of four dose levels (15, 45, 90, and 120 mcg/kg) administered as a single IV injection on each of two consecutive days. Five patients will be treated at each dose level. The primary objective of the study is to evaluate the safety and tolerability of Visilizumab when administered to patients with severe RA. The secondary objective is to obtain preliminary evidence of biologic activity in RA and document clinical responses, as defined by the ACR20 Response Criteria for Improvement. Clinical Trial 3 proposes to develop and test a microsphere-based vaccine for Type I diabetes mellitus (T1DM). The
Studies
35
rationale for this trial is indirectly derived from data developed by the investigators in the NOD mouse using a dendritic cell-based approach to induce immune hyporesponsiveness to autoantigens involved in the pathogenesis of DM. In those studies, dendritic cells (DC) were modified with antisense oligonucleotides or decoys to modulate expression of CD40, CD80, CD86, and/or NF kappa B transcription factor. Because of appropriate concerns about the logistical and regulatory issues associated with the development of a cell-based therapy, the investigators propose to develop a microsphere-based vaccine consisting of dendritic and Langerhans cell (LC) mobilizing factors and immunoregulatory oligonucleotides that will arrest the deterioration of residual beta cell mass in new onset T1DM. The investigators postulate that injection of microspheres releasing chemokines into the skin will recruit DC and LC to the injection site. Immunoregulatory oligonucleotides incorporated into the microsphere will be taken up by the antigen presenting cells, converting them to a tolerizing phenotype. No pre-clinical data supporting the activity of these microspheres in the NOD model are provided. The proposed clinical trial is a safety trial of a vaccine for T1DM that will involve sequential administration of water-based microspheres containing LC and DC attractive chemokines, followed by injection of a second microsphere containing either NF kappa B oligonucleotides decoys or antisense oligonucleotides to CD40, CD80, and CD86. In Specific Aim 1, the investigators will assess the safety of single and multiple administrations of microsphere encapsulated combinations of DC/LC attracting chemokines and immunoregulators in normal volunteers and recent onset T1DM. In Aim 2, the investigators propose to examine the clinical efficacy of single and multiple administrations of microspheres in recent onset T1DM. In Aim 3, the investigators will evaluate immune responses in microsphere-treated individuals and correlate the results with clinical remission or improvement. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTRACTILE SIGNAL TRANSDUCTION IN ULCERATIVE COLITIS Principal Investigator & Institution: Cao, Weibiao; Rhode Island Hospital (Providence, Ri) Providence, Ri 02903 Timing: Fiscal Year 2003; Project Start 10-JAN-2003; Project End 31-DEC-2004 Summary: (provided by applicant): Ulcerative colitis is a chronic inflammatory condition affecting the large bowel: Although it is most frequent in the rectosigrnoid area, it may involve the whole colon. Inflammation in ulcerative colitis is histologically limited to the mucosa, and its effects have been better characterized in the superficial than in the deeper layers such as muscularis propria. Inflammation, however, may affect the muscle layer, leading to motor dysfunction, which contributes to key clinical symptoms, including diarrhea, constipation, and crampy abdominal pain. To define inflammation, associated changes in motor function we will examine the circular muscle from the sigmoid colon from patient with active ulcerative colitis and compare it with muscle from disease-free margins of histologically normal colon tissue from cancer resections. The sigmoid is most often involved and frequently resected, and this avoids variations associated with different anatomical locations of the disease. In preliminary experiments, we find that inflammatory mediators such as interleukin-1beta and hydrogen peroxide are present in the muscularis propria. Our central hypothesis is that inflammatory mediators, first produced by inflammatory cells in the mucosa, may induce production of additional mediators by the target cells themselves, and that in time the muscularis propria becomes affected leading to motor disturbances. We therefore propose to: A) Define inflammation-induced changes in contractile signal
36
Colitis
transduction pathways of human sigmoid colon. B) Test the effect of selected inflammatory mediators, known to be present in ulcerative colitis mucosa, to determine their individual contribution to the observed changes in colonic motor function. C) Determine whether inhibition of selected inflammatory mediators may reverse inflammation-mediated changes in colonic motor function. Examining the relationship between inflammatory mechanisms and changes in motor function may help in understanding the functional disturbances associated with ulcerative colitis and identifying new targets for therapeutic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTROL OF COLONIC MOTILITY IN HEALTH AND DISEASE Principal Investigator & Institution: Sarna, Sushil K.; Professor; Surgery; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532264801 Timing: Fiscal Year 2001; Project Start 01-APR-1984; Project End 31-DEC-2001 Summary: Abnormal colonic motility in idiopathic human ulcerative colitis as well as in animal models of colonic inflammation is characterized by the suppression of rhythmic phasic contractions, decrease n tone and increase in the frequency of giant migrating contraction (GMCs). These motility abnormalities play a key role in producing the symptoms of diarrhea, urgency of defecation and abdominal cramping. The cellular mechanisms for the generation of tone, phasic contractions and GMCs in the colon are not known. The first aim of this proposal is to investigate the roles of specific signal transduction pathways in the generation of tone and stimulation of phasic contractions in the colon. The second aim is to determine how these signal transduction pathways are modulated by the inflammatory response to suppress the tone and phasic contractions. Key intracellular messengers including cytosolic free Ca2+, Ca2+ efflux from intracellular stores, IP3, DAG and PKC, will be measured to support the physiological and pharmacological observations. Patch clamp studies will be done on freshly dissociated cells and circular muscle strips taken from normal and inflamed canine colon. Extensive in vivo and in vitro data are available from this species to help in the interpretation of our data and relating it to clinical diseases. Mucosal exposure to ethanol and acetic acid will be used to induce inflammation. The motility abnormalities in this model are similar to those reported in human ulcerative colitis. An understanding of the differences n signal transduction pathways that generate tone and stimulate phasic contractions may present the opportunity to regulate each type of contraction separately from the other. In inflammatory bowel disease and other forms of gut inflammation it would be desirable to selectively stimulation phasic contractions and tone to minimize diarrhea, urgency of defecation and abdominal discomfort. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--GENETIC ANIMAL MODEL FACILITY Principal Investigator & Institution: Terhorst, Cox; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2001; Project Start 05-FEB-1991; Project End 31-DEC-2005 Summary: (Adapted from the application) The Genetic Animal Core represents one of the centerpieces of the CSIBD's research program for the next proposed funding period. The availability of powerful murine models of IBD offers the opportunity to assess key aspects of the hypotheses underlying the development of the research program of the CSIBD. In addition, these models will allow defining mechanisms contributing to the expression of chronic intestinal inflammation. Overall, the availability of these murine
Studies
37
models allows for a rapid analysis of the contributions of genetic mutations or novel therapeutic agents to the pathogenesis of colitis. Moreover, this Core has the ability to compare and crosscheck the influence of mutations or of therapeutic agents that may illuminate underlying mechanisms in the onset of disease. The genetic mouse models used in this Core are subdivided into three categories: 1) spontaneous chronic colitis; 2) colitis induced by adoptive transfer of wt or mutant T cells into immunodeficient mice; and 3) colitis induced by bone marrow transplantation into immunodeficient mice. In addition, the Core's mandate has been expanded over the past two years in response to the needs of CSIBD investigators to include two additional services: 4) chemicallyinduced colitis in mutant mice (DSS or TNBS); and 5) isolation of intestinal epithelial lymphocytes and lamina propria lymphocytes from wt and mutant mice. Thus, the overall goals of this Core include provision of these genetic murine models to CSIBD investigators and continued development and refinement of the models themselves. The core currently has a large "menu" of mice available to center investigators, which is listed in Tables 10 and 11 in the grant application. The core will also, in collaboration with the morphology core, characterize the genetic profile of the experimental animals and parallel documentation of IBD, primarily using PCR and histology. The core will also facilitate obtaining samples from animals and finally will play a role in developing new genetic models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COX GENE REGULATION IN INTESTINAL MYOFIBROBLASTS Principal Investigator & Institution: Powell, Don W.; Professor of Medicine; Internal Medicine; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2001; Project Start 01-JUN-1999; Project End 31-MAY-2004 Summary: The general hypothesis of this grant proposal is that intestinal subepithelial myofibroblasts (ISEMF) are the source of soluble factors that modulate epithelial growth, differentiation, and repair and play a pivotal role in mucosal immunophysiology and cancer. Located at the interface between the epithelium and lamina propria, ISEMF modulate information transfer between these tissue compartments. Through elaboration of basement membrane components, prostaglandins (PGs). and growth factors, ISEMF modulate processes of epithelial cell growth, differentiation, and wound repair. One major pathway by which ISEMF influence epithelial and lamina propria cells is through the production of PGs by cyclooxygenase-2 (COX-2). Data indicate that the bulk of mucosal PG synthesis occurs in the lamina propria, possibly in ISEMF. Because COX-2 regulation appears to be different in the various cell types thus far studied, this proposed research will test the hypothesis that ISEMF are major sites of COX-2 expression and that pro- and antiinflammatory agents act in part by inducing or inhibiting COX-2 expression in ISEMF. Specific Aims: 1. Determine the mechanisms by which proinflammatory cytokines (IFN-gamma, TNFalpha, IL-1) and eicosanoids (arachidonic acid, various HETEs) induce COX-2 gene expression in ISEMF, 2. Analyze the mechanisms responsible for inhibition of COX-2 gene expression in ISEMF by antiinflammatory cytokines (IL-4, IL-13) and therapeutic corticosteroids, and 3. Characterize COX-2 expression in human ISEMF in situ and in primary ISEMF cultures from normal small intestine and colon and from various inflammatory diseases such as ulcerative colitis, Crohn's disease, and collagenous colitis and various neoplastic states such as adenomatous and hamartomatous polyps and both sporadic and familial adenomatous polyposis colon cancers. We will use an ISEMF cell line (18Co) isolated from human colon, reporter gene constructs containing
38
Colitis
full length and mutant COX-2 regulatory elements, gel shift assays, in vitro and in vivo promoter footprinting to determine the role of NF-kappaB/cRel, cEBP/NF-IL6, CREB/ATF, and other transcription factors in the induction and inhibition of COX-2 expression in ISEMF. Key findings from studies with 18Co will be confirmed in primary cultures of ISEMF from normal and various disease states. Using immunohistocytochemistry and in situ hybridization techniques we will identify the cellular sites of COX-2 gene expression in normal and diseased tissue and thus shed light on the role of ISEMF in gastrointestinal disease. These studies should define the processes which mediate signalling between intestinal subepithelial myofibroblasts and other immune and non-immune cells, and how these processes are disrupted in pathological states such as IBD, fibrotic disorders, and cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CYTOKINES AND COMPLEMENT IN NEPHRITIS AND COLITIS Principal Investigator & Institution: Lin, Feng; Pathology; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 31-JAN-2006 Summary: (provided by applicant):This proposal is for a three year training program at Case Western Reserve University (CWRU) for the development of a career in academic experimental immunology. The principal investigator, a Ph.D. in molecular biology who is now completing postdoctoral training in molecular immunology, will expand upon his skills and transition to independent research through an integrated program involving further work with his mentor and other investigators.The program will expand knowledge in the interplay of complement activation and cytokine generation in the settings of digestive and particularly renal diseases and in therapeutics in animal models. Dr. Edward Medof will mentor the PI's scientific development. He is a recognized leader in complement regulatory proteins that protect self tissues from complement attack, and pioneered research in the decay accelerating factor (DAF), the first of these to be described. He is a Professor in Pathology, is Associate Director of the CWRU Immunology Postdoctoral and Predoctoral Training Programs, and has trained numerous postdoctoral fellows and graduate students. To enhance the training, the program will include Dr. Steven Emancipator, Professor of Pathology, an authority in immunological diseases of the kidney, Dr. Alan Levine, Associate Professor of Medicine, a recognized expert in cytokines and inflammatory bowel disease, Dr. David Salant, Chief of Nephrology at Boston University, a world renowned expert in antibodyinduced renal diseases, and Dr. Peter Heeger, an expert of cellular immune mechanisms. Additional faculty will provide scientific and career advice.Research will focus on inflammatory mediators that are generated in experimental models of inflammatory bowel disease and particularly nephritis. The applicant has generated a DAF knockout mouse and shown that in the absence of DAF, tissue injury is greatly enhanced in nephrotoxic serum-induced nephritis and dextran sulfate sodium-induced colitis and in delayed, possibly NK cell-mediated allograft rejection. Specific aims are to 1) define the patterns and site(s) of cytokine production in the two disorders and characterize the mechanism of allograft rejection, 2) investigate these issues in related diseases, and 3) explore the effects of targeted recombinant DAF modules on disease pathogenesis. The results will constitute the first in vivo analysis of the interplay between complement activation and cytokine production, and could have therapeutic benefits.The integrated research activities at CWRU encompassing Pathology, Medicine, and the Biomedical Sciences Training Program incorporate diverse expertise and a full range of state-of-theart facilities that provide an ideal setting for training in specific programs. It should
Studies
39
maximize the opportunity for a promising young scientist to develop a niche for an independent career. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CYTOPROTECTIVE ROLE OF HEAT SHOCK PROTEINS IN IBD Principal Investigator & Institution: Chang, Eugene B,.; Martin Boyer Professor of Medicine; Medicine; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2003; Project Start 30-SEP-1993; Project End 31-JAN-2008 Summary: (provided by applicant): This revised renewal application proposes studies aimed at defining the regulation and mechanisms of action of two intestinal epithelial heat shock proteins (hsp), hsp25/27 and hsp72, both exhibiting epithelial- and colonspecific expression in the gut. Both hsps have essential roles protecting the gut epithelium against many forms of stress, particularly those associated with inflammation such as oxidants. From new studies of IBD and of acute and chronic experimental colitis, the expression of both hsps is significantly impaired in areas of active inflammation, a finding that would likely render the mucosa highly susceptible to extensive and severe injury. Three specific aims are proposed: (1) to further characterize the relative deficiency of hsp25/27 and hsp72 expression in areas of active mucosal inflammation, determine if perturbed expression alters the course of DSS-induced colitis, and identify potential mechanisms for selective hsp downregulation, (2) to define the determinants of normal colon- and epithelial-specific expression of hsp25 and hsp72, with particular attention to the role of colonic flora and mucosal immune cells, and (3) to understand how hsps protect four vital cell functions of intestinal epithelial cells (IEC). For the first specific aim, hsp27 and hsp72 expression and localization in normal and inflamed colons will be assessed. Unique mouse models expressing high or negligible colonic hsps will be studied to determine if the course of DSS induced colitis is mitigated by hsp presence. Potential "hsp-suppressive" cytokines will be identified. Next, we will determine what aspects of enteric flora and mucosal immunocytes maintain the in vivo expression of hsp25 and hsp72. Specific luminal and lamina propria signals that maintain hsp expression will be determined by a combination of in vitro and in vivo approaches. Finally, we will determine how oxidants, major mediators of inflammation-associated stress and injury, impair specific and vital IEC functions, e.g. (1) Na absorption mediated by the Na-H exchanger, NHE3, (2) Na, K-ATPase function and basolateral-restricted expression, (3) mitochondrial and microtubular interaction and function, and (4) tight junction-mediated barrier function. How hsps limit the extent of oxidant-induced impairment of these functions will also be examined. A better understanding of natural defense mechanisms of the gut can be exploited to develop novel therapies aimed at restoring or augmenting the impaired hsp response in areas of active inflammation to limit the extent and severity of mucosal injury in IBD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DIAGNOSIS OF DYSPLASIA BY FLUORESCENCE SPECTROSCOPY Principal Investigator & Institution: Van Dam, Jacques; Associate Professor; Medicine; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2001; Project Start 25-SEP-2000; Project End 31-AUG-2005 Summary: (Applicant's Description) The goal of this research proposal is to provide salary support to facilitate the advancement and completion of an NCl-funded clinical research proposal. The Principal Investigator, a clinically active physician scientist, is a collaborator on NCI R01 CA 53717 "Real Time In Vivo Diagnosis of Dysplasia by
40
Colitis
Fluorescence." The goal of the R01 is, in part, to develop endoscope-compatible, fluorescence spectroscopy systems for the real time detection of precancerous (dysplastic) alterations in the luminal gastrointestinal tract. Both fiber optic-based contact probe techniques for localized detection and fluorescence spectral endoscope systems for wide area imaging of disease will be developed and applied clinically. Multi-wavelength excitation fluorescence and reflectance system will be used to characterize the optical/spectroscopic properties of relevant tissue types. The results of this study will be used to select optimal excitation wavelength(s) and design fiber probes with controllable sampling depth for targeting detection of superficial lesions. By combining this information with tissue optical parameters, models of colon and esophageal fluorescence measured at colonoscopy and gastroscopy respectively, will be developed. Inverse modeling will be developed for extracting histopathological information from the clinical spectra. The existing fluorescence imaging colonoscope will be modified for additional clinical studies, including application in patients with Barrett's esophagus. The techniques developed in this program will be clinically tested for rapid detection of colorectal dysplasia/carcinoma in chronic ulcerative colitis and dysplasia in Barrett's esophagus and as such are "translational" in nature. Based on extremely successful preliminary data, light (white light) scattering spectroscopy (LSS) will be used to determine the size and degree of "crowding" of nuclei of superficial mucosal cells in the columnar-lined (Barrett's) esophagus. LSS will be used to guide the endoscopic detection (and pathological grading) of mucosal dysplasia. The Principal Investigator is devoted to training clinical researchers and will continue the formalized instruction and mentoring of young clinicians so that they may successfully engage in meaningful clinical research. In this way, the Principal Investigator will help mentor the next generation of physician scientists. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DNA MICROARRAY FOR GASTROENTEROLOGY RESEARCH Principal Investigator & Institution: Curto, Ernest V.; Integriderm, Llc. 2800 Milan Ct Birmingham, Al 35211 Timing: Fiscal Year 2001; Project Start 28-SEP-2001; Project End 31-OCT-2002 Summary: We propose to create a highly informative DNA microarray specifically for gastrointestinal (GI) research with an emphasis on genes associated with inflammatory bowel disease (IBD). RNAs will be harvested from pertinent GI tissues and cell types and screened for genes of high differential expression ("signature biomarker genes") utilizing currently available human DNA microarrays. Gene expression of GI tissues will be profiled against available sequence-validated human cDNAs (ca. 40,000). The 4400 most differentially expressed genes will be selected for inclusion on the array, providing an eight-to-ten fold enrichment of important genes over housekeeping genes. From the selected set of genes we will choose a very informative subset of 384 genes to be triplicated on the array. This triplicate subset will provide statistical validation for what we believe will be some of the most important genes in GI research. Our patentpending method will drive the selection criteria with a bias toward those genes deemed of particular interest to gastroenterology researchers. The GI array will provide researchers with a cost-effective tool to study gene expression in GI tissues. PROPOSED COMMERCIAL APPLICATIONS: The success of the human genome project has sparked growing interest into the genetics of the GI tract. Our GI array will fill a niche in this market, providing a highly informative and cost effective DNA array for researchers eager to pursue this new technology to develop new clinical diagnostics and in vitro
Studies
41
assays for drug therapies. This timely product will complement our best selling dermatology array DermArray(TM). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EARLY EVENTS IN COLITIS-ASSOCIATED COLORECTAL CANCER Principal Investigator & Institution: Chang, Wen-Chi; Fox Chase Cancer Center Philadelphia, Pa 19111 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): Ulcerative colitis is associated with an increased risk of colonic dysplasia and progression to invasive colorectal cancer (CRC). Although the molecular events required for tumor formation remain to be established, recent data suggest that this pathway differs from that of sporadic CRC. In particular, mutation of the p53 gene appears to be an early event in colitis-associated CRC as is evident from the presence of p53 mutations in the non-tumor inflamed colon tissue. In addition, 70-80% of colitis-associated CRCs have p53 mutations, but only 27% of them have APC mutations. However, there are no mouse models that recapitulate the genetic and histopathological changes that accompany human colitis-associated CRC. The dextran sulfate sodium (DSS) model of induced colitis provides a unique opportunity to evaluate the spectrum of histological changes that lead to the development of colitis and subsequent dysplasia similar to ulcerative colitis in humans. Induction of colitis in p53 mice with DSS should lead to the establishment of an excellent model with which to examine the hypothesis that inflammation-related p53 mutation is an initiating event in CRC associated with colitis. Colitis will be induced in heterozygous p53 mice (p53) by administration 4 cycles of DSS (4 days of 4% DSS followed by 17 days of plain water). The gatekeeper function of the p53 and APC genes in colitis-associated CRC will be determined by mutational analysis of these genes in microdissected inflamed noncancerous colonic epithelial cells. Microarray-based techniques will be utilized to identity early changes in the expression of genes within the inflamed noncancerous colonic epithelium that may serve as molecular targets for chemopreventivc intervention. The effect of a p53 deficiency on both the formation of colitis-associated colorectal dysplasias/cancers and the pathological characteristics of these lesions will be assessed in this mouse model by allowing animals to live for an extended period of time following DSS exposure. Establishment of the first clinically relevant model for ulcerative colitis-associated CRC is anticipated to facilitate the elucidation of the molecular mechanisms of colitis-associated colon tumor formation and the identification of cellular targets for early chemopreventive intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECT OF MUCOSAL BARRIER ON SHIGA TOXIN ABSORPTION Principal Investigator & Institution: Morgan, Timothy W.; Veterinary Pathology; Iowa State University of Science & Tech Ames, Ia 500112207 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: (provided by applicant): Diarrheal diseases caused by enteropathogenic Gram-negative bacteria are a risk factor for morbidity and mortality in people who live in both underdeveloped and developed countries including the United States. E. coli 0157:H7 has increasingly been recognized as a cause of hemorrhagic colitis and the associated complicating condition, hemolytic uremic syndrome. E. coli 0157:H7 colonizes the intestine, intimately attaches to the intestinal mucosa in a process that requires intimin (an adhesion factor), induces hemorrhage and acute inflammation, and
42
Colitis
releases Shiga toxins (Stx) that are absorbed systemically and cause vascular damage. The process by which Stx enters the systemic circulation is poorly understood. Studies in rabbits and our preliminary data suggest that reduction of leukocyte (i.e. neutrophil) adherence by adhesion molecule inhibitors reduces the clinical severity of disease and reduces death caused by E. coli 0157:H7. It is our hypothesis that damage to the intestinal mucosa enhances passive absorption and systemic spread of Stx, resulting in enhanced Stx-induced lesions in brain and blood vessels. This damage may be caused by the bacteria, the host inflammatory response, or a combination of the two. A 3-day old pig model of E. coli 0157:H7 enteritis produced by a wild type (Stx positive, intimin positive strain) will be developed. This model will be used to determine if infection by an intimin positive, Stx negative strain of E. coli 0157:H7 or if chemically induced mucosal ulceration enhance absorption of exogenous Stx. In each of these studies, one group of pigs will be treated with a selectin inhibitor, TBC 1269, to reduce neutrophil infiltration and the results wilt be compared to the non-treated control groups to determine the contribution of neutrophils to mucosal damage and Stx absorption in a 3day old pig model of E. coli 0157:H7 enteritis. The results of these studies will help define the mechanistic basis of Stx absorption, potentially leading to new therapeutic approaches to treating E. coli 0157:H7 enteritis and the associated systemic lesions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENDOGENOUS LIGANDS: ROLE IN NEUROLOGICAL DISORDERS Principal Investigator & Institution: Mechoulam, Raphael; Hewbrew University of Jerusalem Timing: Fiscal Year 2002; Project Start 15-SEP-1995; Project End 31-MAR-2007 Summary: (provided by applicant): Anandamide and 2-arachidonyl-glycerol (2-AG) which we isolated from porcine brain in 1992 and from canine gut in 1995 respectively are the major endogenous cannabinoids identified so far. We have strong indications based on chromatographic separations monitored by receptor binding studies that additional endocannabinoids are present in brain. We shall try to isolate and identify them. We have indications that 2-AG is released in brain on closed head injury and that 2-AG reduces edema and neurological consequences of the injury. We aim at solidifying the data which could show that endocannabinoids play a neuroprotective role. We have found that 2-AG reduces the formation of TNF-alpha, a multipotential cytokine. We plan to look at the activity of 2-AG with other cytokines. We plan to synthesize 2-AGtype compounds which will parallel 2-AG in its actions but will not be hydrolyzed in vivo and could thus serve as lead compounds for novel drugs with neuroprotective and anti-inflammatory activity. We have synthesized major cannabidiol (CBD) metabolites. As CBD is a potent anti-arthritic cannabinoid, with no psychotropic effects, we shall investigate the activities of these metabolites on the production of several cytokines as well as in models of multiple sclerosis and experimental colitis. We shall attempt to synthesize CB1 agonists which act outside the brain only. (Added, May 2001) 1. We have now isolated and identified a new endocannabinoid 2. We have shown that 2-AG reduces brain infarct volume and hippocampal cell death due to closed head injury. An antagonist blocks these 2-AG actions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ENTEROHEMORRHAGIC E COLI ALTER INTESTINAL FUNCTION Principal Investigator & Institution: Hecht, Gail A.; Professor of Medicine; Medicine; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612
Studies
43
Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-JUL-2005 Summary: Infection with enterohemorrhagic E. coli (EHEC), acquired from contaminated food or water, represents a major health problem worldwide with EHEC being the fourth most costly foodborne pathogen in the USA. Although many EHEC strains produce Shiga toxin (Stx), its role in pathogenesis is not understood. In some species, the presence of attaching and effacing (A/E) lesions correlate more closely with intestinal symptoms than does the expression of Stx. While the formation of A/E lesions may be sufficient to induce diarrhea, the production of Stx may be a prerequisite for hemorrhagic colitis. These findings underscore the lack of understanding of the pathogenesis of EHEC. While much effort has been focused on the extraintestinal manifestations of EHEC, the effects of this important pathogen on the intestine have been grossly understudied. The hypothesis of this proposal is that EHEC has direct effects on its initial host target tissue, the intestinal epithelium, which contribute to the associated symptoms. The studies proposed here will utilize two separate models to investigate the effects of EHEC infection on intestinal epithelial function, a reductionist model of cultured human intestinal epithelia and a murine model. Preliminary data show that two major physiological processes, tight junction (TJ) barrier function and the epithelial-initiated inflammatory cascade, are altered in both of these models following infection with EHEC. It is likely that both of these alterations contribute to EHECassociated diarrhea. The impact of EHEC infection on these physiological functions and the underlying mechanisms will be explored by three Specific Aims. The first Specific Aim is to characterize the effect of EHEC on intestinal epithelial tight junction barrier function. The mechanisms by which EHEC perturbs the TJ barrier will be addressed focusing on the role of cytoskeletal contraction and changes in key TJ-associated proteins. Specific Aim 2 is to define the signaling pathways by which EHEC activates the inflammatory response within intestinal epithelial cells. The events that lead to the activation of NF-kappaB, the upregulation of pro- inflammatory cytokines, such as IL-8, and neutrophil transmigration will be explored. The studies outlined in Specific Aims l and 2 will use the established in vitro cell culture model. Specific Aim 3 is to establish and characterize a murine model of intestinal EHEC infection, The effects of EHEC infection on TJ barrier function as well as epithelial-initiated inflammation will be explored. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENVIRONMENTAL FACTORS AND INFLAMMATORY BOWEL DISEASE Principal Investigator & Institution: Higuchi, Leslie M.; Children's Hospital (Boston) Boston, Ma 021155737 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): This K08 award application is designed to enrich the candidate's career development in the epidemiology of gastrointestinal diseases. The program integrates mentored "hands on" experience in the proposed research plan on inflammatory bowel disease (IBD), didactic coursework to advance the knowledge and skills of the candidate, and enhanced interactions with other investigators through seminars, conferences, and scientific meetings. In the later years of the 5-year proposed program, the candidate plans to expand her work in the epidemiology of pediatric gastrointestinal illnesses. The candidate's sponsor is Dr. Richard J. Grand, an accomplished pediatric gastroenterologist with significant established experience in the field of IBD. Her co-sponsor is Dr. Graham A. Colditz, the Principal Investigator of the Nurses' Health Study at the Channing Laboratory. The program combines the
44
Colitis
institutional resources of the Children's Hospital, Boston and the Channing Laboratory of the Brigham and Women's Hospital, Harvard medical School. The Research proposal is a prospective cohort study to examine the association of environmental factors and the two types of IBD, Crohn's disease (CD) and ulcerative colitis (UC). The study base population will be composed of the Nurses' Health Study (NHS I) and the Nurses' Health Study II (NHS II) cohorts. Specific Aim 1 is to establish a database of confirmed cases of CD and UC in the NHS I and NHS II cohorts. Specific aims 2 through 4 will examine the association of specific dietary factors, smoking, and exogenous estrogen therapy and the development of CD or UC. Since the establishment of the NHS I in 1976 and the NHS II in 1989, information pertaining to participants' dietary intake and lifestyle factors has been updated at regular intervals, prior to the onset of CD or UC. Cases of CD and UC will be identified by biennial questionnaires and confirmed by medical chart review using established criteria. Analyses will compare age-specific incidence rates of CD and UC within different exposure categories, multivariate analyses, using the Cox proportional hazards model, will be performed. The proposed study will establish a unique database of repeated dietary and lifestyle assessments over several decades and will provide the opportunity to examine the influence of nutritional and lifestyle risk factors on IBD risk, improve our understanding of IBD pathogenesis, and define potential methods of prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EOSINOPHIL PROTEINS AND GASTROINTESTINAL DISEASE Principal Investigator & Institution: Furuta, Glenn T.; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2001; Project Start 01-SEP-1998; Project End 31-AUG-2003 Summary: (taken from application) The candidate: Dr. Furuta began working in a basic science laboratory during his GI fellowship. This experience led him to choose a career path that would allow him to become a basic scientist. He received a National Research Service Award and a Career Development Award from the Crohn's Colitis Foundation. He has demonstrated the sustained productivity necessary to become an independent investigator. He now seeks to develop skills in molecular gene regulation and epithelial physiology that will permit him to study the role of the eosinophil in GI disease. He is committed to a career in academic medicine and basic science research. The environment: The candidate will work under the close supervision of expert's in gene regulation, epithelial ion secretion, eosinophil biology and gastrointestinal immunology. Dr. Tenen will serve as the primary mentor and Drs. Colgan, Ackerman and Wershil as co-mentors. Dr. Furuta has worked with each of his mentors previously and has established solid working relationships. The Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, and Harvard Medical School are committed to providing nurturing scientific environments. These environments provided both the physical plant necessary to complete the proposed studies and the training activities necessary of his development into an independent investigator. His division is committed to providing the protected time and salary support to completed the studies detailed in this proposal. The research: A number of gastrointestinal disease are characterize by the infiltration of eosinophils into the tissue layers, but the precise participation of the eosinophil in GI disease has not been defined. In preliminary data, we show that eosinophil-derived major basic protein can 1. induce the production of IL8 from intestinal fibroblasts, 2. potentiate chloride secretion from colonic monolayers, and 3. induce tissue swelling and neutrophil infiltration in a murine model of inflammation. These findings suggest new mechanisms by which eosinophils may
Studies
45
participate in the in [sic] GI diseases. We hypothesize that eosinophil derived granule proteins (EDGPs) participate in GI disease by stimulating pro-inflammatory cytokine/chemokine production and epithelial chloride secretion. We will determine the mechanisms of: 1. EDGP stimulated IL-8 production in intestinal fibroblasts and EDGP stimulated neutrophil transmigration across intestinal epithelium, 2. EDGP stimulated epithelial cell chloride ion secretion and 3. EDGP stimulated neutrophil infiltration, changes in vascular permeability and fluid secretion in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXCELLENCE IN CLINICAL RESEARCH IN CHILDREN'S SURGERY Principal Investigator & Institution: Moss, R Lawrence.; Surgery; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2003; Project Start 15-JUL-2003; Project End 31-MAY-2008 Summary: (provided by applicant): This application seeks five years of support to allow R. Lawrence Moss, MD, to make major contributions to the level of Children's Surgery by achieving his career objectives in patient-oriented clinical research. His foremost professional objective is to introduce scientific rigor and established clinical research techniques into the manner in which surgical treatments in children are evaluated. Dr. Moss is an active clinical Pediatric Surgeon and an internationally recognized and established clinical investigator. He is the principal investigator for the first ever multicenter clinical trial in Children's Surgery ROl HD 38462. He serves as Stanford Site Director and only surgeon of the first multi-disciplinary patient-oriented research network in Pediatrics. He holds multiple national leadership positions in Pediatric Surgery, and is recognized as a leader in clinical research in the field. He has mentored twelve postdoctoral fellows in clinical research of whom the past five have each obtained extramural funding based on their outstanding productivity. Stanford University is an exceptionally rich environment for patient-oriented research, and has identified clinical investigation as a major focus of the Medical School for the next decade. Dr. Moss' work is an integral component of this institutional mission in clinical research. Examples of work to be conducted during the training period include; 1) leading a twelve-center trial of peritoneal drainage versus laparotomy for infants with perforated necrotizing enterocolitis; 2) establishment of the first multi-center neonatal surgical database for children with congenital anomalies; and 3) development of a multiinstitutional consortium to study biliary atresia. With the support of this award, the awardee's underlying objectives are three-fold: 1) to make substantive contributions to the field Children' s Surgery that will directly impact the health and well-being of children; 2) to conduct multiple clinical research projects that change the shape of the discipline of academic Pediatric Surgery; and 3) to mentor the next generation of physician scientists in Children's Surgery to be critical thinkers who are well versed in clinical research techniques. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GASTROINTESTINAL CANCER SCREENING AND SURVEILLANCE Principal Investigator & Institution: Provenzale, Dawn T.; Medicine; Duke University Durham, Nc 27706 Timing: Fiscal Year 2001; Project Start 29-SEP-2000; Project End 31-MAR-2005 Summary: (Applicant's Description) My research plan focuses on gastrointestinal cancer screening and surveillance. The integrated research approach targets three clinical areas (screening for colorectal cancer, and surveillance of patients with Barrett's esophagus
46
Colitis
and ulcerative colitis). The study methods link decision modeling with clinical research to answer important clinical questions regarding screening and surveillance. The integrated research process includes: 1) Identifying the relevant screening and surveillance questions for study, 2) structuring a decision analytic model (using published literature) to answer the study questions, 3) identifying the optimal strategy given the available data, 4) targeting critical parameters in the model for which there are incomplete data, 5) designing and implementing observational studies for primary collection of these data, and 6) integrating the results of the clinical studies into decision models to provide clinicians and policy makers with new, patient specific data about the optimal management strategy. Research projects focus on the development of the acceptable and cost-effective colon cancer screening strategies for veterans. Future projects will determine the costs and resource needs to implement these preferred strategies. Another study evaluates risk factors for presentation with late stage colorectal cancer. If modifiable factors such as access to screening, or physician delay in follow-up of positive screening tests are identified, then interventions can be made to improve access and reduce delay with the aim of reducing colorectal cancer mortality. Ongoing and future studies will examine the health related quality of life of patients with Barrett's esophagus and ulcerative colitis using standardized measures (SIP, SF-36, RFIPC, TTO). The results will be summarized and incorporated into the decision models to determine their effect on surveillance strategies. The other critical component of my career plan is the structured mentoring program for gastroenterology/health services research fellows. The program integrates coursework leading to a Master of Science in Clinical Research with a mentoring program that provides the fellow with the opportunity for patient centered research experience. There is a gradual increase in his/her research independence under my supervision, leading to the design and execution of his/her own research project, including data analysis, abstract and manuscript preparation and presentation of the study results at a national meeting. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC STUDIES IN INFLAMMATORY BOWEL DISEASE Principal Investigator & Institution: Cho, Judy H.; Assistant Professor; Medicine; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2001; Project Start 15-MAR-1998; Project End 31-JAN-2003 Summary: The research project involves identifying susceptibility loci for IBD through genome-wide screening of affected relative pairs using non- parametric linkage analysis and gene identification through a variety of approaches. Unique aspects of the genetics of inflammatory bowel disease include the overlap between Crohn's disease and ulcerative colitis and its high prevalence in Ashkenazi Jews. Data on putative loci on chromosomes 16 and 12 are provided. Strategies for fine localization of loci, including fine-mapping by linkage disequilibrium, are proposed. alternative approaches to gene identification and mutation detection are discussed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GI INFLAMMATION
NEMATODES
AND
FUNCTIONAL
RESPONSES
TO
Principal Investigator & Institution: Shea-Donohue, Terez; Professor; Henry M. Jackson Fdn for the Adv Mil/Med Rockville, Md 20852 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007
Studies
47
Summary: (provided by the applicant): The overall hypothesis of the proposed studies is that the gastrointestinal tract contributes to host defense through stereotypic functional responses that are orchestrated by the profile of cytokines present. Crohn's disease and most murine models of colitis are linked to exaggerated production of Th1 cytokines. In contrast, the host defense to enteric nematode infection is dependent primarily on the type 2 cytokines, IL-4 and IL- 13. Of the type 2 cytokines, IL-4 is most important for the establishment of the Th2 profile and for the down regulation of Th1 pathway, yet there are few studies of IL-4, or other type 2 cytokines, in vivo. In addition, IL-13 shares many biological activities with IL-4 by acting at a common receptor chain. The central premise of this proposal is that colitis-induced changes in the smooth muscle and epithelial cell function will be improved by administration of exogenous IL-4 or IL-l3, or by upregulation of their endogenous production via nematode infection. We propose that the mechanism by which cytokines alter gut function involves receptor-mediated activation of Stat6 signaling pathways, mast cells and mast cell mediators, and enteric nerves. There are 3 specific aims. 1.) Determine that the profile of cytokines present in the gut controls epithelial cell and smooth muscle function in colitis and nematode infection; 2.) Determine the role of altered Th2 cytokines in colitis-induced alterations in epithelial cell and smooth muscle function; 3.) Determine the mechanisms of altered epithelial cell and smooth muscle function in mice with and without colitis and treated with IL-4, IL13, or nematode infection. Based on our preliminary data, we expect that type 2 cytokines have significant region-specific actions on the small and large bowel, and that restoration of the balance of type 1/type 2 profiles will be of therapeutic benefit to the impaired secretomotor function in IBD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GIF REGULATION OF B CELLS AND CD4 CELLS Principal Investigator & Institution: Sugie, Katsuji; La Jolla Allergy/Immunolgy Allergy and Immunology San Diego, Ca 921211118
Institute
for
Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-AUG-2004 Summary: (provided by applicant): GIF is a 13-kDa cytokine discovered in the course of the study on IgE synthesis. It is encoded by a single gene in the genome and its nucleotide sequence is identical is that published for macrophage migration inhibitory factor (MIF). MIF(GIF)-/- mice show enhanced susceptibility to Leishmania major. These mice are incapable of developing the experimental colitis. These findings support the notion that GIF is involved inactivating the innate immune system. GIF protein is expressed in the cytosol of hematopoietic and nonhematopoietic cells. GIF secreted from T cells is cysteinylated at C60, whereas that contained in the cytosol of the same cells is unmodified. The modification at C60 is required for the capability of this cytokine to bind to target cells, to inhibit BCR-mediated uptake of antigen, and to inhibit IL-4 secretion from CD4 cells. Binding assays demonstrated that GIF receptors are expressed on T and B cells after these cells are activated, but not on macrophage and dendritic cell lines. Chemical crosslinking experiments suggest that GIF binds to a 50-52 kDa cell surface protein. GIF-/- mice show enhanced antibody responses to T-dependent antigens. GIF-/- CD4 cells were polarized toward a Th2 phenotype as compared with wild type cells. To clarify the role of this cytokine in T-dependent and -independent humoral responses, GIF+/+ and -/- mice crossed to BALB/c and those to B6 will be immunized with various antigens and adjuvants. The role of GIF in cognate T-B interaction will be analyzed in vitro and in vivo using TCR Tg mice and BCR Tg mice on GIF+/+ and -/- backgrounds. The biochemical mechanisms by which GIF regulates BCR-mediated antigen presentation will be analyzed. TCR Tg GIF+/+ and -/- mice will
48
Colitis
be compared for the signals that regulate Th differentiation. These mice will also be used to determine the involvement of the innate immunity in the regulation of Th differentiation. The functional relevance of GIF-dependent Th development will be addressed in the mouse model of allergic airway inflammation. Finally, using C60modified rGIF, GIF receptor will be molecularly characterized. These experiments will be useful to determine whether this cytokine directly regulates innate immunity or antigen-specific immunity and whether the form secreted from T cells or that contained in the cytosol plays an important role in its function. This project will fill a critical gap in our knowledge in cytokine biology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GROWTH FACTORS AND INFLAMMATORY BOWEL DISEASE Principal Investigator & Institution: Lund, Pauline K.; Professor in Physiology, Pediatrics And; Cellular/Molecular Physiology; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2002; Project Start 01-SEP-1995; Project End 31-MAY-2007 Summary: (provided by applicant): Major objectives of this research are to gain a better understanding of positive and negative mediators of inflammation induced intestinal fibrosis, an incurable complication of Crohn's disease (CD). Findings in animal models of acute colitis and in patients with CD indicate benefits of growth hormone (GH) therapy in CD but the documented fibrogenic effects of GH and insulin-like growth factor-I (IGF-I) which is induced by GH, support a hypothesis that GH therapy may exacerbate fibrosis in CD. Locally expressed IGF-I is up-regulated in myofibroblasts at sites fibrosis in CD and animal models of chronic intestinal inflammation implicating IGF-I as an endogenous mediator of fibrosis. Preliminary data support a hypothesis that suppressors of cytokine signaling (SOCS), may limit the fibrogenic actions of therapeutic or endogenous cytokines and growth factors in the inflamed intestine. Other data support a hypothesis that IGF-I interacts with another key cytokine, TNF-alpha to mediate collagen synthesis or proliferation in intestinal myofibroblasts, key cellular mediators of fibrosis in CD. Specific aims are as follows:Aim 1 will define if systemic GH increases fibrosis, circulating or locally expressed IGF-I during PG-PS induced enterocolitis. Cellular sites and levels of SOCS expression will be assessed to verify that SOCS2 or SOCS3 are expressed at in vivo sites that would permit them to limit fibrosis.Aim 2 will define if IGF-I mediates GH action on collagen synthesis or proliferation in intestinal myofibroblasts and test whether SOCS limit GH or IGF-I action.Aim 3 will define if mice with absolute or mesenchyme-specific SOCS2 deficiency show altered fibrosis, JGF-I induction or GH action during TNBS-colitis.Aim 4 will define mechanisms if TNF-alpha has additive or synergistic effects with IGF-I, to induce collagen synthesis in intestinal myofibroblasts and if SOCS limit these effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GUT PEPTIDES IN INTESTINAL PERISTALSIS Principal Investigator & Institution: Grider, John R.; Professor; Physiology; Virginia Commonwealth University Richmond, Va 232980568 Timing: Fiscal Year 2001; Project Start 01-JUL-1984; Project End 31-AUG-2004 Summary: The objective of this proposal is to characterize the neuronal circuits that mediate the peristaltic reflex in normal and inflamed colon, and determine the effect of inflammatory cytokines (IL-1beta and IL-6) and neurotrophins (GDNF and BDNF) on neurotransmitter expression and neuronal remodeling. Previous studies and
Studies
49
preliminary experiments have lead us to identify neuronal circuits within the myenteric plexus consisting of modulatory neurons coupled to motor neurons that mediate the reciprocal activity of circular and longitudinal muscle. The experimental approach exploits novel preparations that enable identification of the neural pathways: (1) compartmented intestinal segments to measure release of sensory (CGRP), modulatory neural pathways: (1) compartmented intestinal segments to measure release of sensory (CGRP), modulatory (somatostatin, GABA, [Met]enkephalin], and excitatory (ACh and SP) or inhibitory (IP, PACAP and NO) motor neurotransmitters in animals and humans; (2) longitudinal muscle strips with adherent myenteric plexus to identify the coupling of interneurons to each other and to excitatory motor neurons; (3) circular muscle strips with axonal remnants, and synaptosomes derived from these strips to identify presynaptic regulation of neurotransmitter release; (4) freshly dispersed and cultured myentric ganglia to examine feedback regulation of somatostatin interneurons and neuronal remodeling by neurotrophins; (5) organotypic cultures of smooth muscle to identify the interplay of cytokines and neurotrophins; (5) organotypic cultures of smooth muscle to identify the interplay of cytokines and neurotrophins in normal and TNBS-induced colitis. The Specific Aims of the proposal are: (1) to characterized the modulatory roles of somatostatin, GRP and NPY in the ascending and descending phases of the peristaltic reflex, and identify the pre- synaptic interactions between motor neurons; (2) to characterize the sensory pathways activated by chemical stimuli and identify the 5-HT4 receptor splice variant mediating desensitization of the reflex; (3) to characterize the roles of the cytokines, IL-1beta and IL-6, and trophic (GDNF) and antitrophic (BDNF) neurotrophins in mediating changes in peristaltic neurotransmission and neuronal remodeling in TNBS-induced colitis. The aims are supported by preliminary studies and will provide a deeper understanding of neurotransmission in health and disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HELMINTHIC CONDITIONING OF THE MUCOSAL IMMUNE RESPONSE Principal Investigator & Institution: Weinstock, Joel V.; Professor; Internal Medicine; University of Iowa Iowa City, Ia 52242 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 31-MAY-2004 Summary: (Adapted from the Applicant's Abstract): The frequency of Crohn's disease (CD) has increased substantially in industrialized countries over the last 40 years. CD is an overly exuberant Th1 response probably directed at normal constituents of the intestinal flora. Helminthes live within the human gut interacting with the mucosal immune system. The host mounts a mucosal Th2-type reaction to limit helminthic colonization. Helminthic worms and their eggs are potent stimulators of mucosal Th2 and suppressors of Th1 responses. Th2-type reaction to a helminth can modulate the immune response to other concomitant parasitic, bacterial and viral infections. Many people live in increasingly hygienic environments and acquire fewer helminthes. The major hypothesis of this proposal is that helminthic colonization conditions our mucosal immune system to appropriately respond to stimuli without excessive release of strong tissue-destructive, Th1 cytokines. Failure to undergo helminthic colonization and to experience this mucosal conditioning predisposes people to Crohn's disease, which is an overly exuberant Th1 reaction. To test this hypothesis, the investigator is using normal mice exposed to TNBS and IL-10 mutant mice that develop IBD spontaneously to show if exposure to a murine intestinal helminth affords protection against the subsequent aberrant intestinal Th1-type inflammation. The project has three specific aims. Aim 1
50
Colitis
will determine if helminthes protect mice from acute TNBS colitis and determine the role of T cells and cytokine pathways in mediating this protective process. Aim 2 will evaluate the effect of helminthic conditioning on the natural development of chronic mucosal inflammation in the IL-10-/- mouse. The investigator will determine if exposure to helminthes can prevent or down-modulate ongoing spontaneous Th1-type colitis. Also, the investigator will identify mechanisms through which this exposure affords protection. Aim 3 will determine if immune dysregulation or various agents used to treat IBD alter the host/helminth interaction. These experiments are important, since it must determined how patients with dysregulated immunity may respond to docile live helminthes used as therapy. This investigation could provide new insight into the pathogenesis of CD. The results may lead to novel therapies for disease prevention and treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST CELLULAR RECEPTORS AND HUS Principal Investigator & Institution: Newburg, David S.; Eunice Kennedy Shriver Center; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655 Timing: Fiscal Year 2001; Project Start 01-JAN-1997; Project End 31-DEC-2002 Summary: Enterocolitis caused by enterohemorrhagic Escherichia coli (EHEC), i.e., E. coli that produce Shiga-like toxins (SLTs), usually precedes HUS, but fewer than 10% of children with EHEC infection progress to HUS. We hypothesize that individual differences in toxin receptors of the host account for some of this differential susceptibility to HUS, and that these receptors are essential determinants of HUS pathogenesis. Following EHEC infection, SLT may enter the circulation and bind to host cell globotriaosylceramide (Gb3) toxin receptors; such binding in the endothelium is thought to be central to HUS pathology. Globotriaosylceramide is one of the major glycolipids that binds to SLTs in solid-phase assays, and Gb3 is accepted as a major functional receptor for SLT toxicity to cultured cells. Different molecular species of Gb3 that differ in their specific fatty acid moieties have different binding affinities to SLT. Variation of specific species of glycolipids among tissues is not known; such variations may underlie SLT sensitivity. The relative affinities of individual Gb3s for SLT differ greatly under different assay conditions; therefore, large, well defined and carefully studied human populations will be used to relate individual levels of specific species of Gb3 with susceptibility to HUS. We propose that an underlying genetically based predisposition toward HUS will be revealed by erythrocyte glycolipid analyses. The relationship between incidence of HUS, blood group type, and erythrocyte Gb3 profiles will be studied retrospectively in a genetically homogeneous population with unusually high HUS susceptibility, and prospectively in EHEC-infected Canadian children, with emphasis on defining the roles of different species of Gb3 in the etiology of HUS. The relationship between endothelial Gb3 profiles and erythrocyte Gb3 profiles will be studied in blood and human endothelial cells derived from the same umbilical cords. The relationship between endothelial cell Gb3 and susceptibility to SLT will be studied in cultured human endothelial cells. Thus, this project addresses the role of specific toxin receptors in the pathobiology of HUS, the relationship between regulation of host cell receptors and HUS susceptibility, and genetic differences in human glycolipid metabolism that relate to susceptibility to vascular endothelial injury. Such information may identify aspects of HUS pathobiology that are amenable to therapeutic intervention and may aid in identifying patients at high risk for HUS who could be targeted for increased vigilance and prophylactic measures.
Studies
51
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN INTESTINAL ANION EXCHANGERS: FUNCTION & REGULATION Principal Investigator & Institution: Dudeja, Pradeep K.; Associate Professor; Medicine; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2001; Project Start 01-JUN-1998; Project End 31-MAY-2006 Summary: (Adapted from the Investigator's Abstract): The short chain fatty acids (SCFA) are the main energy-yielding substrates for the mammalian colonic mucosa and are known to play a pivotal role as regulators of fluid and electrolyte absorption as well as cellular differentiation in the colonic epithelia. Recent studies from the PI's laboratory, utilizing purified membrane vesicles from organ donor colons, have demonstrated the presence of SCFA/HCO3 exchangers in the human colonic apical and basolateral membrane vesicles with kinetically distinct characteristics. To date, however, the molecular nature of these SCFA transporters is not fully defined. Recent studies from the PI's laboratory and others indicated the involvement of monocarboxylate transporter 1 (MCT1) in the SCFA uptake by the human colonic apical membranes as well as the expression of other MCT isoforms in the human colon. The PI hypothesizes that: 1) MCT1 plays a critical role in the SCFA absorption in the human colon, 2) MCT1 regulation involves regulation by kinases, or via alterations in trafficking or targeting to plasma membranes in polarized epithelial cells; and 3) its expression is transcriptionally regulated. The Specific aims are designed to: i) characterize the expression, distribution and function of the apical membrane MCT transporter(s) of the human intestine; ii) to elucidate the structure-function relationship of the human MCT1 and to delineate the sequences essential for protein trafficking and polarized distribution in epithelial cells; and iii) to characterize genomic clones corresponding to the 5' regulatory region for the human MCT1. For distribution, membrane localization and crypt/surface expression of MCT1 or other MCTs, mRNA and protein in the human intestine, RT-PCR, Rnase protection, Western analysis, in situ hybridization and immunohistochemistry in parallel to an analysis of MCT function will be performed. MCT1 structure/function relationship will be elucidated by utilizing truncation and deletion mutants and expression in a human breast cancer epithelial cell line to determine the relationship of various domains to SCFA transport, inhibition, and possible regulation by kinases. For trafficking studies, green fluorescent protein constructs of hMCT1 and expression in intestinal epithelial cells will be followed by confocal microscopy. MCT1 promoter will be cloned and DNA-protein interactions will be studied by mobility shift and foot printing analyses to yield important information on the cis- and trans-acting elements involved in regulation of MCT1 function and expression. An investigation of the molecular mechanisms of the colonic SCFA transporters, their structure-function analysis and their regulation would be critical for a better understanding of the role of SCFA in basic physiology of the colonocyte as well as in modulation of colonic electrolyte absorption, colitis and colonic malignancies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HUMAN INFLAMMATION
PHAGOCYTES,
OXYGEN
METABOLITES
AND
Principal Investigator & Institution: Weiss, Stephen J.; Upjohn Professor of Medicine, Chief; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 01-JUL-1984; Project End 31-MAR-2003
52
Colitis
Summary: In chronic inflammatory disease states ranging from rheumatoid arthritis to ulcerative colitis, blood monocytes infiltrate affected tissues and differentiate into tissue-destructive populations of macrophages. Unlike neutrophils or eosinophils which predominantly rely on their ability to generate halogenated oxidants and release serine proteinases to mediate tissue damage, the destructive systems mobilized by human macrophages remain undefined. In order to identify and characterize the mechanisms by which macrophages mediate tissue-destructive effects in chronic inflammatory disease states, human monocytes will be cultured in vitro and induced to mature into a macrophage population capable of expressing an extracellular matrix-degrading phenotype hundreds of times greater than that of any other leukocyte population described previously. Based on preliminary data, the macrophage's unique destructive activity is mediated by the exocytosis/secretion of active cysteine proteinases, a class of acid proteases normally categorized as intracellular, lysosomal catabolic enzymes. To date, little is known with regard to the function of these enzymes in human macrophages since many members of this proteinase family have only recently been identified and few molecular or biochemical tools have been developed for their analysis in intact cell systems. Furthermore, the mechanisms by which lysosomal enzymes could be routed to an extracellular compartment in which conditions permissive for cysteine proteinase activity could be generated and maintained remain unknown. Thus, in an attempt to identify a novel role for cysteine proteinases in macrophage effector functions, the following five aims will be addressed. First, to characterize the intracellular and extracellular expression of the cysteine proteinases, cathepsins B, L and S, as well as the cysteine proteinase inhibitor, cystatin C, in monocyte-derived macrophages. Second, to determine the role of the mannose-6phosphate receptor recognition systems in directing cysteine proteinase traffic from the lysosomal to the extracellular compartment. Third, to characterize the role of the macrophage vacuolar-type H+-ATPase and L-cystine transport systems in generating an acidic and reducing extracellular environment permissive for cysteine proteinase activity. Fourth, to assess the role of the cysteine proteinase system in the macrophagemediated degradation of the extracellular matrix via the selective "knockout" of individual cathepsins, the vacuolar-type H+-- ATPase or the L-cystine transport system. Fifth, and finally, to determine the response and function of the macrophage cysteine proteinase system during chemotactic factor-induced tissue invasion. The characterization of the cysteine proteinase system mobilized by human macrophages at inflamed sites should not only provide new insights into the pathogenesis and treatment of chronic inflammatory disease states, but also into the regulation of the tissue-invasive phenotype in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IDENTIFICATION OF THE IBD GENES ON CHROMOSOMES 3P AND 6P Principal Investigator & Institution: Rioux, John D.; Research Scientist; Whitehead Institute for Biomedical Res Biomedical Research Cambridge, Ma 02142 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Crohn's disease (CD) and ulcerative colitis (UC) are idiopathic inflammatory bowel diseases (IBD) that have a combined prevalence of approximately 100-200 per 100,000 in developed countries. Both diseases involve altered expression of proinflammatory and immunoregulatory cytokines within the intestinal mucosa; however, the clinical and pathological profiles for CD and UC are distinct. Epidemiological studies reveal a significant genetic contribution to the pathogenesis of
Studies
53
IBD. The relative risk to siblings of affected individuals (ns) is estimated at 30-40 fold for CD and 10-20 fold for UC. In this application we propose to identify the genetic variation located in chromosomal regions 3p and 6p that confers genetic susceptibility to IBD. These regions were selected because of repeated evidence of linkage that has been observed in multiple genome-wide scans and strong evidence in a meta-analysis that we recently performed. Moreover, the chromosome 6p region contains the human leukocyte antigen (HLA) cluster of genes for which many associations to IBD have been reported, although the causal variants have yet to be identified. Prior studies in our laboratory provided the first extensive high resolution SNP analysis of the human genome. Specifically we performed SNP discovery by re-sequencing 470 kb in 8 individuals (>3.7 Mb of total sequence) in the cytokine gene cluster of chromosome 5q31 and discovered the underlying haplotype (haplotype = specific combinations of alleles) structure of the human genome. We recently demonstrated that the use of this haplotype structure could provide a powerful approach to performing association studies. The successful application of this approach enabled the identification of the genetic variation in the 5q31 cytokine gene cluster that confers susceptibility to Crohn's disease. In the current proposal we aim to take advantage of the haplotype structure of the genome to narrow down the linked regions on chromosomes 3p and 6p and to identify the causal genetic variation conferring susceptibility to IBD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IFN-BETA CONTROL OF TH CELL DIFFERENTIATION/FUNCTION Principal Investigator & Institution: Van Seventer, Gijsbert A.; Associate Professor; Environmental Health; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-DEC-2003 Summary: Regulation by IFN-beta of Th Cell Differentiation and Function. An effective T helper (Th) cell immune response is dependent upon the activation and differentiation of resting naive CD4+ T cells into memory/effector Th cells displaying appropriate effector functions. Differentiated Th cells can be characterized as functionally distinct subsets according to their pattern of secreted cytokines, which has led to the now established paradigm of inflammatory Th1-like cells (secreting IL-2, IFN-gamma and LT) and anti-inflammatory Th2-like cells (secreting IL-4, IL-5 and IL-10). Aberrant expression of Th1-like cells has been shown to cause inflammatory autoimmune disease in certain animal models, such as experimental allergic encephalomyelitis (EAE) (multiple sclerosis model), experimental colitis (inflammatory bowel disease model) and collagen-induced arthritis (rheumatoid arthritis model). Recently, interferon-beta (IFN-beta), a type I IFN, has been shown to prevent the development of EAE. Furthermore, in patients with multiple sclerosis (MS) IFN-beta provides clinical improvement and is now standard therapy for the disease. The mode of action of IFNbeta in preventing EAE and in treating MS is unknown. We have recently shown, in a series of in vitro studies, that IFN-beta influences human Th cell subset differentiation by 1) preventing the generation of IFN-gamma-secreting Th1-like cells, through the inhibition of CD40-induced IL-12 secretion by dendritic cells, and 2) by inducing the generation of a novel Th cell subset (non-Th1-\Th2-like) that secretes high levels of the anti-inflammatory cytokine IL-10, but does not secrete IFN-gamma, IL-4 or IL-5. We hypothesize that one of the ways in which IFN-beta downregulates inflammatory autoimmune responses is through its effects on Th cell differentiation, specifically, through its ability to prevent the generation of IFN-gamma secreting Th1 cells and to induce a novel IL-10-secreting regulatory Th cell subset. The studies outlined in this
54
Colitis
research proposal will identify the molecular mechanism(s) by which IFN-beta regulates the secretion of IFN- gamma and IL-10 by human Th cells during their differentiation (Aim #1), and will functionally characterize the human Th cell subset induced by IFNbeta (Aim #2). In addition, murine models will be used to examine the role of both IFNbeta and Th cell subsets induced by IFN-beta in regulating immune responses (Aim #3). The information from these studies will identify mechanism(s) involved in the regulation of Th cell differentiation. The results will provide insight into an often not well appreciated interplay which is integral to the generation of a physiological immune response, that is the interaction between components of the innate immune system (i.e. type 1 IFNs) and the adaptive immune system (i.e. Th cell subsets). Lastly, defining the mechanism(s) by which IFN-beta modulates Th cell differentiation and effector function may not only lead to the development of new, more effective drugs and complementary therapies for the treatment of MS, but could also lead to the use of IFN-beta as treatment of other inflammatory autoimmune diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IKK BETA IN INTESTINAL INFLAMMATION Principal Investigator & Institution: Egan, Laurence J.; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-JAN-2007 Summary: Inflammatory bowel disease is a major cause of suffering in the developed world. Pro-inflammatory cytokines, chemokines and eicosanoids are present in high concentrations in inflammatory bowel disease. Many of these inflammatory mediators can be positively regulated by nuclear factor kappa B (NF-kappaB) family of transcription factors. However, it is not known if NF-kappaB activation in vivo promotes intestinal inflammation, or plays a role in protective host responses by inhibiting apoptosis in the inflamed intestine. Our central hypothesis is that NF-kappaB activation in cells of the innate immune system regulates intestinal inflammation and host responses to inflammation in vivo. This hypothesis will be tested by studying the key molecule that activates NF-kappaB, inhibitory kappa B kinase beta (IKKbeta). Studies in specific aim 1 will generate and characterize a transgenic mouse line that expresses cre recombinase exclusively in intestinal epithelial cells. Studies in specific aim 2 will determine the role of IKKbeta in the activation of NF-kappa B in cells of the mucosal innate immune system. Two conditional knockout mouse strains will be generated by cre/loxP-mediated recombinant of the IKKbeta locus: a) Mice that express cre recombinase in intestinal epithelial cells will be crossed with mice bearing a loxPflanked IKKbeta locus to produce intestinal epithelial IKKbeta knockout mice; b) Existing mice that express cre recombinase in macrophages and neutrophils will be crossed with mice bearing a loxP-flanked IKKbeta locus to produce macrophage and neutrophil IKKbeta knockout mice. Studies in specific aim 3 will determine the role of NF-kappa B activation in the pathogenesis of intestinal inflammation by analzing the course of colitis induced by feeding dextran sulfatesodium to mice that lack IKKbeta in intestinal epithelial cells or in macrophages and neutrophils. The mentored clinical Scientist Development Award will provide me with essential resources with which to perform this research. I will acquire the theoretical and experimental skills to launch a productive independent investigate career with the assistance of this award and of my institution, the Mayo Foundation for Medical Education and Research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
55
Project Title: INFLAMMATORY BOWEL DISEASE IN TCR-MUTANT MICE Principal Investigator & Institution: Bhan, Atul K.; Associate Pathologist; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2002; Project Start 15-SEP-1994; Project End 31-AUG-2007 Summary: (provided by applicant): The spontaneous chronic colitis in T cell receptor (TCR) alpha mutant (knockout) mice provides an excellent experimental model of inflammatory bowel disease. The colitis shares many features with ulcerative colitis and is mediated by the T helper 2 pathway. Colonies of TCRalpha knockout mice deficient in cytokines and B cells have been developed at the Massachusetts General Hospital. The project will focus on the hypothesis that an unregulated immune response to enteric bacterial antigens at the mucosal site results in chronic colonic inflammation and autoantibody production. Certain enteric bacteria may play a protective role in the development of intestinal inflammation. The role of the appendix in the presentation of enteric bacterial antigens and in providing both pathogenic and regulatory cells in the pathogenesis of chronic colitis will be explored. A major focus of the project will be to examine the regulatory role of B cells in colitis. We have developed a new model of granulomatous colitis in B cell and lL-4 deficient TCRalpha knockout mice. Thus, the development of two distinct colitis models in mice that are of genetically of identical background and exposed to the same environment, provides an opportunity to analyze the mechanisms involved in T helper 2-mediated ulcerative colitis-like and T helper 1mediated Crohn's disease-like colitis. Additional models of T helper 1-mediated colitis in IL-10 KO mice and CD45RB high transfer model will also be studied. Experiments will be designed to develop specific interventions, including B cell based therapies, to prevent and suppress chronic intestinal inflammation and contribute to the development of new therapeutic modalities for human inflammatory bowel disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INFLAMMATORY BOWEL DISEASE: NON-INVASIVE DIAGNOSIS Principal Investigator & Institution: Nair, Padmanabhan P.; Nair Consultants, Llc 4520 Hemlock Cone Way Ellicott City, Md 21042 Timing: Fiscal Year 2001; Project Start 01-SEP-1999; Project End 31-AUG-2003 Summary: (Verbatim from the Applicant's Abstract): Inflammatory Bowel Disease (IBD) remains an intractable chronic disease affecting nearly a quarter million individual in the United States. A persistent inflammatory reaction is an integral component of this disease. Radiologic, endoscopic and pathologic examinations of biopsy specimens are the current accepted approach for its diagnosis. While this is an essential set of procedures for confirming a diagnosis of IBD, it remains an invasive and expensive strategy for screening subjects and for frequent follow-up of established cases. Recent technological advances in the exfoliative biology of the colon have shown that colonic cells and inflammatory cells could be recovered in a viable state from stool samples and examined for markers of colonic disease. It is now possible to apply this noninvasive approach to screen patients suspected of having IBD by demonstrating the presence of inflammatory cells in stools by flow cytometry and by PCR amplification of COX-2, the biomarker for the inflammatory response. This new emerging science of coprocytobiology, involving the isolation of cells from stool and screening these cell populations for markers of colonic pathology (eg. malignancy, IBD) is an exciting development. The objective of this SBIR, Phase II is two-fold. The first one is to conduct a double blind cross sectional clinical trial to establish the relationship between IBD disease severity and the expression of GOX-2 in isolated colonocytes and inflammatory
56
Colitis
cells of lymphoid lineage. The second one is to determine the correlation between indices of clinical findings (GELS, Global Estimates of Lesion Severity) and an Index of Inflammatory Activity (IIA) generated from two sets of outcome measures - ratio of PCR band density COX-2/COX-1 and the ratio COX-2/Cytokeratin l9. The Index of Inflammatory Activity (IIA) may become a non-invasive standard by which physicians can follow IBD patients more frequently for monitoring epithelial restitution of the colonic mucosa during treatment. PROPOSED COMMERCIAL APPLICATION: A standardized kit may become available to clinicians to monitor IBD disease severity by an objective laboratory test. Diagnostic laboratories, research centers, clinical drug trials will be potential users. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHIBITION OF MICROFLORA-INDUCED COLITIS BY NF-KB Principal Investigator & Institution: Horwitz, Bruce H.; Assistant Professor of Pediatrics; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-DEC-2007 Summary: (provided by applicant): The purpose of this proposal is to define the cellular and molecular mechanisms by which the NF-kappaB subunits p50 and p65 inhibit inflammation within the lower bowel. The inhibitory functions of p50 may be especially relevant to the control of inflammation within the colon, as our laboratory has shown that mice lacking p50 (p50-/-) are sensitive to colitis induced by Helicobacter hepaticus, and this sensitivity is significantly exacerbated in mice that both lack p50 and are heterozygous for p65 (p50-/-p65+/-). These mice are sensitized to the development of colitis by a defect intrinsic to the innate immune system. This defect may reflect an inability to control H. hepaticus-induced inflammatory gene expression within antigen presenting cells (APCs), as H. hepaticus infection induces higher levels of the critical inflammatory cytokines IL-12p40 and IP-10 in p50-/- and p50-/-p65+/- macrophages than in WT macrophages. The goals of this proposal are: 1) To determine the mechanism by which p50 and p65 within cells of the innate immune system contribute to inhibiting the inflammatory response to H. hepaticus. Using a novel mouse strain created in our laboratory (p50-/-p65+/-RAG-2-/-), we will evaluate the possibility that p50/p65 activity is required within the innate immune system to facilitate the inhibitory function of regulatory T cells. 2) To determine the mechanisms by which p50 and p65 inhibit H. hepaticus induced inflammatory gene expression. We will use molecular techniques to compare the function of endogenous IL-12p40 and IP-10 promoters in WT, p50-/-, and p50-/-p65+/- macrophages. 3) To determine whether p50 and p65 prevent an overaggressive immune response that injures the host, or alternatively, whether p50 and p65 prevent an immune deficiency that leads to increased bacterial burden. We will compare bacterial burden in RAG-2-/- and p50-/-p65+/-RAG-2-/- mice, and determine whether introduction of functional innate immune cells into p50-/-p65+/-RAG-2-/mice can prevent H. hepaticus-induced inflammation. Taken together, we believe that these studies will lead to insights regarding the molecular pathogenesis of inflammatory bowel disease that could lead to novel therapeutic strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INTERVENTION STRATEGIES OF HEMORRHAGIC COLITIS AND HUS Principal Investigator & Institution: Boedeker, Edgar C.; Professor; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201
Studies
57
Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2005 Summary: (provided by applicant): The broad aim of this proposal is to develop and utilize new and established animal model of enterohemorrhagic E. coli (EHEC) infection, in rabbits and dogs, to develop therapeutic regimens to prevent and treat EHEC disease. It is well recognized that shiga-toxin- (Stx)-producing strains of E. coli, acquired by ingestion of inadequately cooked meat, or other contaminated foods, cause hemorrhagic colitis, and may induce fatal hemolytic uremic syndrome (HUS). EHEC strains produce potent protein toxins named Shiga-like toxins (Stxs) because of their relatedness to Shiga toxin of Shigella dysenteriae. In addition, most EHEC share the ability to adhere intimately to intestinal epithelial cells by "attaching and effacing" (A/E)(7) mechanisms (Fig.2). Although EHEC attachment mechanisms may directly contribute to diarrheal disease, and may influence toxin delivery, the most severe intestinal and renal manifestations of EHEC infection result from toxin-mediated damage to vascular endothelium, with tissue edema, inflammatory infiltrates, cytokine production and vascular thrombi. At present, only supportive care is available to prevent the development of the severe, and frequently fatal, complications of EHEC infection. Strategies aimed at decreasing the toxin burden and preventing the interaction of Stxs with their endothelial receptors should prevent or ameliorate disease and damage in target organs (gut, CNS and kidney). Interventions developed in animal models can subsequently be applied to the prevention and management of EHEC disease. E. coli strain RDEC-HI9A infection of rabbits serves as the established animal model of EHEC disease for the initial intervention studies (Aims 1-4). RDEC-H19A, produced by the transfer of the toxin-converting phage H19A of an O26:H11 EHEC to the rabbit entero-pathogenic E. coli RDEC-1, is an attaching and effacing rabbit pathogen which produces high levels of Shiga-like toxin I (Stx-I), colonizes cecum and colon, and induces intestinal disease in rabbits with pathologic changes resembling human EHEC disease. Specific aims (1-4) of the proposal are to use animal models of EHEC infection to: 1). Test the ability of new toxin-receptor analogs, administered paretenteraly or enterically to prevent EHEC disease. 2). Further test the ability of passively administered immunoglobulin with anti-toxic activity to prevent EHEC disease. 3). Further examine whether antibiotic therapy has beneficial or harmful effects on the course of disease. 4). Further develop strategies for active immunization against EHEC using the Stx toxins of EHEC. 5). Specific aim 5 is to utilize canine specific A/E strains to produce new STECcapable of infecting dogs, which are susceptible to renal vascular lesions. We will transfer our labeled Stx-1 encoding phage to dog-specific A/E strains of E. coli and test their ability to produce intestinal and renal disease. The clinical studies in dogs will be performed at Kansas State University by Dr. Brad Fenwick who has described the Cutaneous and Renal Glomerular Vasculopathy (CRGV) in greyhound dogs exposed to Stx. 6). Specific Aim 6 is to extend our rabbit and dog models to be able to test similar strategies against EBEC strains expressing Stx-2. We will label and transfer toxin converting phage encoding Stx-2 to rabbit and dog specific A/E strains. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTESTINAL ADENOSINE A2B RECEPTOR Principal Investigator & Institution: Sitaraman, Shanthi V.; Pathology and Lab Medicine; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2005 Summary: (adapted from the application) The overall aim of this project is to better define the characteristics of intestinal epithelial cell-neutrophil interaction as it relates to
58
Colitis
fluid and electrolyte secretion. Many intestinal disorders, particularly the acute flare of inflammatory bowel disease (IBD), are characterized by migration of neutrophils across the intestinal epithelium into the lumen to form 'crypt abscess'. Crypt abscesses are pathognomic of active IBD and infectious colitis and correlate with severity of disease as well as clinical symptoms. We have previously shown that neutrophil migration into the intestinal lumen elicits electrogenic chloride secretion (secretory diarrhea) and the major effector of this chloride secretory response is the neutrophil-derived secretagogue, 5'AMP. Intestinal epithelia express an ectonucleotidase, which converts 5' AMP to adenosine which then interacts with intestinal epithelial adenosine 2b (A2b) receptor to elicit chloride secretion. Thus the A2b receptor plays a central role in orchestrating chloride secretion induced by neutrophils. An understanding of the regulation and signaling mechanism of A2b receptor may therefore lead to designing of novel treatments for this component of IBD. In this proposal, I intend to characterize the biology of intestinal A2b receptor using two intestinal epithelial cell models: T84 cells and Caco-2 bbe cells transfected with the A2b receptor. A2b receptor is the only adenosine receptor in T84 cells while Caco-2 bbe cells lack A2b receptor. First, I will study the polarity of surface expression, distribution, kinetics of turnover, structural requirements for ligand binding, desensitization, and G-protein recognition. Second, I will analyze the existence of ectonucleotidase and A2b receptor in signaling membrane microdomain such as caveolae. These microdomains represent invagination of plasma membrane enriched in glycosphingolipid, which have been shown to contain signaling proteins. Third, I will study the role of adenosine receptor in the modulation and feedback regulation of neutrophil-epithelial interaction including transmigration and chemokine secretion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTESTINAL SECRETION & INFLAMMATION - IMPACT OF AMMONIA Principal Investigator & Institution: Matthews, Jeffrey B.; Christian R. Holmes Professor and Chairm; Surgery; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221 Timing: Fiscal Year 2001; Project Start 01-SEP-1996; Project End 31-AUG-2005 Summary: Numerous diseases affecting the GI tract, ranging from secretory diarrhea to cystic fibrosis, are characterized by dysregulation of epithelial C1- secretion. This project originally identified that ammonium ion (NH4+, normally present at high concentrations in the colonic lumen) may be a novel endogenous regulator of C1secretion via effects via effects on K+ channels and begins to define the interaction of NH4+ with the basolateral membrane K+ transporters also required for Cl-secretion. Based on work already accomplished, the current application considers how altered K+ channel regulation may influence various intestinal disease states. Preliminary data indicate that the ammonia-derived oxidant monochloramine (NH2Cl) may contribute to the diarrhea of colitis by potentiating Ca2+- dependent K+ channels. Experiments also suggest that docosahexaenoic acid (DHA, a component of fish oil) can augment Ca+2dependent K+ channels, finding of particular interest as DHA begins clinical evaluation as therapy in CF. Preliminary findings suggest that the actin cytoskeleton an functionally alter Ca2+-dependent K+ channels, and conversely, that these K+ channels can modulate cell functions such as epithelial restitution that involve actin remodeling. Three sets of studies are proposed. First, the impact of ammonia on colonic epithelial transport will be further characterized in cultured epithelial ells and in human colonic mucosal preparations, with attention to the interaction of NH4+ with the basolateral Na+-k+-2Cl- co- transporter, Na+_K+ ATPase, and K+ channels. Second, potentiation of
Studies
59
basolateral Ca+2-dependent K+ channels by cAMP and NH2Cl will be explored using cultured epithelial cells as model systems with the goal of defining a common mechanism for K+ channel potentiation by these seemingly diverse stimuli. The potential for therapeutic modulation of basolateral K + channels will be explored, specifically examining wheth4r docosahexaenoic acid (DHA) can augment Ca2+dependent Cl- secretion in T84 cells and human colon, and, if so, to determine its mechanism of action. Finally, the studies will define the effect of chemical manipulation of F-actin on Ca2+-dependent K+ channel regulation and extend preliminary findings suggesting that K+ channel regulation affects the actin-regulated process of epithelial restitution. These studies highlight the importance of basolateral K+ channels in the regulation of secretion and other epithelial functions and reinforce their potential as targets for new drug design. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTL PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) MEETING Principal Investigator & Institution: Fiocchi, Claudio; Professor; Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2004 Summary: (provided by applicant): Funding is requested for a scientific workshop entitled "International Pediatric Inflammatory Bowel Disease (IBD) Meeting". The workshop is under the auspices of Case Western Reserve University and the Crohn's & Colitis Foundation of America, and will be held from September 16 through 18, 2003. The workshop will be attended by approximately 100 participants and will include five scientific sessions, each one presided by leading investigators and including 6 speakers. The conference, the very first ever of its kind, will focus on the issue of the raising incidence of IBD in the pediatric population worldwide, and address the serious lack of studies on the pathogenesis of Crohn's disease and ulcerative colitis in children. The major topics will include the development of the immune system in children and its impact on neonatal and adult immunity, the differential reactivity of T-cells in early and adult life in health and disease, the intestinal microbiota and its relevance to IBD, the impact of environmental factors on IBD pathogenesis and manifestations, and new trends in the treatment to pediatric IBD in face of emerging diagnostic and therapeutic technologies. These are completely novel and unexplored areas of undeniable importance to IBD. The outcome of the workshop is expected to define the reasons for the lack of pathophysiology-based research in pediatric IBD and stimulate investigation in areas so far unexplored by pediatric gastroenterologists and IBD investigators. A major goal of the conference is to foster a close interaction and scientific exchange between scientists outside of the field of IBD with established and new investigators interested in Crohn's disease and ulcerative colitis. An additional goal of the workshop is to expose a substantial number of trainees, post-doctoral fellows and junior faculty members to novel ideas, concepts and methodologies that will become the center of scientific attention in pediatric IBD in the immediate future. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INVESTIGATING PATHOGENESIS
ENTAMOEBA
HISTOLYTICA
COLONIC
Principal Investigator & Institution: Singh, Upinder; Professor; Medicine; Stanford University Stanford, Ca 94305
60
Colitis
Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-DEC-2007 Summary: (provided by the applicant): The protozoan parasite Entamoeba histolytica causes an estimated 50 million cases of invasive disease annually. The most common manifestation of amebic infection is colonic disease (dysentery). Several virulence factors have been identified that are important for parasite pathogenesis, however the molecular mechanisms that the parasite utilizes as it establishes invasive disease remain unclear. Transcriptional regulation of amebic genes has been shown in a number of biologically relevant conditions including encystation, phagocytosis, drug resistance, stress and nutrient deprivation. Our hypothesis is that amebic virulence determinants that are important in causing invasive colonic disease will be regulated by the stimuli present in the colonic environment and can be identified by methods that detect message abundance. Our goal is to develop and use E. histolytica DNA micro-arrays to investigate amebic colonic pathogenesis. To identify virulence determinants that are important in causing colonic disease we will identify amebic genes that are regulated due to interaction of the parasite with (i) enteric bacteria, (ii) colonic epithelial cells, and (iii) erythrocytes. These conditions to a large extent mimic the environment encountered by the parasite within the host colon. For each given condition we will identify cohorts of genes whose transcript abundance is increased, decreased, or unchanged. Ultimately we would hope to identify genes, which are coordinately regulated (i.e. induced under all the conditions tested or repressed under all the conditions tested) as these may represent virulence determinants in causing colonic disease. Genes of interest will be characterized and their roles in amebic invasiveness and virulence investigated using molecular and genetic approaches. This approach promises to unveil novel molecular aspects of amebic pathogenicity and provide a number of genetic targets for improved diagnostic and treatment strategies. Additionally, the micro-arrays generated as a part of this grant will have a multitude of uses and will prove useful to a number of scientists in the scientists in the Entamoeba scientific community to study varied aspects of amebic pathogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INVOLVEMENT OF TNF-ALPHA IN INTESTINAL INFLAMMATION IN A MODEL OF COLITIS Principal Investigator & Institution: Appleyard, Caroline B.; Associate Professor; Ponce School of Medicine G.P.O. Box 7004 Ponce, Pr 00731 Timing: Fiscal Year 2001; Project Start 30-SEP-1986; Project End 31-MAY-2005 Description (provided by applicant): Ailments of the gastrointestinal tract are often very debilitating yet despite decades of research, the basic pathogenic mechanisms involved in inflammatory bowel diseases (IBD) are unknown with no cure for diseases such as Crohn?s and Ulcerative Colitis. Until now the lack of a clinically relevant animal model which mimics the periods of remission and relapse seen in the human condition has limited our understanding of the disease pathogenesis. The recent development of a "reactivated" model of colitis represents a more realistic model for the study of colitisinduced inflammation and ulceration. Previous investigations have shown significantly increased levels of inflammatory mediators in inflammatory bowel disease (IBD). This has led to the suggestion that cytokines, prostaglandins and leukotrienes may play an important role in the pathogenesis of IBD. Recent data suggest that the proinflammatory mediator tumor necrosis factor alpha (TNF-alpha) may be a key player in thc inflammatory process. Three sets of experiments will test this central hypothesis: (1) Absolute levels of TNF-alpha will be measured in a reactivated animal model of colitis and the possible cellular source will be investigated (hypothesis: TNF-alpha levels are
Studies
61
increased in periods of relapse and inflammation in inflammatory bowel disease). (2) The underlying mechanism of action of TNF-alpha will be characterized by the administration of various inhibitors, drugs or antibodies (hypothesis: involvement of TNF-alpha in this reactivated model of colitis is an essential step in the inflammatory process and resultant ulceration; moreover this is regulated by the nuclear transcription factor kappa beta, NF-kB). (3) The effect of TNF-alpha on ion transport will be investigated using Ussing chambers (hypothesis: TNF-alpha contributes to the pathogenesis of one of the major symptoms of IBD, diarrhea). This research will advance our understanding of the cytokine network and interactions involved in inflammatory bowel disease. It will provide new avenues for potential therapeutic intervention and, ultimately, offer a preferable alternative to the pharmacologic agents and surgical procedures currently employed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: METABOLISM AND CARCINOGENICITY OF HETEROCYCLIC AMINES Principal Investigator & Institution: Zenser, Terry V.; Internal Medicine; St. Louis University St. Louis, Mo 63110 Timing: Fiscal Year 2003; Project Start 01-JUL-1998; Project End 31-AUG-2008 Summary: (provided by applicant): Colorectal cancer is one of the leading causes of cancer deaths in the United States. Both cooked red meat intake and chronic inflammation/infection play a role in the etiology of colon cancer. During the cooking process, genotoxic heterocyclic amines (HCAs), i.e., 2-amino-3-methylimidazo[4,5f]quinoline (IQ), are formed which can initiate colon cancer. Colorectal carcinoma incidence in patients with inflammatory bowel disease is 20-fold higher and occurs 20 years earlier than the general population. Findings in patients are paralleled in animal models with persistent severe inflammation in the colonic mucosa thought to cause development of colorectal cancer. Dextran sulfate sodium (DSS)-induced colitis is an animal model for studying both inflammation and colitis-associated neoplasia. Reactive nitrogen oxygen species (RNOS), components of the inflammatory response, contribute to deleterious effects of inflammation. RNOS catalyze nitrosation, oxidation, and nitration reactions. However, the influence of RNOS on HCA carcinogenicity has not been evaluated. Such an evaluation is essential to understanding the strong association between cooked red meat intake and chronic infection/inflammation in colon cancer. Because we recently demonstrated RNOS transformation of IQ to an N-nitroso product N-NO-IQ), which forms DNA adducts and is mutagenic, we hypothesize that RNOS derived from the inflammatory response react with HCAs forming N-nitroso products that initiate colon cancer. Critical to testing this hypothesis is the identification and measurement of N-nitroso products in animals and cells responding to inflammatory stimuli; the demonstration that N-nitroso products are genotoxic and that HCA-induced colon cancer is increased in DSS-treated mice. The following specific aims will test our hypothesis: 1. Investigate HCA transformation by RNOS; 2. Determine reactivity and potential genotoxicity of HCAs and their RNOS-derived N-nitroso products; 3. Evaluate formation and metabolism of N-NO-IQ and its products by in vitro cellular systems, using inflammatory models; 4. Assess formation and metabolism of N-NO-IQ in mice with DSS-induced colitis; 5. Determine effect of DSS-induced colitis inflammation) in IQ carcinogenicity. The long-term goal is to understand the role of RNOS on HCA carcinogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
62
Colitis
•
Project Title: MUCOSAL IMMUNE REGULATION BY BACTERIAL DNA Principal Investigator & Institution: Raz, Eyal; Professor; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 92093 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: The intestinal tract is exposed to numerous commensal bacteria, and is an important entry portal for clinically relevant bacterial pathogens. Toll-like receptors (TLRs) are a family of receptors that recognize bacterial products and, once activated, can initiate innate immune defenses in the host. TLR9 recognizes bacterial DNA (bDNA) and its synthetic derivatives carrying an unmethylated CpG motif, which is absent from mammalian DNA. Functional TLR9 is expressed by various immune and inflammatory cells (macrophages, B cells), and, as shown in preliminary studies, also in intestinal epithelial cells. Administration of bDNA to mice can be immunostimulatory (e.g., adjuvant functions in immunizations), but can also downregulate inflammatory responses, as we showed in murine colitis models. To explain these different effects ofbDNA, when administered exogenously or after release from pathogenic and commensal intestinal bacteria, this Research Unit will focus on the physiologic functions of the receptor for bDNA, TLR9, in the intestine. Our studies will test the overall hypothesis that TLR9 exerts anti-inflammatory functions in the intestine in vivo. The studies have the following Specific Aims: Aim 1. To define the signaling pathways activated by bDNA in intestinal epithelial cells. We will define the polarity and subcellular localization of TLR9 in polarized human intestinal epithelial cells in vitro and in vivo, and determine the signaling pathways and cellular functions induced by TLR9 activation in these cells. Aim 2. To determine the functions of TLR9 in regulating colonic inflammation. These studies will use TLR9 deficient mice to define the physiologic functions of TLR9 in different murine colitis models, and in mediating the beneficial effects ofprobiotic bacterial preparations in colitis. Aim 3. To define the importance of indoleamine 2,3-dioxygenase (IDO) in mediating the anti-inflammatory functions of bDNA in colitis. Based on preliminary data that inhibition of the tryptophan-catabolizing enzyme, IDO, reverses the anti-inflammatory effects of bDNA, the studies will use IDO deficient mice and pharmacological and histological approaches to begin to address mechanisms by which bDNA and TLR9 modulate intestinal inflammation. Together, these studies will yield new insights into the physiologic functions of bacterial DNA and TLR9 in the intestine, which will form a basis for the design of new therapeutic strategies that exploit the underlying biological principles. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MUCOSAL PROTECTIVE FACTORS IN HUMAN MILK Principal Investigator & Institution: Rao, Radhakrishna; Professor; Physiology and Biophysics; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2004 Summary: Neonatal necrotizing enterocolitis (NEC), the acute necrosis of the small intestine, is the most common non-respiratory, life-threatening disease among infants admitted to neonatal intensive care units. Although etiologic and epidemiologic characteristics of NEC are poorly understood, two major factors closely associated with NEC are prematurity and enteral feeding. A striking observation made by several groups of scientists is that feeding breast milk reduces the risk of NEC in premature infants. Such a beneficial effect was not observed by feeding infant formula. We recently
Studies
63
demonstrated that human milk contains protective factors that protect the intestinal epithelial barrier function from oxidative-stress induced disruption. Our preliminary studies indicate that there are at least two protective factors in human milk, one heat stable and the other heat-sensitive. On the basis of preliminary results it is hypothesized that milk-borne factors protect the intestinal mucosal barrier function. Our long-range goal is to determine the mechanism involved in breast milk-mediated protection of the gastrointestinal mucosa, and to determine the role of milk-borne mucosal protective factors in preventing neonatal gastrointestinal diseases, such as NEC. Our next step towards this goal will be to isolate two distinct milk-borne protective factors that prevent hydrogen peroxide-induced barrier disruption, and to characterize their physical and chemical properties to reveal their identity. This goal will be achieved by: 1) isolation of protective factors to homogeneity by liquid chromatography, and 2) characterization of physical and chemical properties of isolated protective factors. These studies will reveal the identity of at least two distinct mucosal protective factors in breast milk, and provide the basis for further characterization of the mechanisms involved in mucosal protection by breast milk, and their role in preventing neonatal gastrointestinal diseases Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTERED RANDOMIZED TRIAL OF HIGH-DOSE URSO IN PSC Principal Investigator & Institution: Lindor, Keith D.; Professor and Director; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2006 Summary: (provided by applicant): Primary sclerosing cholangitis (PSC) is a progressive chronic cholestatic liver disease of unknown etiology that is commonly associated with chronic colitis. PSC, a common liver disease among adults, usually leads to advanced liver disease and liver failure, and as such, is an important indication for liver transplantation. Unfortunately, no effective medical therapy currently exists for PSC. The group of investigators has a longstanding track record of clinical trials in chronic cholestatic liver disease, particularly in primary sclerosing cholangitis. Recently we have generated promising results from a pilot study using high doses of ursodeoxycholic acid in the treatment of PSC. Lower doses of ursodeoxycholic acid in patients with PSC led to biochemical improvement but did not affect other clinically important endpoints in a previous study. Our pilot data is supported by data from another group showing in a small, randomized trial that high dose ursodeoxycholic acid led to biochemical, histologic, and cholangiographic improvement compared to placebo at two years. In this submission, we propose a large-scale multi-center placebo-controlled randomized trial with a minimum follow-up of four years for 150 patients with primary sclerosing cholangitis. Primary endpoints of the study will include histologic progression to cirrhosis, development of esophageal or gastric varices, need for liver transplantation, and survival. Secondary endpoints will include measurements of the effects of urosodeoxycholic acid (28-30 mg/kd/d) on liver biochemistries, histologic stage, cholangiographic features, Mayo risk score, and quality of life, using validated questionnaires. This study will be the largest ever conducted in PSC and the follow-up will be the most extensive. This will provide an invaluable resource for studying the natural history of this disease and as part of this study we will also collect serum, cells for extraction of DNA, bile, and tissue from the liver and colon as a resource for future studies. The multi-centered nature of this trial will allow recruitment of patients into this study from a diverse patient population, representative of the gender and racial
64
Colitis
distribution of this disease. Chances of successful completion of this study are enhanced by the large PSC patient population that the participating centers currently manage, recognition of these sites as referral centers for new patients with PSC, as well as a longstanding track record in clinical trials in cholestatic liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MYCOBACTERIUM AVIUM SUBSPECIES IN CROHN'S DISEASE Principal Investigator & Institution: Naser, Saleh A.; Molecular Biol & Microbiology; University of Central Florida 4000 Central Florida Blvd Orlando, Fl 32816 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2006 Summary: Crohn's disease (CD) is a debilitating chronic inflammatory bowel disease characterized by patches of inflamed tissue. The underlining cause of inflammation and provocation of the immune response in CD patients has yet to be determined. In theory, the immune system usually reacts against an invading organism such as an insect bite or bacterial infection, or is over-sensitive, as in allergic reactions to grass pollen etc. These reactions cause irritation and pain in the affected area, which subside when the immune system has dealt with the potential threat. Defects in the immune system of CD patients have been reported, both in the ability of the cell to phagocytose and in immune killing after phagocytosis, The cytokine pattern in CD is Th1-like and defect in the ratio of proinflammatory to anti- inflammatory cytokines has been proposed. A specific antigenic stimuli has not been identified, but pathogenic bacteria such as Mycobacterium avium subsp paratuberculosis (MAP) and specific invasive E. coli strains have been proposed. In addition, autoantibodies derived from molecular mimicry from bacterial antigens, or from host origin may also be causative agents of the inflammatory lesions in CD. Defects in the ability of macrophages to present antigen to T-cells and B-cells may also have a role. The mycobacterial theory is based on the significant similarity between CD and Johne's disease, a chronic enteritis in cattle that is caused by MAP. The two diseases share histological and pathological characteristics similar to those in tuberculosis and sarcoidosis. It is believed that MAP may be causing an immune reaction in the gut, resulting in a continuous immune response, which gets better and worse as the number of bacteria increase and decrease. Another possibility is that some parts of MAP like the heat shock proteins similar to parts of the gut lining resulting in triggering an immune response: a process known as autoimmunity. Finally, there may be defects in the immune reaction to MAP or proteins in the gut. In this case, the immune cells fail to deal with the invading organism, which is able to persist in the tissues, causing further inflammation. Many studies have been performed in an attempt to investigate a mycobacterial role in the etiology of CD and its pathogenesis. The outcome has been inconsistent which has added to the controversy. The role of MAP, if any, in the etiology of CD has become increasingly debated in recent years causing a need for clear elucidation. While positive results would change the course of therapy and investigation in CD, a negative result will go a long way toward clearing up the MAP debate. In this study, our team will investigate the overall role of MAP, if any, in CD etiology by addressing the following questions: Is MAP present in CD lesions? Is it culturable? Can MAP be identified using PCR, RT-PCR or fluorescence in situ hybridization (FISH) techniques? Is there any immune reaction activity against MAP in CD patients? Is it cellular, humoral or both? What types of immune cells are present in CD lesions compared to non-inflammatory tissue or tissue from non-IBD and healthy controls? Are there any abnormalities in bacterial phagocytosis by peripheral blood monocytes and neutrophils from CD patients compared to normal cells? Are there factors inhibitory to phagocytosis in CD serum? Are there any abnormalities in antigen
Studies
65
presentation and lymphocyte transformation to recall antigens from MAP? Are there any inhibitory or augmenting factors present in the serum from CD patients (cellular and serum crossover)? Our approach in this project is to determine if MAP or reactions against MAP are present in full thickness surgical tissue, heparinized blood and sera specimens from patients with CD using well-developed methodology in the fields of microbiology, immunology and molecular microbiology. We will investigate the presence of MAP in tissue specimens directly by using nested PCR, RT-PCR and FISH and indirectly by culture using a newly developed culture media appropriate for isolation of cell wall deficient form of MAP. We will also investigate the humoral immune reaction in CD sera using p20 antigen, a MAP specific protein. Additionally, the type and state of immune cells will be determined in inflamed versus non-inflamed tissue specimens from CD patients. We will also examine how these cells from CD patient blood are able to ingest and kill MAP, and whether this ingestion results in a normal immune response. This is the first study designed to comprehensively examine the overall presence/absence of MAP in CD tissue and the immune response in CD patients. The results will give us a better idea as to whether MAP causes CD, or whether there is an inherent defect in the immune system, which allows bacterial persistence or autoimmunity to occur in the gut. Ultimately, the outcome of this study will go a long way toward clearing up the MAP debate. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROENDOCRINE MEDIATION OF E. COLI 0157:H7 INFECTION Principal Investigator & Institution: Lyte, Mark; Professor; Minneapolis Medical Research Fdn, Inc. 600 Hfa Bldg Minneapolis, Mn 55404 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: This application proposes the new theory of directed neuroendocrinebacterial interactions as a mechanism governing the ability of an enteric pathogen to infect a host. This hypothesis is based on the in vitro and in vivo ability of the neuroendocrine hormone norepinephrine (NE) to increase growth and production of virulence-associated factors of the enteric pathogen Escherichia coli O157:H7. High concentration of NE occur in foods such as ground beef which are contaminated by E. coli O157:H7. Equally high concentrations of NE also occur within the gastrointestinal tract due to enteric nervous system activity. The proposed research will therefore examine whether the presence of NE from the time of E. coli O157:H7 contamination of NE-rich foods to infection within the gut may be a factor mediating the development of hemorrhagic colitis. Results from this laboratory have shown that the effect of NE on E. coli O157:H7 contamination of NE-rich foods to infection within the gut may be a factor mediating the development of hemorrhagic colitis. Results from this laboratory have shown that the effect of NE on E. coli O157: H7 is due to the production of an autoinducer of growth. Thus, our Specific Aims are: 1) To determine the ability of a purified diet supplemented with levels of NE found in commonly contaminated foods to "prime" E. coli O157:H7 for the NE-rich environment within the gastrointestinal system; 2) To examine the ability of E. coli O157:H7 isolated from gastrointestinal trat of stressed and non-stressed mice since differences in luminal levels of NE between stressed and control animals would provide greater understanding of the recognized ability of stress to alter susceptibility to colitis; 4) To determine the ability of stress of alter the susceptibility of mice to oral challenge with E. coli O157:H7 exposed in vitro to control of NE supplemented diets; 5) To examine whether blockage of NE release within the gastrointestinal tract can alter susceptibility to challenge with E. coli P157:H7; and 6) To purify the serum-bound form of the NE-induced E. coli O157:H7 autoinducer of
66
Colitis
growth and determine its structure which may provide the basis for the development of agents to specifically interrupt bacterial division as well as identify the gene(s) involved in its production. Collectively, the above aims will seek to establish a direct cause and effect relationship between the NE content within food and the gastrointestinal trat to influence the ability of E. coli O157:H7 to cause infection. The demonstration of direct neuroendocrine-bacterial interaction as a mechanism in the pathogenesis of E. coli O157:H7 infection may yield new treatments for both the prevention and treatment of hemorrhagic colitis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NITROXIDE THERAPY FOR INFLAMMATORY BOWEL DISEASE Principal Investigator & Institution: Hsia, Carleton Jc.; Synzyme Technology, Inc. 1 Technology Dr, E-309 Irvine, Ca 92618 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 31-OCT-2001 Summary: (Adapted from the application): Free radicals play important roles in inflammatory bowel disease (IBD), and the reduction or elimination of the adverse effects of these oxidants could provide novel therapies. Antioxidants have been reported to reduce tissue injury in colitis models, but more potent, stable and bioavailable antioxidant compounds are required. This project will test a new class ofantioxidants based on polynitroxylation technology, or linkage of nitroxides (stable N-oxyl radicals) to biological macromolecules. In a preliminary study, polynitroxyl-starch (PNS) acted synergistically with the free (unbound) nitroxide compound Tempol to reduce oxidants (especially superoxide) and attenuate inflammation in TNBS-induced murine colitis. We hypothesize that TNBS colitis involves significant superoxide-mediated injury, and that PNS and Tempol can attenuate this injury. Specific aims are: (1) Produce PNS and characterize its antioxidant activity. (2) Pharmacokinetically define optimal dose and route of administration. (3) Define efficacy in TNBS-induced mouse colitis. If this is successful, Phase II will define mechanisms of action in animal models of IBD (including the IL-10-/- knockout mouse which spontaneously develops colitis) and other studies required for progression to clinical testing in IBD. PROPOSED COMMERCIAL APPLICATION: Inflammatory bowel disease is a significant health problem. If successful this research will lead to the development of a novel therapeutic agent(s) for the treatment of IBD. This would represent a significant commercial opportunity and provide substantial benefit to patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NOD2: A SUSCEPTIBILITY GENE FOR CROHN'S DISEASE Principal Investigator & Institution: Nunez, Gabriel; Professor; Pathology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 08-APR-2002; Project End 31-MAR-2007 Summary: The idiopathic inflammatory bowel diseases (IBD) which includes Crohn's disease and ulcerative colitis are chronic disorders of the gastrointestinal tract of unknown etiology with a combined prevalence of about 150-200 cases per 100,000 in western countries. Although the etiology of IBD is unknown, a large body of evidence suggest that these diseases are multifactorial and likely caused by an abnormal inflammatory response directed against luminal and/or enteric microflora in a genetically susceptible host. However, the genetic basis for this abnormal inflammatory response to enteric bacteria is unknown. Genome-wide searches for IBD-susceptibility genes have resulted in the identification of several loci harboring potential predisposing
Studies
67
genes for Crohn's disease. Of these, linkage to the pericentromeric region of chromosome 16 (IBD1 locus) has been replicated by several independent studies to confer susceptibility to disease. We have identified Nod2, a gene that encodes a protein with homology to plant disease resistance gene products, that is located in the peak region of linkage disequilibrium on chromosome 16. We have found that a frameshift mutation and genetic variants of Nod2 are highly associated with susceptibility to Crohn's disease by genetic analysis in multi-case disease families and case-control studies. Nod2 is expressed in monocytes and activates NF- kappaB. Significantly, wildtype Nod2 confers responsiveness to bacterial lipopolysaccharides and this activity is deficient in mutant-Nod2 associated with Crohn's disease. These observations suggest a link between an innate immunity pathway controlled : byNod2 and susceptibility to Crohn's disesase. Our overall hypothesis is that Nod2 recognizes lipopolysaccharidesin the cytosol and activates a NF-kappaB signaling pathway in the host cell that protects the host against entericbacteria. Our preliminary results suggest a model in which deficiency in the Nod2 pathway leads to an abnormal T cell-mediated response to enteric bacteria and tissue destruction. We propose three Specific Aims to explore our hypothesis: (i) Determine the sequence of Nod2 that mediates functional activity and - recognition of bacterial LPS. The analyses will include study of Nod2 variants associated with Crohn's disease and systematic mutagenesis of Nod2; (ii) Determine the structure of LPS recognized by Nod2 and (iii) Characterize mice deficient in Nod2 to determine its role in the response to luminal and pathogenic enteric bacteria. The proposed studies should improve our understanding of the role of Nod2 in innate immunity and provideimportant insight into the link between genetic variation in Nod2 and susceptibility to Crohn's disease. The studies may lead to novel therapeutic approaches for Crohn's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL PARS INHIBITOR FOR THERAPY OF COLITIS Principal Investigator & Institution: Jagtap, Prakash; Corporation 100 Cummings Ctr, Ste 419E Beverly, Ma 01915
Inotek
Pharmaceuticals
Timing: Fiscal Year 2001; Project Start 15-APR-1999; Project End 31-MAY-2003 Summary: (Applicant's Abstract): Current treatment of inflammatory bowel disease (IBD) is of limited efficacy, as there are no entirely non-toxic pharmaceuticals that totally halt or reverse the progression of IBD. To address this need, Inotek has invented a novel anti-colitic agent (PJ-34) that is a nanomolar-potent inhibitor of poly (ADP-ribose) synthetase (PARS). PARS are a nuclear enzyme whose activation by inflammatory oxidant stress results in energetic depletion, NF-kappa B nuclear translocation, granulocyte recruitment, and intestinal mucosal barrier dysfunction. We have shown that PARS deficient mice are virtually protected from autoimmune models of enterocolitis. In the Phase I SBIR, we have obtained proof of principle that the ultrapotent PARS inhibitor PJ-34 reverses established murine colitis, resulting in a dramatic reduction in intestinal tissue injury, inflammatory cell infiltration, mortality, and weight loss. In the Phase II SBIR, we intend to demonstrate that the in vivo toxicological profile of PJ-34 meets FDA standards for progression to clinical studies. Specific Aim #1: Scale-up synthesis of PJ-34 to kilogram batch production level. Preclinical evaluation of PJ-34, including toxicology, metabolism, and pharmacokinetic studies, requires process scale-up to produce kilogram scale GLP-grade material. Specific Aim #2: Determine the biochemical, hematological, and histopathologic toxicology profile of PJ-34. Range-finding toxicity studies will provide a comprehensive behavioral, biochemical, and histopathologic profile. These studies will provide the
68
Colitis
foundation for clinical testing, commercial development, and first market entry of an ultrapotent PARS inhibitor for therapy of IBD. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL USE OF ZEBRAFISH FOR APOPTOSIS ASSAY Principal Investigator & Institution: Parng, Chuenlei; Pharmaceuticals, Inc. 100 Inman St, Ste 300 Cambridge, Ma 02139
Scientist;
Phylonix
Timing: Fiscal Year 2003; Project Start 15-APR-1999; Project End 31-MAR-2005 Summary: (provided by applicant): Inappropriate apoptosis is the cause of many human diseases, including cancer, neuronal degeneration, hearing loss, organ failure, myelodysplastic syndrome, multiple sclerosis, type 1 diabetes mellitus, thyroiditis, and ulcerative colitis. Compounds that affect apoptosis are potential therapeutics. Cell based assays are widely used in drug development, however, many promising candidates fail in subsequent mammalian testing. Zebrafish assays can serve as an intermediate step between cellular evaluation and mammalian testing. Zebrafish has several advantages, including transparent embryos for easy visual analysis, rapid embryonic development and low cost. Furthermore, similar pharmacological responses to those in the mammalian apoptotic machinery are present in zebrafish. Currently the standard whole animal apoptosis assay is TUNEL, a histochemical staining technique which detects apoptotic cells in sectioned tissue. This assay is time-consuming and permits examination at only a single time point. Since many degenerative diseases occur in stages, assay formats that permit continuous examination of changes in the apoptosis pattern and the duration of drug effects are needed. Using zebrafish embryos, this proposal will develop a quantitative microplate assay for high throughput screening of compounds. Complementary visual and flow cytometry based assays will also be developed to provide comprehensive analysis of apoptosis in zebrafish. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ORAL CONDITIONS AND PREGNANCY--NEONATAL OUTCOMES Principal Investigator & Institution: Auten, Richard L.; Duke University Durham, Nc 27706 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2002 Summary: This supplemental application extends the evaluation of oral inflammation and infection, effects on pregnancy to the potential impact on premature newborns and the leading complications of prematurity, lung and brain damage. The general hypothesis is that subclinical infection, possibly originating in periodontal disease, affects the inflammatory and immune responses in women, placing them at higher risk for preterm labor and delivery. Pro-inflammatory cytokines, associated with periodontal disease and intrauterine infection, have been implicated in the initiation of preterm labor. Our proposed studies will assess how these maternal processes affect the inflammatory cascade in the premature low birth eight infant and the risk for inflammatory complication of prematurity. Prenatal infection and inflammation are associated with brain injury in premature newborns, in particular intraventricular hemorrhage and periventricular leukomalacia. Inflammatory cytokines are found in the tracheal secretions of premature newborns who later develop bronchopulmonary dysplasia. Necrotizing enterocolitis is another serious life-threatening complication of prematurity associated with elevations in pro-inflammatory cytokines. Genetic polymorphisms encoding IL-1beta and TNFalpha are associated with increased cytokine
Studies
69
expression and may predispose to an exaggerated inflammatory response. We will measure pro-inflammatory cytokines in pregnant women and compare them to those in their premature newborns. Cytokines will be correlated with the inflammatory complications of prematurity: bronchopulmonary dysplasia, intraventricular hemorrhage/periventricular leukomalacia, and necrotizing enterocolitis, using logistic regression analysis. Polymorphisms will be identified and correlated with these inflammatory complications with the abundance of cytokine protein and mRNA in tracheal aspirates cells and in blood. We will test whether a panel of mediators identified at risk with high sensitivity and specificity. Our long-term aim is to develop markers that identify newborns at highest risk and provide the basis for future therapy to prevent these complications of prematurity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF EXPERIMENTAL BOWEL NECROSIS Principal Investigator & Institution: Hsueh, Wei; Professor; Children's Memorial Hospital (Chicago) Chicago, Il 606143394 Timing: Fiscal Year 2001; Project Start 01-DEC-1983; Project End 31-MAR-2002 Summary: In this study we will use a model of ischemic bowel necrosis, or necrotizing enterocolitis (NEC) in rats and mice, by injecting PAF systemically. That PAF may be an important mediator for NEC is based on our previous findings: 1)PAF induces small bowel necrosis. 2)PAF mediates bowel injury induced by LPS, TNF or hypoxia. 3)PAF is rapidly produced after LPS injection, especially in the ileum. 4) PAF-R expression is very high in the small bowel. 5)Experimental NEC induced by hypoxia and formula feeding is prevented by PAF antagonist. 6) NEC patients have elevated serum PAF, and suppressed acetylhydrolase, the enzyme degrading PAF. We recently found that PAF at low dose (without gross bowel injury) also has profound effects on the small bowel, including inducing villus apoptosis and increasing mucosal permeability. Thus, Aim 1 is to examine the effect of low dose PAF on intestinal apoptosis and mucosal permeability (an early event before NEC occurs); and to study the respective mechanisms (roles of Fas/FasL, PMNs, lymphocytes, TNF, ROS, iNOS (inducible nitric oxide synthase), tyrosine kinase, eiconsanoids, tyrosine kinases, IFN- gamma and gut bacteria/LPS). Aim 2 is to test the hypothesis that intestinal necrosis occurs due to an imbalance between the protective cNOS (constitutive NOS) and the injurious iNOS ans xanthine oxidase (XO). This is based on our finding that PAF suppresses the former and stimulates the latter two. Aim 3 is based on our observations that (a) PAF up- regulates ileal PAF-R expression, an effect mediated via endogenous PAF and TNF, (b) PAF-receptor (PAF-R) localizes mainly in lamina propria (LP) eosinophils, (C) PAF permits LPS entry, which binds to LP eosinophils and (d)LPS/bacterial products are required for the development of NEC. We will examine the role of PAF-R, LP eosinophils and LPS in PAF induced LPS entry (a consequence of mucosal permeability increase), and its effect on the pathogenesis of bowel necrosis, release of mediators (e.g., PAF, LTC4,TNF) and consequent intestinal injury. These 3 closely related aims may lead to the elucidation of the pathophysiological function of PAF in the bowel, and the mechanisms of intestinal defense and injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PATHOGENESIS OF FEVER IN HUMANS Principal Investigator & Institution: Dinarello, Charles A.; Professor of Medicine; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508
70
Colitis
Timing: Fiscal Year 2003; Project Start 01-DEC-1986; Project End 31-JAN-2008 Summary: (provided by applicant): Anti-cytokine therapy for acute and chronic inflammatory diseases has entered clinical medicine. The main targets for anti-cytokinebased therapies are tumor necrosis factor (TNF) and interleukin-1 (IL-1), pleiotropic, proinflammatory cytokines. The IL-1 receptor antagonist (IL-1Ra) has been approved by the FDA for the treatment of rheumatoid arthritis. Other inhibitors of the IL-1 beta are in Phase II trials for various diseases. IL-18, a member of the IL-1 family and closely related to IL-1 beta, also appears to be a target for therapeutic intervention in disease. Specific inhibitors of ICE reduce the release and hence the biological activity of both IL-1 and IL18. We have demonstrated that IL-18 has broad effects similar to those of IL-1 beta such as inducing the synthesis of other pro-inflammatory cytokines, the family of chemokines, activation of neutrophils, and upregulation of Fas ligand and endothelial adhesion molecules. Therefore, the host likely mounts various strategies to limit the biological activities of IL-18. We isolated and cloned a novel IL-18 inhibitor, the IL-18 binding protein (IL-18BP), which binds and neutralizes IL-18; the IL-18BP is a constitutively expressed and secreted inhibitor of IL-18 activity. Another member of the IL-1 family is the IL-1 homologue 4 (IL-1H4), which is structurally related to IL-18, binds to IL-18 receptor alpha chain, which is the ligand binding chain of the IL-18 receptor complex. However, IL-1H4 exhibits no agonist activities. Although likely to be the "receptor antagonist" for IL-18, recombinant IL-1H4 exhibits no receptor antagonist activities for IL-18. We propose to study the function of IL-1 H4 and assess its role in disease as a naturally occurring inhibitor of IL-18 activity. Preliminary data indicate that IL-1H4 binds to the IL-18BP and that this complex recruits the signaling beta chain of the IL-18 receptor complex, thereby depriving the cell of the beta chain for signal transduction. As such, IL-1H4 appears to function as a "decoy" cytokine. The proposed studies are intended to show that IL-1H4 plays a role in disease via this novel mechanism using animal models of inflammatory disease. Human IL-1H4 appears to reduce the activities of mouse IL-18, therefore, we will generate transgenic mice overexpressing human IL-1H4 and challenge these mice using IL-18-dependent models of disease. These studies may have implications for the use of IL-1H4 to treat IL-18related diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEPTIDE ANTIGENS IN CD45RBHIGH CD4+T CELL COLITIS MODEL Principal Investigator & Institution: Saubermann, Lawrence J.; Boston Medical Center Gambro Bldg, 2Nd Fl, 660 Harrison Ave, Ste a Boston, Ma 02118 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: (provided by applicant): Chronic human inflammatory bowel diseases (IBD), such as Crohn?s Disease and Ulcerative Colitis, afflicts approximately two million individuals in this country alone. These disorders are primarily characterized by the presence of activated forms of T lymphocytes in the intestinal mucosal compartment. Through a number of investigations in murine models of IBD, as well as human studies, it is becoming increasingly recognized that IBD is associated with luminal or environmental stimuli in a genetically susceptible host. One of the best-characterized murine models of IBD is the CD45RBhigh CD4+ T cell transfer model. Adoptive transfer of this particular subset of T cells into a severe combined immunodeficient (SCID) congeneic recipient, who lacks functional B or T cells, results in colitis. However, adoptive transfer of the CD45RBlow CD25+ CD4+ T cells inhibits colitis. Recent evidence indicates that both T cell subsets are dependent on MHC class II and are
Studies
71
activated through a restricted set of T cell receptors, which indicates expansion to a limited set of antigens. The model is also dependent on environmental antigen exposure, as SCID mice raised under germ-free conditions, do not develop colitis following cell transfer. Taken together, this implies that the effector and regulatory CD4plus T cells in this transfer model of colitis are most likely activated by a limited number of peptide antigens presented in a MHC class II dependent fashion, and possibly derived from the luminal environment. Therefore, the primary goal of this project is to elucidate the peptide antigen(s) involved in the CD45RBhigh CD4+ T cell population effector response or the CD45RBlow CD25+ CD4+ inhibitory response. Specifically, we plan to use a methodological approach involving cDNA expression libraries to identify unknown peptide antigens for these subsets of T cells. Preliminary experiments with murine DO11.10 CD4+ T cell hybridoma cells, which recognize a 17 amino-acid peptide epitope of chicken ovalbumin in the context of MHC class II, has indicated the initial parameters of this methodology. The primary goal is to identify expressed peptide(s) from recombinant fusion proteins created from cDNA libraries made from tissue and cecal bacteria extracts. The libraries will be screened for reactive epitopes by proliferation and cytokine production. Next, these important T cells will undergo T cell receptor evaluation. Potentially, by this approach, antigens responsible for CD45RBhigh CD4plus T cell adoptive transfer model of colitis can be elucidated, this may lead to a better understanding of human inflammatory bowel disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POLYAMINES AND EARLY GI MUCOSAL RESTITUTION Principal Investigator & Institution: Johnson, Leonard R.; Professor and Chairman; Physiology and Biophysics; University of Tennessee Health Sci Ctr Health Science Center Memphis, Tn 38163 Timing: Fiscal Year 2001; Project Start 01-SEP-1997; Project End 31-JUL-2002 Summary: The overall goal of this grant application is to understand how polyamines influence the migration of GI mucosal cells during the process of early mucosal restitution. Experiments supported during the past 10 years have shown that: 1) polyamines are essential to the healing of gastric and duodenal mucosal, 2) polyamines are required for the mucosal restitution that depends on cell migration, 3) polyamines are essential to migration in a normal line (IEC-6) of intestinal epithelial cells in a model that mimics mucosal restitution, and 4) polyamines alters some components of the cytoskeleton that are essential for cell migration. The first set of specific aims is designed to define the manner in which polyamines interact with the cytoskeleton. These studies will examine the effect of polyamines on the equilibrium between and distribution of, Fand G-actin, determine whether polyamines alter the amounts of distribution of G-actin binding proteins, determine whether polyamines are involved in the attachment of cells to their substrates, and then whether they alter the amounts and distributions of integrins and attachment proteins. Most of these studies will be carried out using immunocytochemical techniques. Preliminary evidence from the PI's laboratory indicates that the small GTP binding protein Rho regulates cell migration in IEC-6 cells. The second set of specific aims tests this hypothesis by inhibiting Rho function and examining the effects on cell migration and the cytoskeleton. Rho function will be inhibited with toxins A and B from C. difficile, C3 toxin from C. botulinum, and recombinant dominant negative Rho(A) T19N protein. These experiments will establish the role of Rho in the regulation of GI epithelial cell migration. In the third set of specific aims, studies will determine whether and how polyamines affect Rho function. Western blot analysis of preliminary results indicates that polyamine depletion decreases the
72
Colitis
amount of Rho protein. These studies will be pursued along with those involving Rho mRNA and Rho GTPase activity. The experiments outlined will explain the original observations of the PI on mucosal healing in whole animals in terms of cell function and describe, in turn, how it is regulated at the molecular level. These results will provide the first description of the involvement of polyamines in the migration of any cell type, and be the first to indicate how Rho regulates GI mucosal cell migration and how it in turn is dependent on polyamines. These studies have clinical application in peptic ulcer disease, cancer, colitis and all conditions where cell migration is important. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: QUALITY OF LIFE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE Principal Investigator & Institution: Perrin, James M.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2004 Summary: (provided by applicant): Measurement of the quality of life (QoL) of children and adolescents with inflammatory bowel diseases (IBD) has had little attention, despite the importance of understanding key factors affecting QoL, especially for measuring the effects of clinical trials to improve IBD outcomes. The main purpose of this pilot study is to examine the impact of clinical severity and treatment social factors on the quality of life (QoL) of a diverse population of children and adolescents with inflammatory bowel disease (IBD). Secondary purposes include determining the effects of sociodemographic factors on QoL and exploring the concordance of views of parents and children of QoL. The study aims are to 1) determine the associations of of clinical characteristics (condition type, activity/severity, and treatment) with specific components of general health-related quality of life and IBD-specific QoL; 2) describe the effects of sociodemographic characteristics (SES, age, and gender) on these measures; and 3) compare the views of different observers (parent and child with IBD) of the child's QoL. The study will apply both general and condition-specific QoL measures among a random sample of 250 children and adolescents with IBD, ages 5-18 years, in six clinical sites. We will obtain measures of QoL from both the child and a parent in each case. The study will obtain additional data regarding the subjects' clinical condition (condition type, severity/activity, treatment [including surgery], age of onset) and socioeconomic status (household structure and income). Main analyses will compare general and specific measures of QoL and examine the influence of clinical and sociodemographic variables on QoL, through multivariate regression techniques. We will also examine the differences in child and parent assessments of QoL. The information from this study will provide a stronger base for future studies of treatment and natural history of IBD. It will help to clarify the life domains that are affected by IBD and will inform interventions to improve QoL for children with IBD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RECOMBINANT SHIGA-TOXIN-SPECIFIC HUMAN ANTIBODIES Principal Investigator & Institution: Tzipori, Saul V.; Professor and Head; Biomedical Sciences; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-JUL-2005 Summary: This proposal is in response to RFA: DK-00-005 "Foodborne Illness, Gastrointestinal and Renal Complications", specifically addressing "Development of interventions and/or clinical strategies to prevent complications of E. coli 0157:H7-
Studies
73
related illnesses during the initial critical interval between the occurrence of hemorrhagic colitis and the development of HUS". The goal of this proposal is to develop an effective immune-based formulation which can be administered safely to children at risk of developing Shiga-toxin (Stx)-related hemolytic uremic syndrome (HUS). The target populations for this treatment include children in whom the disease can directly or indirectly be attributed to Stx. Currently there is no effective treatment or prevention for HUS. In this proposal we demonstrate that exogenous Stx-specific human monoclonal antibodies (Hu-mAbs) which we have generated under a separate NIH award, protect gnotobiotic piglets against Stx-mediated fatal neurological symptoms when administered 6-12 hours after oral challenge with E. coli 0157:H7. In contrast, piglets treated with placebo develop vascular-mediated fatal neurological symptoms within 2-3 days after the oral challenge. In this application we wish to express several of these anti-Stx Hu-mAbs in an eukaryotic system. This will allow us to produce them in large quantities (Specific Aim 1) and in different forms, such as isotype-variants (Specific Aim 2) and Fab fragments (aim 3) to determine which form would provide the most effective protection in vitro and in vivo (Specific Aim 4). We anticipate the final product will contain a cocktail of Hu-mAbs active against the A and B subunits of Stx1 and Stx2 (Specific Aim 4). Given our Preliminary Data, we are confident that specifically designed and highly concentrated Hu-mAbs will be safe and effective in protecting children at risk of HUS. We believe recombinant Hu-mAbs, either as whole molecules or Fabs, will be equally effective. Recombinant Hu- mAbs will considerably improve the efficiency of production of these reagents and make them available for clinical use. In contrast to other sources, such as polyclonal antibodies or murine/chimeric mAbs, HumAbs have longer half-life, better affinity for targets, higher potency, require a lower dose, are safer, and are clearly the wave of the future. We are confident that at the end of the five-year support period we will have expressed in an eukaryotic system, a fully characterized panel of effective recombinant Stx-specific Hu-mAbs, ready to be produced under FDA guidelines for clinical evaluation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF COLITIS BY CYCLOOXYGENASE-2 Principal Investigator & Institution: Wilson, Keith T.; Associate Professor of Medicine; Medicine; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-JAN-2003 Summary: (adapted from the application) Our investigations to date indicate that inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, enzymes which produce high output nitric oxide and prostanoids, respectively, are consistently upregulated in gastrointestinal mucosal inflammation. Further, expression of these genes can regulate inflammatory pathways. We have identified important protective effects of iNOS and COX-2 in specific in vivo and in vitro models. We have also found important differences in the effects of NOS and COX-2 on inflammatory events. We have used mice with targeted deletion of either iNOS or COX-2 to assess mucosal responses to a known and common pathogen, Helicobacter pylori. iNOS deletion had no effect on H. pylori infection or the severity of gastritis. In contrast, COX-2 deletion resulted in a marked exacerbation of both acute and chronic histologic gastritis, resulted in frequent duodenal ulcer formation, which was not present in controls, and increased colonization levels of H. pylori. In addition, the tissues from H. pylori-infected COX-2deficient [COX-2(-/-)] mice exhibited an exacerbation of the Th1-predominant, IL-12driven dysfunctional immune response which characterizes H. pylori gastritis. COX-2 deletion was also associated with increased epithelial injury due to apoptosis. We have
74
Colitis
also confirmed these alterations of the immune response and apoptosis in vitro. The importance of understanding the role of COX-2 in different forms of GI mucosal inflammation is highlighted by the recent FDA approval and rapid utilization of multiple COX-2 selective inhibitors for treatment of musculoskeletal diseases. Based on our preliminary data and my long-standing interest in inflammatory bowel disease, in the current proposal we will determine the role of COX-2 in several important mouse models of colitis. We will use hapten models in which the mucosal immune response has been described, as well as two pertinent colonic infections, namely Helicobacter hepaticus and Citrobacter rodentia. These infection models were selected because of our findings in H. pylori gastritis and the recognition that murine IBD models appear to depend on the presence of enteric bacteria. Our specific aims are to compare COX-2(-/-) vs. (+/+) mice and wild-type mice treated with COX-2 inhibitors vs. placebo and determine the regulatory role of COX-2 in: 1. models of Th1 (TNBS) and Th2 (oxazolone) mediated colitis and 2. Colonic inflammation and injury due to H. hepaticus and C. rodentia. In both aims we will assess the effect of COX-2 on A. gross and microscopic injury; B. I1-12, Th1, pro-inflammatory and Th2 cytokine levels; and C. epithelial apoptosis. These studies are designed to establish these models and the role of COX-2 in the associated diseases, and will serve as the basis for future investigations and funding applications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF GASTROINTESTINAL EOSINOPHILS Principal Investigator & Institution: Rothenberg, Marc E.; Associate Professor; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2003 Summary: Eosinophil accumulation in the gastrointestinal tract occurs in numerous diseases (i.e. food allergy, eosinophilic gastroenteritis, allergic colitis, and gastroesophageal reflex). Some of these disorders are highly prevalent and clinically important. For example, food allergy has been documented in 2-4% of children and can by life threatening. Despite the common finding of eosinophils in tissue specimens from these patients, and increasing evidence that these cells have a pathogenic role in these disorders, there has been only a limited understanding of the biological and pathological significance of eosinophils in the gastrointestinal tract. We have begun to elucidate the mechanisms of eosinophil trafficking into the gastrointestinal tract and have developed a novel model of food allergen-induced gastrointestinal inflammation. This grant application proposes to elucidate the cellular and molecular mechanisms involved in regulating eosinophil trafficking into the gastrointestinal tract. The application is based on the main hypothesis that eosinophils normally reside in the gastrointestinal tract and that their homing into this organ is regulated by locally generated eotaxin, a CC chemokine with eosinophil selective activity, that works cooperatively with interleukin (IL)-5. The regulation of gastrointestinal eosinophils by these two cytokines and T cells will be evaluated in healthy states, following oral allergen challenge in the model of allergen-induced gastrointestinal inflammation, and by transgenic over-expression of these cytokines specifically in the intestine. Four aims will be undertaken: (I) the mechanisms of eosinophil homing into the gastrointestinal tract during health states; (ii) characterization of the early and late phase response in the gastrointestinal tract during allergic inflammation; (iii) the mechanism of eosinophil trafficking into the gastrointestinal tract during allergic inflammation; and (IV) the consequences of transgenic expression of eotaxin and IL-5 in the intestine. The proposed experiments will define the mechanisms that regulate gastrointestinal eosinophils at
Studies
75
baseline and following acute (allergic) and chronic (transgenic) inflammatory stimuli in the gastrointestinal tract. These basic studies will hopefully provide a better understanding of physiological processes in the gastrointestinal tract and diseases processes such as food allergy which may be related, at least in part, to dysregulation of eosinophil trafficking. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF GUT SUBSTANCE P RECEPTORS Principal Investigator & Institution: Vigna, Steven R.; Associate Professor; Medicine; Duke University Durham, Nc 27706 Timing: Fiscal Year 2002; Project Start 01-APR-1996; Project End 31-DEC-2006 Summary: (provided by applicant): Substance P (SP) is a neuropeptide involved in physiological regulation and has also been implicated in the pathway resulting in pain and inflammation. In the previous funding period we showed that the SP neurokinin-1 receptor (NK-1R) desensitizes more rapidly and extensively than may other G proteincoupled receptor and that this is caused by receptor phosphorylation and is correlated with receptor-mediated physiological responses. In addition, we showed that the NK-1R undergoes vigorous agonist-dependent endocytosis and recycling as a primary mechanism of resensitization. We also showed that the NK-1R in the rat intestine mediates Clostridium difficile toxin A-induced inflammation, secretion, and tissue damage. These observations suggest that the NK-1R is highly regulated and plays a major role in intestinal inflammation, but the mechanisms of NK-1R regulation are incompletely understood. The current proposal describes studies designed to reveal additional mechanisms of NK-1R regulation. The proposed specific aims are to 1) test the hypothesis that the N-terminus of SP plays a role in homologous desensitization of the NK-1R even though the C-terminus contains all of the agonist activity of the peptide, 2) test the hypothesis that the cytoplasmic microfilament component of the cytoskeleton in NK-1R-expressing cells plays a role in SP-mediated signaling, and 3) test several hypotheses concerning the mechanisms of SP-stimulation of MAP Kinase activity via the NK-1R. These hypotheses will be tested by multiple approaches including assessment of NK-1R signaling and desensitization after site-directed NK-1R mutagenesis. These studies will lead to insight into the normal mechanisms of SP NK-1R regulation and will suggest possible mechanisms of abnormal NK-1R regulation in intestinal inflammatory diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE OF CHEMOKINES IN T CELL MEDIATED COLITIS Principal Investigator & Institution: Lillard, James W.; Assistant Professor; Microbiology, Biochemistry & Immunology; Morehouse School of Medicine Atlanta, Ga 30310 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-AUG-2003 Summary: Inflammatory bowel diseases (IBD) are chronic, relapsing and tissue destructive diseases. T helper type l (Thl) cells secreting TNF-alpha and IFN-gamma have been emphasized in ulcerative colitis, while Th2 cells may be more closely associated with Crohn's disease. However, either Thl or Th2 cells can induce colitis in several mouse models; hence the precise causes of these two forms of IBD are incompletely understood. It has recently been shown that the mechanisms of IBD involve antigen- dependent interactions between CD4+ T cells and antigen-presenting cells (APCs) as well as genetic factors. A major deficiency in understanding the steps
76
Colitis
responsible for IBD, is the lack of comprehension for the role innate and early acting factors play in mucosal immune responses. Chemokines are a family of proteins that are resistant to inactivation by pH or proteolysis as well as affect the chemotaxis and angiogenesis of leukocytes and endothelial cells. Therefore, chemokines no doubt play a pivotal role in the regulation (i.e., initiation, maintenance, and suppression) of mucosal inflammation and tissue destruction. In fact, human interleukin-8 (IL-8), IFN-gamma inducible protein - l0 (IP-l0), CXCR3 (the receptor for IP-10), RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted), and MCP-l/JE (monocyte chemotactic protein-1) have been shown to be unregulated at the sites of mucosal inflammation (IBD). The current proposal stems from our recent findings that RANTES, IP-10, IL- 8, lymphotactin (Lptn), but not MCP-l/JE, can enhance mucosal adaptive immune responses. Since these chemolcines act at several levels, four Specific Aims will be addressed to elucidate the precise role of these chemokines and their corresponding receptors in IBD. The first aim will define the regulatory role of chemokines that are secreted by CD45RBHI CD4+ T cells subsets, which cause experimental IBD after adoptive transfer. The second aim will assess the role of mIL-8Rh (murine IL- 8/GCP2 receptor), CCR5 (a RANTES receptor), CXCR3, and XCRl (Lptn receptor) interactions in the CD45RBHI CD4+ T cell transfer model of murine IBD. The third aim will evaluate the chemokines, cytokines, and corresponding receptors that are expressed by the IBD inducers (CD45RBHI) and IBD suppressors (CDRB